mbrx20230331

0001437749-23-013582.txt : 20230510 0001437749-23-013582.hdr.sgml : 20230510 20230510160546 ACCESSION NUMBER: 0001437749-23-013582 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 48 CONFORMED PERIOD OF REPORT: 20230331 FILED AS OF DATE: 20230510 DATE AS OF CHANGE: 20230510 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Moleculin Biotech, Inc. CENTRAL INDEX KEY: 0001659617 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 474671999 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-37758 FILM NUMBER: 23906301 BUSINESS ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 BUSINESS PHONE: 713-300-5160 MAIL ADDRESS: STREET 1: 5300 MEMORIAL DRIVE STREET 2: SUITE 950 CITY: HOUSTON STATE: TX ZIP: 77007 10-Q 1 mbrx20230331_10q.htm FORM 10-Q mbrx20230331_10q.htm

Table of Contents

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended March 31, 2023

☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to

Commission File Number: 001-37758

MOLECULIN BIOTECH, INC.

(Exact name of registrant as specified in its charter)

Delaware

2834

47-4671997

(State or Other Jurisdiction of

Incorporation or Organization)

(Primary Standard Industrial

Classification Code Number)

(IRS Employer

Identification Number)

5300 Memorial Drive, Suite 950
Houston, TX							77007
(Address of principal executive offices)							(Zip Code)

713-300-5160

(Registrant’s telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Registration S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.:

Large accelerated filer ☐						Smaller reporting company ☒
Non-accelerated filer ☒						Emerging growth company ☐
Accelerated filer ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act.): Yes ☐ No ☒

Securities registered pursuant to Section 12(b) of the Act:

Title of each class			Trading Symbol (s)			Name of each exchange on which registered
Common Stock, par value $0.001 per share			MBRX			The NASDAQ Stock Market LLC

The registrant had 29,675,510 shares of common stock outstanding at May 1, 2023.

Table of Contents

Moleculin Biotech, Inc.

Form 10-Q

Table of Contents

		Page
	PART I – FINANCIAL INFORMATION	3

Item 1.	Financial Statements (Unaudited)	3
	Condensed Consolidated Balance Sheets as of March 31, 2023 and December 31, 2022	3
	Condensed Consolidated Statements of Operations and Comprehensive Loss for the Three Months ended March 31, 2023 and 2022	4
	Condensed Consolidated Statements of Cash Flows for the Three Months ended March 31, 2023 and 2022	5
	Condensed Consolidated Statements of Stockholders' Equity for the Three Months Ended March 31, 2023 and 2022	6
	Notes to Condensed Consolidated Financial Statements	7

Item 2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	12

Item 3.	Quantitative and Qualitative Disclosures About Market Risk	18

Item 4.	Controls and Procedures	18

	PART II – OTHER INFORMATION	18

Item 1.	Legal Proceedings	18

Item 1A.	Risk Factors	18

Item 2.	Unregistered sales of Equity Securities and Uses of Proceeds	18

Item 3.	Defaults Upon Senior Securities	18

Item 4.	Mine Safety Disclosures	18

Item 5.	Other Information	18

Item 6.	Exhibits	19

	Signatures	20

Table of Contents

PART 1 FINANCIAL INFORMATION

Item 1. Financial Statements

Moleculin Biotech, Inc.

Condensed Consolidated Balance Sheets

(in thousands, except for share and per share data)

(Unaudited)

	*March 31,*			*December 31,*
	*2023*			*2022*
Assets
Current assets:
Cash and cash equivalents	$	37,265		$	43,145
Prepaid expenses and other current assets		2,024			2,451
Total current assets		39,289			45,596
Furniture and equipment, net		244			275
Intangible assets		11,148			11,148
Operating lease right-of-use asset		381			403
Total assets	$	51,062		$	57,422

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable	$	1,939		$	2,095
Accrued expenses and other current liabilities		3,093			2,724
Total current liabilities		5,032			4,819
Operating lease liability - long-term, net of current portion		308			335
Warrant liability - long-term		38			77
Total liabilities		5,378			5,231
Commitments and contingencies (Note 6)
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding		—			—
Common stock, $0.001 par value; 100,000,000 shares authorized; 29,600,323 and 28,627,827 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively		30			29
Additional paid-in capital		155,396			153,985
Accumulated other comprehensive income		8			12
Accumulated deficit		(109,750	)		(101,835	)
Total stockholders’ equity		45,684			52,191
Total liabilities and stockholders’ equity	$	51,062		$	57,422

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Moleculin Biotech, Inc.

Condensed Consolidated Statements of Operations and Comprehensive Loss

(in thousands, except share and per share data)

(Unaudited)

	Three Months Ended March 31,
	2023			2022
Revenues	$	—		$	—

Operating expenses:
Research and development		5,687			4,620
General and administrative		2,637			2,422
Depreciation and amortization		30			32
Total operating expenses		8,354			7,074
Loss from operations		(8,354	)		(7,074	)
Other income:
Gain from change in fair value of warrant liability		39			160
Other income, net		8			5
Interest income, net		392			42
Net loss	$	(7,915	)	$	(6,867	)

Net loss per common share - basic and diluted	$	(0.28	)	$	(0.24	)
Weighted average common shares outstanding, basic and diluted		28,749,974			28,578,338

Net Loss	$	(7,915	)	$	(6,867	)
Other comprehensive loss:
Foreign currency translation		(4	)		12
Comprehensive loss	$	(7,919	)	$	(6,855	)

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Moleculin Biotech, Inc.

Condensed Consolidated Statements of Cash Flows

(in thousands)

(Unaudited)

	*Three Months Ended March 31,*
	*2023*			*2022*
Cash flows from operating activities:
Net loss	$	(7,915	)	$	(6,867	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		30			32
Stock-based compensation		499			527
License rights expense settled in stock		772			—
Change in fair value of warrant liability		(39	)		(160	)
Operating lease, net		110			90
Changes in operating assets and liabilities:
Prepaid expenses and other current assets		427			438
Accounts payable		(156	)		860
Accrued expenses and other current liabilities		255			275
Net cash used in operating activities		(6,017	)		(4,805	)
Cash flows from investing activities:
Purchase of fixed assets		—			(6	)
Net cash used in investing activities		—			(6	)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs		141			—
Net cash provided by financing activities		141			—
Effect of exchange rate changes on cash and cash equivalents		(4	)		12
Net decrease in cash and cash equivalents		(5,880	)		(4,799	)
Cash and cash equivalents, - beginning of period		43,145			70,903
Cash and cash equivalents, - end of period	$	37,265		$	66,104

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Moleculin Biotech, Inc.

Condensed Consolidated Statements of Stockholders’ Equity

(in thousands, except for shares)

(Unaudited)

	*Three Months Ended March 31, 2023*
		Common Stock									Accumulated
	Shares		Par Value Amount		Additional Paid-In Capital		Accumulated Deficit			Other Comprehensive Income (Loss)			Total Stockholders' Equity
Balance, December 31, 2022		28,627,827	$	29	$	153,985	$	(101,835	)	$	12		$	52,191
Issuance of common stock with equity purchase agreement		150,381		—		141		—			—			141
Common stock issued for license rights		822,115		1		771		—			—			772
Stock-based compensation		—		—		499		—			—			499
Net loss		—		—		—		(7,915	)		—			(7,915	)
Cumulative translation adjustment		—		—		—		—			(4	)		(4	)
Balance, March 31, 2023		29,600,323	$	30	$	155,396	$	(109,750	)	$	8		$	45,684

	*Three Months Ended March 31, 2022*
		Common Stock									Accumulated
	Shares		Par Value Amount		Additional Paid-In Capital		Accumulated Deficit			Other Comprehensive Income (Loss)		Total Stockholders' Equity
Balance, December 31, 2021		28,578,338	$	29	$	151,733	$	(72,810	)	$	41	$	78,993
Stock-based compensation		—		—		527		—			—		527
Net loss		—		—		—		(6,867	)		—		(6,867	)
Cumulative translation adjustment		—		—		—		—			12		12
Balance, March 31, 2022		28,578,338	$	29	$	152,260	$	(79,677	)	$	53	$	72,665

See accompanying notes to condensed consolidated financial statements.

Table of Contents

Moleculin Biotech, Inc.

Notes to the Condensed Consolidated Financial Statements

(Unaudited)

1. Nature of Business

The terms "MBI" or "the Company", "we", "our", and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in July 2015, with clinical programs for hard-to-treat cancers and viruses. The Company has three core technologies, each of which have had one or more drugs successfully complete a Phase 1 clinical trial, based substantially on discoveries made at and licensed from The University of Texas System on behalf of the MD Anderson Cancer Center (MD Anderson) in Houston, Texas. The Company has two wholly owned subsidiaries, Moleculin Australia Pty. Ltd., which was set up to perform certain preclinical development and Moleculin Amsterdam B.V., which acts as its legal representative for clinical trials in Europe. The Company utilizes its own internal resources and funds to conduct some of these trials and also has trials being conducted via physician-sponsored trials. The physician-sponsored trials utilize primarily external funds, such as grant funds, which are not presented in these financial statements. The Company does not have manufacturing facilities and all manufacturing activities are contracted out to third parties. Additionally, the Company does not have a sales organization. The Company’s overall strategy is to seek potential out-licensing or outsourcing opportunities with development/commercialization strategic partners who are better suited for the marketing, sales and distribution of its drugs, if approved.

2. Basis of presentation, principles of consolidation, and significant accounting policies and liquidity

Basis of Presentation – Condensed Consolidated Financial Information - The accompanying condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for financial information, and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements furnished reflect all normal adjustments, which are, in the opinion of management, necessary for a fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December 31, 2022 and for the year then ended, including the notes thereto contained in the Form 10-K filed with the SEC on March 22, 2023.

Significant Accounting Policies - The Company's significant accounting policies are described in Note 2, Basis of Presentation, principles of consolidation and significant accounting policies, to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to the significant accounting policies during the three months ended March 31, 2023.

Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.

Liquidity and Financial Condition - The Company is an early stage company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with early stage companies. Since inception, the Company has incurred losses and negative cash flows from operating activities. For the three months ended March 31, 2023 and 2022, the Company incurred net losses of $7.9 million and $6.9 million, respectively, and had net cash flows used in operating activities of $6.0 million and $4.8 million, respectively. At March 31, 2023, the Company had an accumulated deficit of $109.8 million and cash and cash equivalents of $37.3 million. The Company expects its cash on hand as of March 31, 2023 will be sufficient to fund the Company's operations beyond the near term. Such projections are subject to changes in the Company’s internally funded preclinical and clinical activities, including unplanned preclinical and clinical activity. The Company does not expect to experience positive cash flows from operating activities in the near future and anticipates incurring operating losses for the next few years as it supports the development of its core technologies to the point of generating revenue, most likely via out-licensing, and continues to invest in research and development for additional applications of the Company's core technologies and potentially increase its pipeline of drug candidates. If the Company needs to raise additional capital in order to continue to execute its business plan, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital could adversely impact the Company's ability to achieve its intended business objectives and meet its financial obligations as they become due and payable. In March 2022, the Company received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are the Company's officers or directors) and entities, and materials related to the development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. During the three months ended March 31, 2023 and 2022, the Company has expensed approximately $0.5 million and $0.1 million, respectively, in related general and administrative fees and expenses.

Table of Contents

Cash and Cash Equivalents - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation’s limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company’s management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held.

Fair Value of Financial Instruments - The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such.

The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:

Level 1 – Unadjusted quoted prices in active markets of identical assets or liabilities.

Level 2 – Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Level 3 – Unobservable inputs for the asset or liability.

The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 3.

The following table provides the financial liabilities reported at fair value and measured on a recurring basis at March 31, 2023 and December 31, 2022 (table in thousands):

Description	*Fair Value*		*Level 1*		*Level 2*		*Level 3*
Fair value of warrant liability as of March 31, 2023:	$	38	$	—	$	—	$	38
Fair value of warrant liability as of December 31, 2022:	$	77	$	—	$	—	$	77

The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of the first quarter and then is adjusted for changes in fair value that occurred during the first quarter. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Three Months Ended March 31, 2023	*Warrant Liability Long-Term*
Balance, December 31, 2022	$	77
Change in fair value - net		(39	)
Balance, March 31, 2023	$	38

Loss Per Common Share - Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. For the three months ended March 31, 2023 and 2022, approximately 6.2 million and 4.8 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect.

Subsequent Events - The Company’s management reviewed all material events through the date of these unaudited condensed consolidated financial statements. See Note 7 - Subsequent Events.

Recent Accounting Pronouncements - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.

Table of Contents

3. Warrants

Liability Classified Warrants

The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants. Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Only the volatility of the Company's own stock is used in the Black-Scholes option pricing model.

The assumptions used in determining the fair value of the Company's outstanding liability classified warrants are as follows:

	*March 31, 2023*	*December 31, 2022*
Risk-free interest rate	4.0% to 4.9%	4.2% to 4.8%
Volatility	58.4% to 67.6%	63.1% to 76.3%
Expected life (years)	0.1 to 2.4	0.1 to 2.6
Dividend yield	—%	—%

A summary of the Company's liability classified warrant activity during the three months ended March 31, 2023 and related information follows:

	*Number of Shares*			*Range of Warrant Exercise*				*Weighted Average*		*Weighted Average Remaining Contractual*
	*Under Warrant*			*Price per Share*				*Exercise Price*		*Life (Years)*
Balance at January 1, 2023		2,656,296		$	6.30	$	16.80	$	9.49		1.7
Expired warrants		(21,450	)	$	16.80	$	16.80	$	16.80		—
Balance at March 31, 2023		2,634,846		$	6.30	$	16.80	$	9.43		1.4
Exercisable at March 31, 2023		2,634,846		$	6.30	$	16.80	$	9.43		1.4

For a summary of the changes in fair value associated with the Company's warrant liability for the three months ended March 31, 2023, see Note 2 - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Financial Instruments.

Equity Classified Warrants

At March 31, 2023, the Company had 646,501 equity classified warrants outstanding and 404,434 warrants were exercisable. At December 31, 2022, the Company had 646,501 equity classified warrants outstanding and 400,859 warrants were exercisable.

The Company recorded stock compensation expense for the non-employee consulting agreements of $46,000 and $83,000 for the three months ended March 31, 2023 and 2022, respectively. At March 31, 2023, there was $391,000 of unrecognized stock compensation expense related to the Company's equity classified warrants.

Table of Contents

4. Equity

Lincoln Park Equity Line

During the three months ended March 31, 2023, pursuant to the 2021 Lincoln Park purchase agreement, the Company issued to Lincoln Park 150,381 shares of common stock for gross proceeds of $0.1 million and in April 2023, the Company issued an additional 75,187 shares of common stock, resulting in gross proceeds of $0.1 million. The 2021 Lincoln Park Agreement, which has $19.8 million available, terminates in June 2024.

Other Components of Equity

In March 2023, the Company and WPD agreed to terminate the WPD Agreement. Pursuant to the termination, the Company agreed to pay WPD (or its designees) $700,000 in cash and shares of its common stock valued at $800,000. In March 2023, the Company issued 822,115 shares of common stock to WPD (or its designee) to satisfy this commitment. See Note 6 - Commitments and Contingencies.

Stock-Based Compensation and Outstanding Awards

The 2015 Stock Plan provides for the grant of stock options, stock awards, stock unit awards, and stock appreciation rights to employees, non-employee directors and consultants. As of March 31, 2023, there were 752,296 shares remaining to be issued under the 2015 Stock Plan.

Stock-based compensation expense for the three months ended March 31, 2023 and 2022, respectively, is as follows (table in thousands):

	*Three Months Ended March 31,*
	*2023*		*2022*
General and administrative	$	369	$	361
Research and development		130		166
Total stock-based compensation expense	$	499	$	527

5. Income Taxes

Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse.

The Company does not expect to pay any significant federal, state, or foreign income taxes in 2023 as a result of the losses recorded during the three months ended March 31, 2023 and the additional losses expected for the remainder of 2023 and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As a result, as of March 31, 2023 and December 31, 2022 the Company maintained a full valuation allowance for all deferred tax assets.

The Company recorded no income tax provision for the three months ended March 31, 2023 and 2022, respectively. The effective tax rate for the three months ended March 31, 2023 and 2022 is nil. The income tax rates vary from the federal and state statutory rates primarily due to the change in fair value of the stock warrants, Internal Revenue Code Section 162(m) limitations and ISO activity, as well as the valuation allowances on the Company’s deferred tax assets. The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.

Table of Contents

6. Commitments and Contingencies

In addition to the commitments and contingencies described elsewhere in these notes, see below for a discussion of the Company's commitments and contingencies as of March 31, 2023.

Lease Obligations Payable

The following summarizes quantitative information about the Company's operating leases for the three months ended March 31, 2023 and 2022, respectively (table in thousands):

	*Three Months Ended March 31,*
	*2023*		*2022*
Lease cost:
Operating lease cost	$	33	$	29
Variable lease cost		7		7
Total	$	40	$	36

In June 2022, the Company extended the lab lease until September 30, 2027, with no further right or option to renew. The Company recorded approximately $12,000 and $10,000 in sublease income from a related party for the three months ended March 31, 2023 and 2022, respectively. Sublease income is recorded as other income, net on the Company's condensed consolidated statement of operations and comprehensive loss. Operating cash flows from operating leases was $38,000 and $35,000 for the three months ended March 31, 2023 and 2022, respectively.

Licenses

MD Anderson - Total expenses related to the Company's license agreements with MD Anderson were $64,000 and $76,000 for the three months ended March 31, 2023 and 2022, respectively.

HPI - The Company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expenses of $59,000 for each of the three months ended March 31, 2023 and 2022

Sponsored Research Agreements - The Company has a sponsored research agreement with MD Anderson expiring December 31, 2024. In April 2023, the Company entered into an amendment to the Sponsored Research Agreement with MD Anderson for total payment of $0.7 million to support the continuation of the project. In addition, the Company also has Sponsored Research Agreements with other universities, one in the US and one in Europe. The expenses recognized under the agreements were $155,000 and $187,000 for the three months ended March 31, 2023 and 2022, respectively.

License Terminations

Since February 2019, the Company was party to a sublicense agreement with WPD Pharmaceuticals (WPD), pursuant to which it sublicensed to WPD certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio (as amended, the “WPD Agreement”). WPD is affiliated with Dr. Waldemar Priebe, the Company's founder. In March 2023, the Company and WPD agreed to terminate the WPD Agreement and agreed to pay WPD (or its designee) $700,000 in cash and shares of its common stock valued at $800,000. In March 2023, the Company issued 822,115 shares of common stock to WPD's designee to satisfy this commitment. With the termination of the WPD Agreement, the Company now has acquired the rights in certain territories previously sub-licensed to WPD to all of its licensed intellectual property, other than the rights related to non-human animals. Additionally, the Company acquired the in-process research and development that WPD has created during the term of the agreement.

In February 2022, the Company and Exploration Invest Pte Ltd. (Exploration) entered into a license termination agreement pursuant to which the Company agreed to pay Exploration $400,000 to terminate certain License Agreements and extend confidentiality requirements until the 10-year anniversary of the license termination agreement. Total expenses, reflected in research and development expenses, related to the Company's license terminations were $1.5 million and $0.4 million for the three months ended March 31, 2023 and 2022, respectively.

7. Subsequent Events

In addition to the subsequent events discussed elsewhere in these notes, see below for a discussion of subsequent events occurring after March 31, 2023.

On May 5, 2023, the Company received a letter from NASDAQ notifying the Company that for the last 30 consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The deficiency letter does not result in the immediate delisting of the Company's common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 1, 2023, to regain compliance with the Bid Price Rule. If, at any time before November 1, 2023, the bid price for the Company's common stock closes at $1.00 or more for a minimum of 10 consecutive business days, the Nasdaq Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(G). If the Company is not in compliance with the Bid Price Rule by November 1, 2023, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split. If the Company does not regain compliance with the Bid Price Rule by November 1, 2023, and is not eligible for an additional compliance period at that time, the Nasdaq Staff will provide written notification to the Company that its common stock may be delisted. The Company would then be entitled to appeal the Nasdaq Staff’s determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be no assurance that, if the Company does appeal a delisting determination by the Nasdaq Staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule.

Table of Contents

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This Form 10-Q, including the Management’s Discussion and Analysis of Financial Condition and Results of Operations, contains certain forward-looking statements. Historical results may not indicate future performance. Our forward-looking statements reflect our current views about future events, are based on assumptions and are subject to known and unknown risks and uncertainties that could cause actual results to differ materially from those contemplated by these statements.

Forward-looking statements include, but are not limited to, statements about:

	•	Our ability to continue our relationship with MD Anderson, including, but not limited to, our ability to maintain current licenses and license future intellectual property resulting from our sponsored research agreements with MD Anderson;
	•	The success or the lack thereof, including the ability to recruit subjects on a timely basis, for a variety of reasons, of our clinical trials through all phases of clinical development;
	•	Our ability to satisfy any requirements imposed by the US Food & Drug Administration (FDA) (or its foreign equivalents) as a condition of our clinical trials proceeding or beginning as planned;
	•	World-wide events including the war in Ukraine, the COVID-19 pandemic, and the general supply chain shortages effects on our clinical trials, clinical drug candidate supplies, preclinical activities and our ability to raise future financing;

•

Our ability to obtain additional funding to commence or continue our clinical trials, fund operations and develop our product candidates;

•

The need to obtain and retain regulatory approval of our drug candidates, both in the United States and in Europe, and in countries deemed necessary for future trials;

•

Our ability to complete our clinical trials in a timely fashion and within our expected budget and resources;

	•	Our ability to source our drug products at reasonable prices;
	•	Compliance with obligations under intellectual property licenses with third parties;

•

Any delays in regulatory review and approval of drug candidates in clinical development;

	•	Potential efficacy of our drug candidates;
	•	Our ability to commercialize our drug candidates;

•

Market acceptance of our drug candidates;

•

Competition from existing therapies or new therapies that may emerge;

•

Potential product liability claims;

•

Our dependency on third-party manufacturers to successfully, and timely, supply or manufacture our drug candidates for our preclinical work and our clinical trials;

•

Our ability to establish or maintain collaborations, licensing or other arrangements;

•

Our ability and third parties’ abilities to protect intellectual property rights;

•

Our ability to adequately support future growth; and

•

Our ability to attract and retain key personnel to manage our business effectively.

We undertake no obligation to publicly update or revise any forward-looking statements, including any changes that might result from any facts, events, or circumstances after the date hereof that may bear upon forward-looking statements. Furthermore, we cannot guarantee future results, events, levels of activity, performance, or achievements.

Our Business

We are a clinical stage pharmaceutical company with a growing pipeline, including Phase 2 clinical programs for hard-to-treat cancers and viruses. We have three core technologies, each of which have had one or more drugs successfully complete a Phase 1 clinical trial (subject to publishing final Clinical Study Report), based substantially on discoveries made at and licensed from MD Anderson Cancer Center (MD Anderson) in Houston, Texas. Three of our six drug candidates have shown human activity in clinical trials and are currently in Phase 1b/2 or Phase 2 clinical trials. Since our inception, our drugs have completed, are currently in, or have received approval to proceed in eleven clinical trials.

Our Core Technologies

Our core technologies consist of the following:

a) Annamycin or L-Annamycin is a “next generation” anthracycline designed to be different than currently approved anthracyclines, which are limited in utility because of cardiotoxicity risks and their susceptibility to multidrug resistance mechanisms. Annamycin was designed to avoid multidrug resistance and has shown no cardiotoxicity¹ in subjects treated in clinical trials to date. Furthermore, we have demonstrated safe dosing beyond the dose limitations imposed by regulatory authorities upon currently prescribed anthracyclines due to their inherent cardiotoxicity;

b) our WP1066 Portfolio, which includes WP1066 and WP1220, two of several Immune/Transcription Modulators in the portfolio designed to inhibit p-STAT3 (phosphorylated signal transducer and activator of transcription 3) among other transcription factors associated with tumor activity, while also stimulating a natural immune response to tumors by inhibiting the errant activity of Regulatory T-Cells (TRegs); and

c) our WP1122 Portfolio, which contains compounds (including WP1122, WP1096, and WP1097) designed to exploit the potential uses of inhibitors of glycolysis such as 2-deoxy-D-glucose (2-DG), which we believe may provide an opportunity to cut off the fuel supply of tumors by taking advantage of their high level of dependence on glucose in comparison to healthy cells, as well as viruses that depend upon glycolysis and glycosylation to infect and replicate.

¹ In discussions of “no cardiotoxicity” of Annamycin, management’s beliefs are based on an expert’s opinion based their review of certain clinical trial subject data including LVEF, ECHO strain analyses, and cardiac biomarkers – troponin’s I & T

Table of Contents

Our Focus

We are focused on internally funded development of:

1) Annamycin for the treatment of Soft Tissue Sarcoma metastasized to the lungs (STS lung metastases or STS lung mets)

2) Annamycin in combination with Cytarabine (also known as Ara-C, the combination with Annamycin of which is referred to as AnnAraC) for the treatment of Relapsed or Refractory Acute Myeloid Leukemia (R/R AML or AML).

3) A better formulation for delivery of WP1066 to further support current and possibly future externally funded oncology clinical trials.

We have also recently established a Recommended Phase 2 Dose (RP2D) for WP1122 to potentially enable future externally funded oncology and virology trials. Beyond this, we support development of our core technologies through several externally funded clinical trials with the potential for others in the near-term.

Our Clinical Trials

In the US and Europe, we or independent investigators have approval to begin, are currently conducting or have completed eleven internally or externally funded clinical trials for four of our drug candidates – Annamycin, WP1066, WP1220, and WP1122 since inception. All clinical trials are or were in the Phase 1 or 2 stage. During 2021, we had four active clinical trials evaluating either Annamycin or WP1066 in the US and Europe. This increased to six active or recently completed trials in 2022 involving Annamycin, WP1066, and WP1122. In 2021 and 2022, there were five “right-to-try” (or their foreign equivalent) uses of Annamycin and WP1066. Three of the six clinical trials active in 2022 are internally funded trials of Annamycin and one is an internally funded Phase 1 clinical trial for WP1122 establishing an RP2D.

Moving into 2023, we are actively recruiting in three clinical trials in a Phase 1b or Phase 2 stage and have recently concluded one trial. These three currently active clinical trials are open label so we expect to be able to periodically announce human activity that is being demonstrated in these trials during 2023. In February 2023, the externally funded Phase 1 clinical trial with WP1066 for the treatment of pediatric brain tumors concluded. We expect up to three externally funded Phase 1b/2 clinical trials for WP1066 in the treatment of GBM and other brain tumors in 2023.

During 2022, we or independent investigators filed applications, began recruiting or are currently recruiting for six internally or externally funded clinical trials in the US and Europe.

	•	Annamycin - A clinical trial application (CTA) in Poland for a Phase 1b/2 trial of Annamycin in combination with Cytarabine or AnnAraC for the treatment of AML (MB-106) was allowed in 2022. This trial was later approved to expand into Italy in 2022 and dosing subjects began there in March 2023. With preclinical data in mice demonstrating a 68% improvement in activity in AML with AnnAraC over Annamycin alone and having concluded our single agent trials of Annamycin in AML showing 80% activity in the highest dosing cohort we are now focusing our efforts in AML exclusively on this combination trial.
	•	Annamycin - We are currently recruiting a Phase 2 clinical trial using Annamycin for the treatment of STS lung mets (MB-107). This multicenter trial is being conducted in the US, with the Phase 2 portion expected to recruit 25 subjects.
	•	Annamycin - An investigator sponsored trial (externally funded) was initiated in Poland in 2022 to study an alternative dosing regimen for Annamycin in the treatment of STS lung mets. This trial began administering drug to subjects in late 2022.
	•	WP1066 - In 2022, an investigational new drug (IND) application we filed in the US for a Phase 1 clinical trial studying WP1066 for treating glioblastoma multiforme (GBM) in adults went into effect. Consistent with our strategy of leveraging external funding for many of our clinical trials, we intend to capitalize on external funding opportunities for investigator-initiated clinical trials in adult cancer patients in 2023. We supplied drug product to an externally funded pediatric brain tumor trial with WP1066 up to its conclusion in February 2023.
	•	WP1122 - Our Phase 1a clinical trial of WP1122 in the United Kingdom for the treatment of COVID-19 (MB-301) began recruiting in 2022, and we completed the trial in late 2022, establishing an RP2D. We are in the process of completing this trial - locking the database and finalizing a clinical study report (CSR). This RP2D will possibly aid in future externally funded trials for the treatment of certain viruses and cancers as we look for investigator led studies.
	•	WP1122 - In 2022, we filed an IND with the FDA that then went into effect, allowing us to proceed with a clinical trial using WP1122 for the treatment of GBM. This may lead to an investigator-initiated trial (IIT) in oncology. Additionally, an investigator independently filed a CTA in Brazil in 2022 to study WP1122 for the treatment of moderate to severe COVID-19. Based on current COVID-19 epidemiology, we do not expect this externally funded trial to be conducted.

Additionally, we are in discussions with research institutions in the US, Asia, and South America regarding possible externally funded trials or programs involving WP1066 and WP1122.

Table of Contents

Recent Business Developments

Below are recent business developments.

Annamycin

MB-106 Annamycin in Combination with Cytarabine for the Treatment of AML

On May 2, 2023, we announced successful completion of the first cohort in our Phase 1b portion of our Phase 1b/2 clinical trial using Annamycin in combination with Cytarabine for the treatment of AML (MB-106). In this cohort three subjects were treated, all of whom are believed to be relapsed from multiple prior therapies. Annamycin was dosed at 190 mg/m², along with Cytarabine at 2.0 g/m2/day for 5 days (total dose of 10g/m²), consistent with the familiar 7+3 regimen. We, at the recommendation of the safety review committee, deemed the first cohort dose as safe and opened the second cohort with the Annamycin dose being increased to 230 mg/m².

The median of prior therapies for these three subjects were 5 (2 to 7). One of the subjects, who was 78 years of age at the time of the study initiation with 2 prior multi-year therapies, was preliminary recorded as a complete response or CR per the protocol and it was confirmed that the CR was durable after four weeks. The other two subjects were shown to have disease progression. Subjects have already been identified as potential candidates for the second cohort which is now recruiting.

MB-107 Annamycin Monotherapy for the Treatment of STS Lung Mets

In our MB-107 clinical trial treating STS lung mets with Annamycin as monotherapy, thirteen subjects have been recruited to date for this Phase 2 trial and treated at the confirmed Recommended Phase 2 Dose (RP2D) of 330 mg/m². Two subjects left the study due to infusion related reactions to the initial dose of the study drug. Ten subjects have received two cycles and had their end of cycle 2 scan. One subject has received their initial dose and has not received cycle 2 scans. To date, six or 60% have exhibited stable disease (SD) after receiving two cycles. Three are continuing with the study drug. One such subject has received six cycles after their end of cycle 4 scan exhibited stable disease. For the three subjects with SD not continuing with the study drug, they are being followed for progression free survival and, for all subjects, overall survival is being monitored. This data is preliminary and subject to change.

Other Trial and Publications

The Phase 1b/2 investigator sponsored trial (externally funded) was initiated in Poland in 2022 to study an alternative dosing regimen for Annamycin in the treatment of STS lung mets. This trial has enrolled and treated two subjects with two cycles in the first cohort of the Phase 1b portion of the study. There will be three subjects per cohort with the first cohort treating subjects with 35 mg/m² of Annamycin per week (3 weeks on and 1 week off per cycle). After two cycles the subjects will receive their end of cycle 2 scan. At the end of two cycles both subjects treated to date demonstrated progressive disease. This is early in where Annamycin is being dosed weekly. Preclinical data demonstrated a benefit to weekly dosing of Annamycin versus traditional chemotherapy dosing of every three weeks.

We announced in April the presentation of positive pharmacokinetics and tissue-organ distribution data demonstrating high antitumor activity of Annamycin in preclinical cancer models, which sponsored research data was presented at the American Association for Cancer Research (AACR) Annual Meeting 2023. In this research, Annamycin demonstrated increased penetration and accumulation in the liver, which correlated with high antitumor activity in HEPA 1-6 hepatocellular carcinoma and CT26 colon cancer liver metastasis models. This poster was presented at the AACR Annual Meeting 2023, which took place April 14-19, 2023, at the Orange County Convention Center in Orlando, FL. The poster titled, Exploration of Annamycin Organotropism to Target Primary and Metastatic Liver Cancers was presented by Rafal Zielinski, Ph.D., Department of Experimental Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center as part of the Experimental and Molecular Therapeutic Session: “Novel Antitumor Agents, PI3K/AKT Inhibitors, Proteasome Inhibitors, and Topoisomerases.” The poster outlined results from the analysis of the pharmacokinetics of two formulations of Annamycin, liposome formulated drug product (L-ANN) and free Annamycin (ANN), in the liver in comparison with doxorubicin (DOX) and to determine its tumoricidal potential in a hepatocellular carcinoma (HCC) model in situ and in experimental models of liver metastasis.

Table of Contents

WP1066

We continue discussions with two US academic institutions and another foreign academic institution for externally funded trials for the use of WP1066 for the treatment of glioblastomas and/or pediatric brain tumors. We expect to finalize agreements in the second quarter with at least one of these institutions and begin trials in the second half of 2023.

WP1122

With the data generated from the MB-301 clinical trial setting an RP2D for WP1122 and additional sponsored research, we continue to explore avenues of external funding for further development of this portfolio.

Corporate

Licensing

WPD Licensing Agreement

Since February 2019, we were party to a sublicense agreement with WPD Pharmaceuticals (WPD), pursuant to which we sublicensed to WPD certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio (as amended, the “WPD Agreement”). WPD is affiliated with Dr. Waldemar Priebe, our founder. In March 2023, we and WPD agreed to terminate the WPD Agreement. Pursuant to the termination, we agreed to pay WPD (or its designee) $700,000 in cash and shares of our common stock valued at $800,000. In March 2023, we issued 822,115 shares of common stock to WPD's designee to satisfy this commitment. With the termination of the WPD Agreement, we now have acquired the rights in certain territories previously sub-licensed to WPD to all of our licensed intellectual property, other than the rights related to non-human animals. Additionally, we acquired the in-process research and development that WPD has created during the term of the agreement. As part of this Agreement, WPD assigned their rights and duties to us for the Phase 1b/2 investigator sponsored trial (externally funded) initiated in Poland in 2022 to study an alternative dosing regimen for Annamycin in the treatment of STS lung mets. The approximate value of the grant supporting this investigator sponsored trial is $1.5 million.

Table of Contents

Results of Operations

The following table sets forth, for the periods indicated, data derived from our statement of operations (table in thousands) and such changes in the periods are discussed below in approximate amounts:

Moleculin Biotech, Inc.

Condensed Consolidated Statements of Operations

(Unaudited)

	Three Months Ended March 31,
	2023			2022
Revenues	$	—		$	—

Operating expenses:
Research and development		5,687			4,620
General and administrative		2,637			2,422
Depreciation and amortization		30			32
Total operating expenses		8,354			7,074
Loss from operations		(8,354	)		(7,074	)
Other income:
Gain from change in fair value of warrant liability		39			160
Other income, net		8			5
Interest income, net		392			42
Net loss	$	(7,915	)	$	(6,867	)

Three Months Ended March 31, 2023 Compared to Three Months Ended March 31, 2022

Research and Development Expense. Research and development (R&D) expense was $5.7 million and $4.6 million for the three months ended March 31, 2023 and 2022, respectively. The increase of $1.1 million is mainly related to the WPD sublicense termination.

General and Administrative Expense. General and administrative expense was $2.6 million and $2.4 million for the three months ended March 31, 2023 and 2022, respectively. The increase of $0.2 million is mainly related to an increase in regulatory and legal services, and consulting & advisory fees.

Gain from Change in Fair Value of Warrant Liability. We recorded a net gain of $0.04 million in the first quarter of 2023 as compared to a net gain of $0.2 million in the first quarter of 2022, for the change in fair value on revaluation of our warrant liability associated with our warrants issued in conjunction with our stock offerings. We are required to revalue our liability-classified warrants at the time of each warrant exercise, if applicable, and at the end of each reporting period and reflect in the statement of operations a gain or loss from the change in fair value of the warrant in the period in which the change occurred. We calculated the fair value of the warrants outstanding using the Black-Scholes model. A gain results principally from a decline in our share price during the period and a loss results principally from an increase in our share price.

Interest income, net. Interest income, net increased by approximately $0.4 million for the comparable quarterly periods due to rising interest rates during the past year.

Table of Contents

Liquidity and Capital Resources

The following table sets forth our primary sources and uses of cash for the period indicated (table in thousands):

	Three Months Ended March 31,
	2023			2022
Net cash used in operating activities	$	(6,017	)	$	(4,805	)
Net cash used in investing activities		—			(6	)
Net cash provided by financing activities		141			—
Effect of exchange rate changes on cash and cash equivalents		(4	)		12
Net decrease in cash and cash equivalents	$	(5,880	)	$	(4,799	)

As of March 31, 2023, there was $0.3 million of cash on hand in a bank account in Australia and we know of no related limitations impacting our liquidity in Australia.

Cash used in operating activities

Cash used in operations was $6.0 million for the three months ended March 31, 2023. This $1.2 million increase over the prior year period of $4.8 million was primarily due to payments for increased clinical trial activity, costs related to the WPD sublicense termination, and increased consulting, legal, and advisory fees. These are all a reflection of the ongoing clinical and pre-clinical activity and the associated increase in general and administrative support for our three core drug technologies.

Cash provided by financing activities

During the three months ended March 31, 2023, utilizing the Lincoln Park Equity Line, we issued 150,381 shares of common stock (including commitment shares), at an average price of $0.94 per share, resulting in gross proceeds of $0.1 million. Subsequent to March 31, 2023, we issued to Lincoln Park an additional 75,187 shares of common stock, (including commitment shares), at an average price of $0.93 per share, resulting in gross proceeds of $0.1 million.

We believe that our existing cash and cash equivalents as of March 31, 2023 will be sufficient to meet our projected operating requirements, which include a potential increase over our current R&D rate of expenditures, beyond the second quarter of 2024. Such projections are subject to changes in our internally funded preclinical and clinical activities, including unplanned preclinical and clinical activity and potential legal costs. We anticipate incurring operating losses for the next several years as we support the preclinical and clinical activities necessary to prepare our drug candidates for successful out licensing, including our efforts to expand our technologies. These factors raise uncertainties about our ability to fund operations in future years. If we need to raise additional capital in order to continue to execute our business plan, there is no assurance that additional financing will be available when needed or that we will be able to obtain financing on terms acceptable to us. A failure to raise sufficient capital could adversely impact our ability to achieve our intended business objectives and meet our financial obligations as they become due and payable.

In March 2022, we received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are our officers or directors) and entities, and materials related to the development of and statements regarding our drug candidate for the treatment of COVID-19. We have received, and expect to continue to receive, periodic further requests from the SEC staff with respect to this matter. We are not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that we have made, we believe in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to us states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. We cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. During the three months ended March 31, 2023 and 2022, we have expended approximately $0.5 million and $0.1 million, respectively, in related legal fees and expenses.

Critical Accounting Policies and Significant Judgments and Estimates

There have been no material changes to our critical accounting policies and use of estimates from those disclosed in our Form 10-K for the year ended December 31, 2022. For a discussion of our critical accounting policies and use of estimates, refer to Management’s Discussion and Analysis of Financial Condition and Results of Operations – Critical Accounting Policies and Significant Estimates in Part II, Item 7 of our Annual Report on Form 10-K for the year ended December 31, 2022.

Table of Contents

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISKS

Not applicable as we are a smaller reporting company.

ITEM 4. CONTROLS AND PROCEDURES

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures designed to ensure that material information required to be disclosed in our filings under the Securities Exchange Act of 1934, as amended, is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms and that material information is accumulated and communicated to our management, including our Chief Executive Officer (CEO), who is our principal executive officer, and Chief Financial Officer (CFO), who is our principal financial and accounting officer, as appropriate, to allow timely decisions regarding required disclosures. Our CEO and CFO have evaluated these disclosure controls and procedures as of the end of the period covered by this quarterly report on Form 10-Q and have determined that such disclosure controls and procedures were effective as of March 31, 2023.

Changes in Internal Control Over Financial Reporting

There was no change in our internal control over financial reporting (as defined in Rules 13a-15(f) and 15-d-15(f) under the Exchange Act) during the three months ended March 31, 2023 that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II – OTHER INFORMATION

ITEM 1. LEGAL PROCEEDINGS

None.

ITEM 1A. RISK FACTORS

For information regarding factors that could affect our results of operations, financial condition and liquidity, refer to the section entitled “Risk Factors” in Part I, Item 1A in our annual report on Form 10-K for the year ended December 31, 2022. Except as updated below, there have been no material changes from the risk factors previously disclosed in our annual report on Form 10-K for the year ended December 31, 2022.

If we fail to satisfy all applicable continued listing requirements of the Nasdaq Capital Market, including the $1.00 minimum closing bid price requirement, our common stock may be delisted from Nasdaq, which could have an adverse impact on the liquidity and market price of our common stock.

Our common stock is currently listed on the Nasdaq Capital Market under the symbol “MBRX.” In order to maintain that listing, we must satisfy minimum financial and other continued listing requirements and standards, including those regarding director independence and independent committee requirements, minimum stockholders’ equity, minimum bid price, and certain corporate governance requirements. There can be no assurances that we will be able to comply with the applicable listing standards.

On May 5, 2023, we received a notice from Nasdaq that we were not in compliance with Nasdaq’s Listing Rule 5550(a)(2), as the minimum bid price of our common stock had been below $1.00 per share for 30 consecutive business days. We have 180 days, or until November 1, 2023, to regain compliance with the minimum bid price requirement. To regain compliance, the minimum bid price of our common stock must meet or exceed $1.00 per share for a minimum of ten consecutive business days during this 180-calendar day grace period. While we may be able to qualify for additional time to attempt to regain compliance, there can be no assurance that we will qualify for additional time to regain compliance, or that we will regain compliance with or without such additional time. If we do not regain compliance within the allotted compliance period(s), including any extensions that may be granted by Nasdaq, Nasdaq will provide notice that our shares of common stock will be subject to delisting.

In the event that our common stock is delisted from Nasdaq and is not eligible for quotation or listing on another market or exchange, trading of our common stock could be conducted only in the over-the-counter market or on an electronic bulletin board established for unlisted securities such as the Pink Sheets or the OTC Bulletin Board. In such event, it could become more difficult to dispose of, or obtain accurate price quotations for, our common stock, and there would likely also be a reduction in our coverage by securities analysts and the news media, which could cause the price of our common stock to decline further. Also, it may be difficult for us to raise additional capital if we are not listed on a major exchange.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

In March 2023, the Company and WPD agreed to terminate the WPD Agreement. Pursuant to the termination, the Company agreed to pay WPD (or its designees) $700,000 in cash and shares of our common stock valued at $800,000. On March 22, 2023, the Company issued 822,115 shares of common stock to WPD (or its designee) to satisfy this commitment. The foregoing securities were issued pursuant to Section 4(a)(2) of the Securities Act.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURE

Not applicable.

ITEM 5. OTHER INFORMATION.

None.

Table of Contents

ITEM 6. EXHIBITS

Exhibit No.						Description

31.1*						Certification of Principal Executive Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

31.2*						Certification of Principal Financial Officer Pursuant to Section 302 of Sarbanes-Oxley Act of 2002

32.1*						Certification of Principal Executive Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

32.2*						Certification of Principal Accounting and Financial Officer Pursuant to Section 18 U.S.C. Section 1350, as Adopted Pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

101.INS*						Inline XBRL Instance Document (the Instance Document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document)

101.SCH*						Inline XBRL Taxonomy Extension Schema Document

101.CAL*						Inline XBRL Taxonomy Extension Calculation Linkbase Document

101.DEF*						Inline XBRL Taxonomy Extension Definition Linkbase Document

101.LAB*						Inline XBRL Taxonomy Extension Label Linkbase Document

101.PRE*						Inline XBRL Taxonomy Extension Presentation Linkbase Document

104						Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

* Filed herewith.

Table of Contents

SIGNATURES

Pursuant to the requirements of Section 13 or 15(d) of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	MOLECULIN BIOTECH, INC.

Date: May 10, 2023	By:	/s/ Walter V. Klemp
		Walter V. Klemp,
		Chief Executive Officer and Chairman (Principal Executive Officer)

Date: May 10, 2023	By:	/s/ Jonathan P. Foster
		Jonathan P. Foster,
		Executive Vice President & Chief Financial Officer (Principal Financial and Accounting Officer)

EX-31.1 2 ex_468529.htm EXHIBIT 31.1 ex_468529.htm

Exhibit 31.1

OFFICER’S CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Walter V. Klemp, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Moleculin Biotech, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant's other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant's disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant's ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 10, 2023

By: /s/ Walter V. Klemp
Walter V. Klemp
Chief Executive Officer
(Principal Executive Officer)

EX-31.2 3 ex_468530.htm EXHIBIT 31.2 ex_468530.htm

Exhibit 31.2

OFFICER’S CERTIFICATION PURSUANT TO

SECTION 302 OF THE SARBANES-OXLEY ACT OF 2002

I, Jonathan P. Foster, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Moleculin Biotech, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant's other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant's auditors and the audit committee of the registrant's board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant's internal control over financial reporting.

May 10, 2023

By: /s/ Jonathan P. Foster

Jonathan P. Foster

Executive Vice President and Chief Financial Officer

(Principal Financial Officer and Principal Accounting Officer)

EX-32.1 4 ex_468531.htm EXHIBIT 32.1 ex_468531.htm

Exhibit 32.1

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 of Moleculin Biotech, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Walter V. Klemp, Chief Executive Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and

•

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2023

By: /s/ Walter V. Klemp
Walter V. Klemp
Chief Executive Officer
(Principal Executive Officer)

A signed original of this written statement required by Section 906 has been provided to Moleculin Biotech, Inc. and will be retained by Moleculin Biotech, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

EX-32.2 5 ex_468532.htm EXHIBIT 32.2 ex_468532.htm

Exhibit 32.2

CERTIFICATION PURSUANT TO

18 U.S.C. SECTION 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report on Form 10-Q for the quarter ended March 31, 2023 of Moleculin Biotech, Inc. (the “Company”) as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Jonathan P. Foster, Chief Financial Officer of the Company, hereby certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

•

The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934 (15 U.S.C 78m or 78o(d)); and

•

The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 10, 2023

By: /s/ Jonathan P. Foster
Jonathan P. Foster
Executive Vice President and Chief Financial Officer
(Principal Financial Officer and Principal Accounting Officer)

EX-101.SCH 6 mbrx-20230331.xsd XBRL TAXONOMY EXTENSION SCHEMA 000 - Document - Document And Entity Information link:calculationLink link:definitionLink link:presentationLink 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) link:calculationLink link:definitionLink link:presentationLink 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) link:calculationLink link:definitionLink link:presentationLink 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:definitionLink link:presentationLink 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) link:calculationLink link:definitionLink link:presentationLink 005 - Statement - Condensed Consolidated Statement of Stockholders Equity (Unaudited) link:calculationLink link:definitionLink link:presentationLink 006 - Disclosure - Note 1 - Nature of Business link:calculationLink link:definitionLink link:presentationLink 007 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity link:calculationLink link:definitionLink link:presentationLink 008 - Disclosure - Note 3 - Warrants link:calculationLink link:definitionLink link:presentationLink 009 - Disclosure - Note 4 - Equity link:calculationLink link:definitionLink link:presentationLink 010 - Disclosure - Note 5 - Income Taxes link:calculationLink link:definitionLink link:presentationLink 011 - Disclosure - Note 6 - Commitments and Contingencies link:calculationLink link:definitionLink link:presentationLink 012 - Disclosure - Note 7 - Subsequent Events link:calculationLink link:definitionLink link:presentationLink 013 - Disclosure - Significant Accounting Policies (Policies) link:calculationLink link:definitionLink link:presentationLink 014 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables) link:calculationLink link:definitionLink link:presentationLink 015 - Disclosure - Note 3 - Warrants (Tables) link:calculationLink link:definitionLink link:presentationLink 016 - Disclosure - Note 4 - Equity (Tables) link:calculationLink link:definitionLink link:presentationLink 017 - Disclosure - Note 6 - Commitments and Contingencies (Tables) link:calculationLink link:definitionLink link:presentationLink 018 - Disclosure - Note 1 - Nature of Business (Details Textual) link:calculationLink link:definitionLink link:presentationLink 019 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 020 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) link:calculationLink link:definitionLink link:presentationLink 021 - Disclosure - Note 3 - Warrants (Details Textual) link:calculationLink link:definitionLink link:presentationLink 022 - Disclosure - Note 3 - Warrants - Assumptions Used (Details) link:calculationLink link:definitionLink link:presentationLink 023 - Disclosure - Note 3 - Warrants - Warrant Activity (Details) link:calculationLink link:definitionLink link:presentationLink 024 - Disclosure - Note 4 - Equity (Details Textual) link:calculationLink link:definitionLink link:presentationLink 025 - Disclosure - Note 4 - Equity - Stock based Compensation (Details) link:calculationLink link:definitionLink link:presentationLink 026 - Disclosure - Note 5 - Income Taxes (Details Textual) link:calculationLink link:definitionLink link:presentationLink 027 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) link:calculationLink link:definitionLink link:presentationLink 028 - Disclosure - Note 6 - Commitments and Contingencies - Lease Cost (Details) link:calculationLink link:definitionLink link:presentationLink 029 - Disclosure - Note 7 - Subsequent Events (Details Textual) link:calculationLink link:definitionLink link:presentationLink EX-101.CAL 7 mbrx-20230331_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 8 mbrx-20230331_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 9 mbrx-20230331_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Document And Entity Information Fair Value of Financial Instruments, Policy [Policy Text Block] Note To Financial Statement Details Textual Significant Accounting Policies Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity mbrx_LicenseAgreementsExpense License Agreements Expense The amount of expense for licensing agreements. Note 3 - Warrants Houston Pharmaceuticals, Inc [Member] Represents Houston Pharmaceuticals, Inc. Note 4 - Equity Note 6 - Commitments and Contingencies Subsequent Events, Policy [Policy Text Block] Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) Note 3 - Warrants - Assumptions Used (Details) Note 3 - Warrants - Warrant Activity (Details) Note 4 - Equity - Stock based Compensation (Details) Income Tax Disclosure [Text Block] Change in fair value of warrant liability Gain from change in fair value of warrant liability Note 6 - Commitments and Contingencies - Lease Cost (Details) Notes To Financial Statements Notes To Financial Statements [Abstract] us-gaap_ShareBasedCompensation Stock-based compensation us-gaap_LiabilitiesCurrent Total current liabilities Earnings Per Share, Policy [Policy Text Block] The 2015 Stock Plan [Member] Represents the 2015 stock plan. Exercisable (in shares) Class of Warrant or Right, Vested and Exercisable (in shares) Number of warrants or rights vested and exercisable. Revenues Exercisable, warrant exercise price (in dollars per share) Exercise price per share or per unit of warrants or rights vested and exercisable. Operating expenses: Balance, weighted average remaining contractual life (Year) The weighted average remaining contractual life of warrants or rights outstanding. mbrx_ClassOfWarrantOrRightCancelledDuringPeriod Expired warrants (in shares) The number of warrants or rights cancelled during period. Expired warrants (in dollars per share) Exercise price per share of warrants or rights cancelled during period. Foreign currency translation Liability Classified Warrants [Member] Represents liability classified warrants. Exercisable, weighted average remaining contractual life (Year) The weighted average remaining contractual life of warrants or rights vested and exercisable. Equity Classified Warrants [Member] Represents equity classified warrants. Fair value of warrant liability Depreciation and amortization Accumulated other comprehensive income us-gaap_AssetsCurrent Total current assets Equity [Text Block] Interest income, net Common stock, $0.001 par value; 100,000,000 shares authorized; 29,600,323 and 28,627,827 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively Measurement Frequency [Axis] Adjustments to reconcile net loss to net cash used in operating activities: Measurement Frequency [Domain] Fair Value, Recurring [Member] Common stock, shares authorized (in shares) Common stock, shares issued (in shares) Fair Value Measurements, Recurring and Nonrecurring [Table Text Block] Common stock, par or stated value per share ( (in dollars per share) us-gaap_AccruedLiabilitiesCurrent Accrued expenses and other current liabilities us-gaap_OperatingLeasePayments Operating Lease, Payments Statistical Measurement [Domain] Maximum [Member] Minimum [Member] Weighted Average [Member] Accounts payable Statistical Measurement [Axis] Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding Preferred stock, shares issued (in shares) us-gaap_PolicyTextBlockAbstract Accounting Policies Preferred stock, shares authorized (in shares) us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares) Preferred stock, par value (in dollars per share) Fair Value, Inputs, Level 3 [Member] us-gaap_PaymentsToAcquirePropertyPlantAndEquipment Purchase of fixed assets Fair Value Hierarchy and NAV [Domain] Fair Value, Inputs, Level 1 [Member] Fair Value, Inputs, Level 2 [Member] Fair Value Hierarchy and NAV [Axis] Current liabilities: us-gaap_Assets Total assets Sponsored Research [Member] Related to sponsored research. us-gaap_SubleaseIncome Sublease Income Cash flows from operating activities: License rights expense settled in stock The amount of common stock issued for license rights under license agreement. Statement [Line Items] us-gaap_NumberOfOperatingSegments Number of Operating Segments Liquidity and Financial Condition [Policy Text Block] Disclosure of accounting policy for liquidity and financial condition. Share-based Payment Arrangement, Expensed, Amount [Table Text Block] Tabular disclosure of allocation of amount expensed for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement. Additional paid-in capital AOCI Attributable to Parent [Member] Stockholders' equity Other income, net Award Type [Domain] Current assets: Net loss Net Income (Loss) Attributable to Parent Net loss Award Type [Axis] us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents Cash and cash equivalents, - beginning of period Cash and cash equivalents, - end of period us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect Net decrease in cash and cash equivalents us-gaap_NetCashProvidedByUsedInFinancingActivities Net cash provided by financing activities us-gaap_Liabilities Total liabilities Commitments and contingencies (Note 6) Sale of Stock [Axis] Sale of Stock [Domain] Effect of exchange rate changes on cash and cash equivalents us-gaap_OperatingIncomeLoss Loss from operations us-gaap_NetCashProvidedByUsedInOperatingActivities Net Cash Provided by (Used in) Operating Activities Net cash used in operating activities Other income: us-gaap_NetCashProvidedByUsedInInvestingActivities Net cash used in investing activities Prepaid expenses and other current assets Counterparty Name [Axis] Counterparty Name [Domain] Commitments and Contingencies Disclosure [Text Block] Furniture and equipment, net mbrx_SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount Amount of cost not yet recognized for nonvested award under share-based payment arrangement. Cash flows from investing activities: Retained Earnings [Member] Proceeds from sale of common stock, net of issuance costs Proceeds from Issuance of Common Stock us-gaap_RelatedPartyTransactionAmountsOfTransaction Related Party Transaction, Amounts of Transaction Additional Paid-in Capital [Member] Common Stock [Member] us-gaap_IncomeTaxExpenseBenefit Income Tax Expense (Benefit) us-gaap_IncreaseDecreaseInAccruedLiabilities Accrued expenses and other current liabilities Equity Components [Axis] Equity Component [Domain] us-gaap_IncreaseDecreaseInAccountsPayable Accounts payable us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1 Balance, warrant exercise price (in dollars per share) Balance, warrant exercise price (in dollars per share) Class of Warrant or Right [Axis] Class of Warrant or Right [Domain] us-gaap_ClassOfWarrantOrRightOutstanding Class of Warrant or Right, Outstanding (in shares) Balance (in shares) Balance (in shares) us-gaap_OperatingExpenses Total operating expenses General and administrative Other comprehensive loss: Cash and cash equivalents Cash and Cash Equivalents, at Carrying Value Share-Based Payment Arrangement, Expense Share-Based Payment Arrangement, Expense Change in fair value - net us-gaap_LegalFees Legal Fees Cash and Cash Equivalents, Policy [Policy Text Block] Document Quarterly Report Amendment Flag Entity Incorporation, State or Country Code General and Administrative Expense [Member] Accounting Policies [Abstract] Significant Accounting Policies [Text Block] us-gaap_ComprehensiveIncomeNetOfTax Comprehensive loss Document Transition Report City Area Code Basis of Accounting, Policy [Policy Text Block] Use of Estimates, Policy [Policy Text Block] New Accounting Pronouncements, Policy [Policy Text Block] Entity Interactive Data Current us-gaap_SharesOutstanding Balance (in shares) Balance (in shares) Security Exchange Name Common stock, shares outstanding (in shares) Preferred stock, shares outstanding (in shares) Title of 12(b) Security Current Fiscal Year End Date Variable lease cost us-gaap_LeaseCost Total Research and Development Expense [Member] Document Fiscal Period Focus Operating lease cost Document Fiscal Year Focus Consolidation, Policy [Policy Text Block] Lease, Cost [Table Text Block] Document Period End Date Income Statement Location [Axis] Income Statement Location [Domain] us-gaap_IncreaseDecreaseInPrepaidExpense Prepaid expenses and other current assets Entity File Number Entity Emerging Growth Company Document Type Interim Period, Costs Not Allocable [Domain] Entity Small Business Entity Shell Company Document Information [Line Items] Document Information [Table] Nature of Expense [Axis] us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue Balance Balance Entity Filer Category Entity Current Reporting Status us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) Stock-based compensation Entity Tax Identification Number Entity Central Index Key Entity Registrant Name Liability Class [Axis] Fair Value by Liability Class [Domain] Entity [Domain] Legal Entity [Axis] Statement [Table] Entity Address, Address Line One Statement of Financial Position [Abstract] Weighted average common shares outstanding, basic and diluted (in shares) Warrant Liability Long Term [Member] Information pertaining the long term warrant liability. Entity Address, City or Town us-gaap_EffectiveIncomeTaxRateContinuingOperations Effective Income Tax Rate Reconciliation, Percent Entity Address, Postal Zip Code Net loss per common share - basic and diluted (in dollars per share) Entity Address, State or Province EX-101.PRE 10 mbrx-20230331_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 11 moleculinnewlogoresized.jpg begin 644 moleculinnewlogoresized.jpg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end XML 12 R1.htm IDEA: XBRL DOCUMENT

Document And Entity Information - shares	3 Months Ended
Document And Entity Information - shares	Mar. 31, 2023	May 01, 2023
Document Information [Line Items]
Entity Central Index Key	0001659617
Entity Registrant Name	Moleculin Biotech, Inc.
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2023
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Mar. 31, 2023
Document Transition Report	false
Entity File Number	001-37758
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	47-4671997
Entity Address, Address Line One	5300 Memorial Drive, Suite 950
Entity Address, City or Town	Houston
Entity Address, State or Province	TX
Entity Address, Postal Zip Code	77007
City Area Code	713
Local Phone Number	300-5160
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Small Business	true
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	false
Entity Shell Company	false
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	MBRX
Security Exchange Name	NASDAQ
Entity Common Stock, Shares Outstanding		29,675,510

XML 13 R2.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) - USD ($) $ in Thousands	Mar. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 37,265	$ 43,145
Prepaid expenses and other current assets	2,024	2,451
Total current assets	39,289	45,596
Furniture and equipment, net	244	275
Intangible assets	11,148	11,148
Operating lease right-of-use asset	381	403
Total assets	51,062	57,422
Current liabilities:
Accounts payable	1,939	2,095
Accrued expenses and other current liabilities	3,093	2,724
Total current liabilities	5,032	4,819
Operating lease liability - long-term, net of current portion	308	335
Warrant liability - long-term	38	77
Total liabilities	5,378	5,231
Commitments and contingencies (Note 6)
Stockholders' equity
Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding	0	0
Common stock, $0.001 par value; 100,000,000 shares authorized; 29,600,323 and 28,627,827 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively	30	29
Additional paid-in capital	155,396	153,985
Accumulated other comprehensive income	8	12
Accumulated deficit	(109,750)	(101,835)
Total stockholders’ equity	45,684	52,191
Total liabilities and stockholders’ equity	$ 51,062	$ 57,422

XML 14 R3.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) - $ / shares	Mar. 31, 2023	Dec. 31, 2022
Preferred stock, par value (in dollars per share)	$ 0.001	$ 0.001
Preferred stock, shares authorized (in shares)	5,000,000	5,000,000
Preferred stock, shares issued (in shares)	0	0
Preferred stock, shares outstanding (in shares)	0	0
Common stock, par or stated value per share ( (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares authorized (in shares)	100,000,000	100,000,000
Common stock, shares issued (in shares)	29,600,323	28,627,827
Common stock, shares outstanding (in shares)	29,600,323	28,627,827

XML 15 R4.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Revenues	$ 0	$ 0
Operating expenses:
Research and development	5,687	4,620
General and administrative	2,637	2,422
Depreciation and amortization	30	32
Total operating expenses	8,354	7,074
Loss from operations	(8,354)	(7,074)
Other income:
Gain from change in fair value of warrant liability	39	160
Other income, net	8	5
Interest income, net	392	42
Net loss	$ (7,915)	$ (6,867)
Net loss per common share - basic and diluted (in dollars per share)	$ (0.28)	$ (0.24)
Weighted average common shares outstanding, basic and diluted (in shares)	28,749,974	28,578,338
Net loss	$ (7,915)	$ (6,867)
Other comprehensive loss:
Foreign currency translation	(4)	12
Comprehensive loss	$ (7,919)	$ (6,855)

XML 16 R5.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Cash flows from operating activities:
Net loss	$ (7,915)	$ (6,867)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization	30	32
Stock-based compensation	499	527
License rights expense settled in stock	772	0
Change in fair value of warrant liability	(39)	(160)
Operating lease, net	110	90
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	427	438
Accounts payable	(156)	860
Accrued expenses and other current liabilities	255	275
Net cash used in operating activities	(6,017)	(4,805)
Cash flows from investing activities:
Purchase of fixed assets	0	(6)
Net cash used in investing activities	0	(6)
Cash flows from financing activities:
Proceeds from sale of common stock, net of issuance costs	141	0
Net cash provided by financing activities	141	0
Effect of exchange rate changes on cash and cash equivalents	(4)	12
Net decrease in cash and cash equivalents	(5,880)	(4,799)
Cash and cash equivalents, - beginning of period	43,145	70,903
Cash and cash equivalents, - end of period	$ 37,265	$ 66,104

XML 17 R6.htm IDEA: XBRL DOCUMENT

Condensed Consolidated Statement of Stockholders Equity (Unaudited) - USD ($) $ in Thousands	Common Stock [Member]	Additional Paid-in Capital [Member]	Retained Earnings [Member]	AOCI Attributable to Parent [Member]	Total
Balance (in shares) at Dec. 31, 2021	28,578,338
Balance at Dec. 31, 2021	$ 29	$ 151,733	$ (72,810)	$ 41	$ 78,993
Stock-based compensation	0	527	0	0	527
Net loss	0	0	(6,867)	0	(6,867)
Foreign currency translation	$ 0	0	0	12	12
Balance (in shares) at Mar. 31, 2022	28,578,338
Balance at Mar. 31, 2022	$ 29	152,260	(79,677)	53	72,665
Balance (in shares) at Dec. 31, 2022	28,627,827
Balance at Dec. 31, 2022	$ 29	153,985	(101,835)	12	52,191
Issuance of common stock with equity purchase agreement (in shares)	150,381
Issuance of common stock with equity purchase agreement	$ 0	141	0	0	141
Common stock issued for license rights (in shares)	822,115
Common stock issued for license rights	$ 1	771	0	0	772
Stock-based compensation	0	499	0	0	499
Net loss	0	0	(7,915)	0	(7,915)
Foreign currency translation	$ 0	0	0	(4)	(4)
Balance (in shares) at Mar. 31, 2023	29,600,323
Balance at Mar. 31, 2023	$ 30	$ 155,396	$ (109,750)	$ 8	$ 45,684

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482765/220-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 65
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480175/815-40-65-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-8

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-9

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 11
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-11

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483443/250-10-50-4

Reference 13: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-10

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section 45
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483581/946-220-45-7

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483586/944-220-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-22

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-07(9))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(1)(d))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480097/470-10-S99-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-30

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 260
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 60B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482689/260-10-45-60B

Reference 32: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-31

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482810/280-10-50-32

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483499/205-20-50-7

Reference 35: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 230
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482740/230-10-45-28

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1A

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482790/220-10-45-1B

Reference 38: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2

Reference 39: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483589/942-220-S99-1

+ Details

- Definition

Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.

+ References + Details

- Definition

Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481372/852-10-55-10

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480167/946-830-55-12

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(19))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SX 210.6-05(4))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479617/946-210-S99-2

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(4)(b))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(6))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 3
-Subparagraph (SX 210.6-09(7))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147483575/946-220-S99-3

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481687/323-10-50-3

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482907/825-10-50-28

Reference 11: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 12: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 13: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1

Reference 14: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 310
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480418/310-10-S99-2

+ Details

XML 18 R7.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Business

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Nature of Operations [Text Block]

1. Nature of Business

XML 19 R8.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Significant Accounting Policies [Text Block]

2. Basis of presentation, principles of consolidation, and significant accounting policies and liquidity

Principles of Consolidation - The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All material long-lived assets of the Company reside in the U.S.

Significant Accounting Policies - The Company's significant accounting policies are described in Note 2, Basis of Presentation, principles of consolidation and significant accounting policies, to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to the significant accounting policies during the three months ended March 31, 2023.

Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.

Liquidity and Financial Condition - The Company is an early stage company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with early stage companies. Since inception, the Company has incurred losses and negative cash flows from operating activities. For the three months ended March 31, 2023 and 2022, the Company incurred net losses of $7.9 million and $6.9 million, respectively, and had net cash flows used in operating activities of $6.0 million and $4.8 million, respectively. At March 31, 2023, the Company had an accumulated deficit of $109.8 million and cash and cash equivalents of $37.3 million. The Company expects its cash on hand as of March 31, 2023 will be sufficient to fund the Company's operations beyond the near term. Such projections are subject to changes in the Company’s internally funded preclinical and clinical activities, including unplanned preclinical and clinical activity. The Company does not expect to experience positive cash flows from operating activities in the near future and anticipates incurring operating losses for the next few years as it supports the development of its core technologies to the point of generating revenue, most likely via out-licensing, and continues to invest in research and development for additional applications of the Company's core technologies and potentially increase its pipeline of drug candidates. If the Company needs to raise additional capital in order to continue to execute its business plan, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital could adversely impact the Company's ability to achieve its intended business objectives and meet its financial obligations as they become due and payable. In March 2022, the Company received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are the Company's officers or directors) and entities, and materials related to the development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. During the three months ended March 31, 2023 and 2022, the Company has expensed approximately $0.5 million and $0.1 million, respectively, in related general and administrative fees and expenses.

Cash and Cash Equivalents - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation’s limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company’s management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held.

Fair Value of Financial Instruments - The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such.

The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3).

Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:

Level 1 – Unadjusted quoted prices in active markets of identical assets or liabilities.

Level 2 – Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument.

Level 3 – Unobservable inputs for the asset or liability.

The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 3.

The following table provides the financial liabilities reported at fair value and measured on a recurring basis at March 31, 2023 and December 31, 2022 (table in thousands):

Description

Fair Value

Level 1

Level 2

Level 3

Fair value of warrant liability as of March 31, 2023:
$ 38 $ — $ — $ 38

Fair value of warrant liability as of December 31, 2022:
$ 77 $ — $ — $ 77

The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of the first quarter and then is adjusted for changes in fair value that occurred during the first quarter. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments.

Three Months Ended March 31, 2023

Warrant Liability Long-Term

Balance, December 31, 2022
$ 77

Change in fair value - net
(39 )

Balance, March 31, 2023
$ 38

Loss Per Common Share - Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. For the three months ended March 31, 2023 and 2022, approximately 6.2 million and 4.8 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect.

Subsequent Events - The Company’s management reviewed all material events through the date of these unaudited condensed consolidated financial statements. See Note 7 - Subsequent Events.

Recent Accounting Pronouncements - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.

XML 20 R9.htm IDEA: XBRL DOCUMENT

Note 3 - Warrants

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Warrants Disclosure [Text Block]

3. Warrants

Liability Classified Warrants

The assumptions used in determining the fair value of the Company's outstanding liability classified warrants are as follows:

	*March 31, 2023*	*December 31, 2022*
Risk-free interest rate	4.0% to 4.9%	4.2% to 4.8%
Volatility	58.4% to 67.6%	63.1% to 76.3%
Expected life (years)	0.1 to 2.4	0.1 to 2.6
Dividend yield	—%	—%

A summary of the Company's liability classified warrant activity during the three months ended March 31, 2023 and related information follows:

	*Number of Shares*			*Range of Warrant Exercise*				*Weighted Average*		*Weighted Average Remaining Contractual*
	*Under Warrant*			*Price per Share*				*Exercise Price*		*Life (Years)*
Balance at January 1, 2023		2,656,296		$	6.30	$	16.80	$	9.49		1.7
Expired warrants		(21,450	)	$	16.80	$	16.80	$	16.80		—
Balance at March 31, 2023		2,634,846		$	6.30	$	16.80	$	9.43		1.4
Exercisable at March 31, 2023		2,634,846		$	6.30	$	16.80	$	9.43		1.4

Equity Classified Warrants

XML 21 R10.htm IDEA: XBRL DOCUMENT

Note 4 - Equity

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Equity [Text Block]

4. Equity

Lincoln Park Equity Line

Other Components of Equity

Stock-Based Compensation and Outstanding Awards

Stock-based compensation expense for the three months ended March 31, 2023 and 2022, respectively, is as follows (table in thousands):

	*Three Months Ended March 31,*
	*2023*		*2022*
General and administrative	$	369	$	361
Research and development		130		166
Total stock-based compensation expense	$	499	$	527

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481062/946-235-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481004/946-505-50-6

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480237/815-40-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480008/505-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(e)(1))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//505/tableOfContent

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-13

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-14

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-16

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 18
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147481112/505-10-50-18

+ Details

XML 22 R11.htm IDEA: XBRL DOCUMENT

Note 5 - Income Taxes

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Income Tax Disclosure [Text Block]

5. Income Taxes

- Definition

The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480990/946-20-50-13

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h)(2))
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147480678/235-10-S99-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org//740/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-14

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-21

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 270
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482526/740-270-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 17
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482685/740-10-50-17

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 6.I.5.Q1)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 11.C)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147479360/740-10-S99-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 740
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org//1943274/2147482603/740-30-50-2

+ Details

XML 23 R12.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Commitments and Contingencies Disclosure [Text Block]

6. Commitments and Contingencies

In addition to the commitments and contingencies described elsewhere in these notes, see below for a discussion of the Company's commitments and contingencies as of March 31, 2023.

Lease Obligations Payable

The following summarizes quantitative information about the Company's operating leases for the three months ended March 31, 2023 and 2022, respectively (table in thousands):

	*Three Months Ended March 31,*
	*2023*		*2022*
Lease cost:
Operating lease cost	$	33	$	29
Variable lease cost		7		7
Total	$	40	$	36

Licenses

MD Anderson - Total expenses related to the Company's license agreements with MD Anderson were $64,000 and $76,000 for the three months ended March 31, 2023 and 2022, respectively.

HPI - The Company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expenses of $59,000 for each of the three months ended March 31, 2023 and 2022

License Terminations

XML 24 R13.htm IDEA: XBRL DOCUMENT

Note 7 - Subsequent Events

3 Months Ended

Mar. 31, 2023

Notes to Financial Statements

Subsequent Events [Text Block]

7. Subsequent Events

In addition to the subsequent events discussed elsewhere in these notes, see below for a discussion of subsequent events occurring after March 31, 2023.

XML 25 R14.htm IDEA: XBRL DOCUMENT

Significant Accounting Policies (Policies)

3 Months Ended

Mar. 31, 2023

Accounting Policies [Abstract]

Basis of Accounting, Policy [Policy Text Block]

Consolidation, Policy [Policy Text Block]

Significant Accounting Policies [Policy Text Block]

Use of Estimates, Policy [Policy Text Block]

Liquidity and Financial Condition [Policy Text Block]

Cash and Cash Equivalents, Policy [Policy Text Block]

Fair Value of Financial Instruments, Policy [Policy Text Block]

Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows:

Level 1 – Unadjusted quoted prices in active markets of identical assets or liabilities.

Level 3 – Unobservable inputs for the asset or liability.

The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 3.

The following table provides the financial liabilities reported at fair value and measured on a recurring basis at March 31, 2023 and December 31, 2022 (table in thousands):

Description	*Fair Value*		*Level 1*		*Level 2*		*Level 3*
Fair value of warrant liability as of March 31, 2023:	$	38	$	—	$	—	$	38
Fair value of warrant liability as of December 31, 2022:	$	77	$	—	$	—	$	77

Three Months Ended March 31, 2023	*Warrant Liability Long-Term*
Balance, December 31, 2022	$	77
Change in fair value - net		(39	)
Balance, March 31, 2023	$	38

Earnings Per Share, Policy [Policy Text Block]

Subsequent Events, Policy [Policy Text Block]

Subsequent Events - The Company’s management reviewed all material events through the date of these unaudited condensed consolidated financial statements. See Note 7 - Subsequent Events.

New Accounting Pronouncements, Policy [Policy Text Block]

Recent Accounting Pronouncements - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.

XML 26 R15.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]

Description	*Fair Value*		*Level 1*		*Level 2*		*Level 3*
Fair value of warrant liability as of March 31, 2023:	$	38	$	—	$	—	$	38
Fair value of warrant liability as of December 31, 2022:	$	77	$	—	$	—	$	77

Three Months Ended March 31, 2023	*Warrant Liability Long-Term*
Balance, December 31, 2022	$	77
Change in fair value - net		(39	)
Balance, March 31, 2023	$	38

XML 27 R16.htm IDEA: XBRL DOCUMENT

Note 3 - Warrants (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Schedule of Warrants or Rights, Assumptions Used [Table Text Block]

	*March 31, 2023*	*December 31, 2022*
Risk-free interest rate	4.0% to 4.9%	4.2% to 4.8%
Volatility	58.4% to 67.6%	63.1% to 76.3%
Expected life (years)	0.1 to 2.4	0.1 to 2.6
Dividend yield	—%	—%

Schedule of Warrant Activity [Table Text Block]

	*Number of Shares*			*Range of Warrant Exercise*				*Weighted Average*		*Weighted Average Remaining Contractual*
	*Under Warrant*			*Price per Share*				*Exercise Price*		*Life (Years)*
Balance at January 1, 2023		2,656,296		$	6.30	$	16.80	$	9.49		1.7
Expired warrants		(21,450	)	$	16.80	$	16.80	$	16.80		—
Balance at March 31, 2023		2,634,846		$	6.30	$	16.80	$	9.43		1.4
Exercisable at March 31, 2023		2,634,846		$	6.30	$	16.80	$	9.43		1.4

XML 28 R17.htm IDEA: XBRL DOCUMENT

Note 4 - Equity (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Share-based Payment Arrangement, Expensed, Amount [Table Text Block]

	*Three Months Ended March 31,*
	*2023*		*2022*
General and administrative	$	369	$	361
Research and development		130		166
Total stock-based compensation expense	$	499	$	527

XML 29 R18.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Tables)

3 Months Ended

Mar. 31, 2023

Notes Tables

Lease, Cost [Table Text Block]

	*Three Months Ended March 31,*
	*2023*		*2022*
Lease cost:
Operating lease cost	$	33	$	29
Variable lease cost		7		7
Total	$	40	$	36

XML 30 R19.htm IDEA: XBRL DOCUMENT

Note 1 - Nature of Business (Details Textual)	Mar. 31, 2023
Number of Core Drug Technologies	3

XML 31 R20.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual) $ in Thousands, shares in Millions	3 Months Ended
	Mar. 31, 2023 USD ($) shares	Mar. 31, 2022 USD ($) shares	Dec. 31, 2022 USD ($)
Number of Operating Segments	1
Net Income (Loss) Attributable to Parent	$ (7,915)	$ (6,867)
Net Cash Provided by (Used in) Operating Activities	(6,017)	$ (4,805)
Retained Earnings (Accumulated Deficit)	(109,750)		$ (101,835)
Cash and Cash Equivalents, at Carrying Value	$ 37,265		$ 43,145
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares) \| shares	6.2	4.8
General and Administrative Expense [Member]
Legal Fees	$ 500	$ 100

- Definition

The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.

+ References

+ Details

- Definition

Amount of accumulated undistributed earnings (deficit).

+ References + Details

XML 32 R21.htm IDEA: XBRL DOCUMENT

Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Warrant Liability Long Term [Member]
Balance	$ 77
Change in fair value - net	(39)
Balance	38
Fair Value, Recurring [Member] \| Warrant Liability [Member]
Fair value of warrant liability	38	$ 77
Fair Value, Recurring [Member] \| Warrant Liability [Member] \| Fair Value, Inputs, Level 1 [Member]
Fair value of warrant liability	0	0
Fair Value, Recurring [Member] \| Warrant Liability [Member] \| Fair Value, Inputs, Level 2 [Member]
Fair value of warrant liability	0	0
Fair Value, Recurring [Member] \| Warrant Liability [Member] \| Fair Value, Inputs, Level 3 [Member]
Fair value of warrant liability	$ 38	$ 77

XML 33 R22.htm IDEA: XBRL DOCUMENT

Note 3 - Warrants (Details Textual) - USD ($)	3 Months Ended
Note 3 - Warrants (Details Textual) - USD ($)	Mar. 31, 2023	Mar. 31, 2022	Dec. 31, 2022
Share-Based Payment Arrangement, Expense	$ 499,000	$ 527,000
Equity Classified Warrants [Member]
Class of Warrant or Right, Outstanding (in shares)	646,501		646,501
Class of Warrant or Right, Vested and Exercisable (in shares)	404,434		400,859
Share-Based Payment Arrangement, Expense	$ 46,000	$ 83,000
Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount	$ 391,000

XML 34 R23.htm IDEA: XBRL DOCUMENT

Note 3 - Warrants - Assumptions Used (Details)	Mar. 31, 2023	Dec. 31, 2022
Minimum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants, assumptions	0.040	0.042
Minimum [Member] \| Measurement Input, Price Volatility [Member]
Warrants, assumptions	0.584	0.631
Minimum [Member] \| Measurement Input, Expected Term [Member]
Warrants, assumptions	0.1	0.1
Maximum [Member] \| Measurement Input, Risk Free Interest Rate [Member]
Warrants, assumptions	0.049	0.048
Maximum [Member] \| Measurement Input, Price Volatility [Member]
Warrants, assumptions	0.676	0.763
Maximum [Member] \| Measurement Input, Expected Term [Member]
Warrants, assumptions	2.4	2.6

XML 35 R24.htm IDEA: XBRL DOCUMENT

Note 3 - Warrants - Warrant Activity (Details) - Liability Classified Warrants [Member] - $ / shares	3 Months Ended	12 Months Ended
	Mar. 31, 2023	Dec. 31, 2022
Balance (in shares)	2,656,296
Balance, weighted average remaining contractual life (Year)	1 year 4 months 24 days	1 year 8 months 12 days
Expired warrants (in shares)	(21,450)
Expired warrants (in dollars per share)	$ 16.80
Balance (in shares)	2,634,846	2,656,296
Exercisable (in shares)	2,634,846
Exercisable, weighted average remaining contractual life (Year)	1 year 4 months 24 days
Minimum [Member]
Balance, warrant exercise price (in dollars per share)	$ 6.30
Balance, warrant exercise price (in dollars per share)	6.30	$ 6.30
Exercisable, warrant exercise price (in dollars per share)	6.30
Maximum [Member]
Balance, warrant exercise price (in dollars per share)	16.80
Balance, warrant exercise price (in dollars per share)	16.80	16.80
Exercisable, warrant exercise price (in dollars per share)	16.80
Weighted Average [Member]
Balance, warrant exercise price (in dollars per share)	9.49
Expired warrants (in dollars per share)	16.80
Balance, warrant exercise price (in dollars per share)	9.43	$ 9.49
Exercisable, warrant exercise price (in dollars per share)	$ 9.43

XML 36 R25.htm IDEA: XBRL DOCUMENT

Note 4 - Equity (Details Textual) - USD ($)	1 Months Ended		3 Months Ended
Note 4 - Equity (Details Textual) - USD ($)	Apr. 30, 2023	Mar. 31, 2023	Mar. 31, 2023	Mar. 31, 2022
Proceeds from Issuance of Common Stock			$ 141,000	$ 0
Stock Issued During Period, Value, New Issues			$ 141,000
The 2015 Stock Plan [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)		752,296	752,296
WPD Pharmaceuticals [Member] \| License Termination [Member]
Stock Issued During Period, Shares, New Issues (in shares)		822,115	822,115
Payment, Related to Termination Clause			$ 700,000
Stock Issued During Period, Value, New Issues		$ 800,000	$ 800,000
Lincoln Park Transaction [Member]
Stock Issued During Period, Shares, New Issues (in shares)			150,381
Proceeds from Issuance of Common Stock			$ 100,000
Purchase Agreement, Common Stock, Available Amount		$ 19,800,000	$ 19,800,000
Lincoln Park Transaction [Member] \| Subsequent Event [Member]
Stock Issued During Period, Shares, New Issues (in shares)	75,187
Proceeds from Issuance of Common Stock	$ 100,000

XML 37 R26.htm IDEA: XBRL DOCUMENT

Note 4 - Equity - Stock based Compensation (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Share-Based Payment Arrangement, Expense	$ 499	$ 527
General and Administrative Expense [Member]
Share-Based Payment Arrangement, Expense	369	361
Research and Development Expense [Member]
Share-Based Payment Arrangement, Expense	$ 130	$ 166

XML 38 R27.htm IDEA: XBRL DOCUMENT

Note 5 - Income Taxes (Details Textual) - USD ($) Pure in Thousands, $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Income Tax Expense (Benefit)	$ 0	$ 0
Effective Income Tax Rate Reconciliation, Percent	0.00%	0.00%

- Definition

Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.

+ References + Details

XML 39 R28.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies (Details Textual) - USD ($)		1 Months Ended		3 Months Ended
	Apr. 30, 2023	Mar. 31, 2023	Feb. 28, 2022	Mar. 31, 2023	Mar. 31, 2022
Sublease Income				$ 12,000	$ 10,000
Operating Lease, Payments				38,000	35,000
License Agreements Expense				64,000	76,000
Research and Development Expense				5,687,000	4,620,000
Stock Issued During Period, Value, New Issues				141,000
MD Anderson [Member] \| Sponsored Research [Member]
Research and Development Expense				155,000	187,000
MD Anderson [Member] \| Subsequent Event [Member]
Payments For Research And Development Agreement	$ 700,000
WPD Pharmaceuticals [Member] \| License Termination [Member]
Payments for Termination of Commitment		$ 700,000
Stock Issued During Period, Value, New Issues		$ 800,000		$ 800,000
Stock Issued During Period, Shares, New Issues (in shares)		822,115		822,115
Exploration Invest Pte Ltd. (Exploration) [Member]
Payments for Termination of Commitment			$ 400,000
License Terminations Expense				$ 1,500,000	400,000
Houston Pharmaceuticals, Inc [Member]
Related Party Transaction, Amounts of Transaction				$ 59,000	$ 59,000

XML 40 R29.htm IDEA: XBRL DOCUMENT

Note 6 - Commitments and Contingencies - Lease Cost (Details) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2023	Mar. 31, 2022
Operating lease cost	$ 33	$ 29
Variable lease cost	7	7
Total	$ 40	$ 36

XML 41 R30.htm IDEA: XBRL DOCUMENT

Note 7 - Subsequent Events (Details Textual) - Subsequent Event [Member]	May 05, 2023 $ / shares
NASDAQ Compliance, Minimum Closing Bid Price Per Share (in dollars per share)	$ 1.00
NASDAQ Compliance, Extension Period (Day)	180 days

XML 42 mbrx20230331_10q_htm.xml IDEA: XBRL DOCUMENT 0001659617 2023-01-01 2023-03-31 0001659617 2023-05-01 0001659617 2023-03-31 0001659617 2022-12-31 0001659617 2022-01-01 2022-03-31 0001659617 2021-12-31 0001659617 2022-03-31 0001659617 us-gaap:CommonStockMember 2022-12-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2022-12-31 0001659617 us-gaap:RetainedEarningsMember 2022-12-31 0001659617 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-12-31 0001659617 us-gaap:CommonStockMember 2023-01-01 2023-03-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2023-01-01 2023-03-31 0001659617 us-gaap:RetainedEarningsMember 2023-01-01 2023-03-31 0001659617 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-01-01 2023-03-31 0001659617 us-gaap:CommonStockMember 2023-03-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2023-03-31 0001659617 us-gaap:RetainedEarningsMember 2023-03-31 0001659617 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2023-03-31 0001659617 us-gaap:CommonStockMember 2021-12-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2021-12-31 0001659617 us-gaap:RetainedEarningsMember 2021-12-31 0001659617 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2021-12-31 0001659617 us-gaap:CommonStockMember 2022-01-01 2022-03-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2022-01-01 2022-03-31 0001659617 us-gaap:RetainedEarningsMember 2022-01-01 2022-03-31 0001659617 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-01-01 2022-03-31 0001659617 us-gaap:CommonStockMember 2022-03-31 0001659617 us-gaap:AdditionalPaidInCapitalMember 2022-03-31 0001659617 us-gaap:RetainedEarningsMember 2022-03-31 0001659617 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2022-03-31 0001659617 us-gaap:GeneralAndAdministrativeExpenseMember 2023-01-01 2023-03-31 0001659617 us-gaap:GeneralAndAdministrativeExpenseMember 2022-01-01 2022-03-31 0001659617 mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001659617 us-gaap:FairValueInputsLevel1Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001659617 us-gaap:FairValueInputsLevel2Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001659617 us-gaap:FairValueInputsLevel3Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2023-03-31 0001659617 mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001659617 us-gaap:FairValueInputsLevel1Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001659617 us-gaap:FairValueInputsLevel2Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001659617 us-gaap:FairValueInputsLevel3Member mbrx:WarrantLiabilityMember us-gaap:FairValueMeasurementsRecurringMember 2022-12-31 0001659617 mbrx:WarrantLiabilityLongTermMember 2022-12-31 0001659617 mbrx:WarrantLiabilityLongTermMember 2023-01-01 2023-03-31 0001659617 mbrx:WarrantLiabilityLongTermMember 2023-03-31 0001659617 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001659617 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2023-03-31 0001659617 srt:MinimumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001659617 srt:MaximumMember us-gaap:MeasurementInputRiskFreeInterestRateMember 2022-12-31 0001659617 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001659617 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2023-03-31 0001659617 srt:MinimumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001659617 srt:MaximumMember us-gaap:MeasurementInputPriceVolatilityMember 2022-12-31 0001659617 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2023-03-31 0001659617 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2023-03-31 0001659617 srt:MinimumMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001659617 srt:MaximumMember us-gaap:MeasurementInputExpectedTermMember 2022-12-31 0001659617 mbrx:LiabilityClassifiedWarrantsMember 2022-12-31 0001659617 srt:MinimumMember mbrx:LiabilityClassifiedWarrantsMember 2022-12-31 0001659617 srt:MaximumMember mbrx:LiabilityClassifiedWarrantsMember 2022-12-31 0001659617 srt:WeightedAverageMember mbrx:LiabilityClassifiedWarrantsMember 2022-12-31 0001659617 mbrx:LiabilityClassifiedWarrantsMember 2022-01-01 2022-12-31 0001659617 mbrx:LiabilityClassifiedWarrantsMember 2023-01-01 2023-03-31 0001659617 srt:WeightedAverageMember mbrx:LiabilityClassifiedWarrantsMember 2023-01-01 2023-03-31 0001659617 mbrx:LiabilityClassifiedWarrantsMember 2023-03-31 0001659617 srt:MinimumMember mbrx:LiabilityClassifiedWarrantsMember 2023-03-31 0001659617 srt:MaximumMember mbrx:LiabilityClassifiedWarrantsMember 2023-03-31 0001659617 srt:WeightedAverageMember mbrx:LiabilityClassifiedWarrantsMember 2023-03-31 0001659617 mbrx:EquityClassifiedWarrantsMember 2023-03-31 0001659617 mbrx:EquityClassifiedWarrantsMember 2022-12-31 0001659617 mbrx:EquityClassifiedWarrantsMember 2023-01-01 2023-03-31 0001659617 mbrx:EquityClassifiedWarrantsMember 2022-01-01 2022-03-31 0001659617 mbrx:LincolnParkTransactionMember 2023-01-01 2023-03-31 0001659617 us-gaap:SubsequentEventMember mbrx:LincolnParkTransactionMember 2023-04-01 2023-04-30 0001659617 mbrx:LincolnParkTransactionMember 2023-03-31 0001659617 mbrx:WPDPharmaceuticalsMember mbrx:LicenseTerminationMember 2023-01-01 2023-03-31 0001659617 mbrx:The2015StockPlanMember 2023-03-31 0001659617 us-gaap:ResearchAndDevelopmentExpenseMember 2023-01-01 2023-03-31 0001659617 us-gaap:ResearchAndDevelopmentExpenseMember 2022-01-01 2022-03-31 0001659617 mbrx:HoustonPharmaceuticalsIncMember 2023-01-01 2023-03-31 0001659617 mbrx:HoustonPharmaceuticalsIncMember 2022-01-01 2022-03-31 0001659617 mbrx:MDAndersonMember us-gaap:SubsequentEventMember 2023-04-30 2023-04-30 0001659617 mbrx:MDAndersonMember mbrx:SponsoredResearchMember 2023-01-01 2023-03-31 0001659617 mbrx:MDAndersonMember mbrx:SponsoredResearchMember 2022-01-01 2022-03-31 0001659617 mbrx:WPDPharmaceuticalsMember mbrx:LicenseTerminationMember 2023-03-01 2023-03-31 0001659617 mbrx:ExplorationInvestPteLtdExplorationMember 2022-02-01 2022-02-28 0001659617 mbrx:ExplorationInvestPteLtdExplorationMember 2023-01-01 2023-03-31 0001659617 mbrx:ExplorationInvestPteLtdExplorationMember 2022-01-01 2022-03-31 0001659617 us-gaap:SubsequentEventMember 2023-05-05 0001659617 us-gaap:SubsequentEventMember 2023-05-05 2023-05-05 thunderdome:item iso4217:USD iso4217:USD shares pure utr:Y utr:D 0001659617 Moleculin Biotech, Inc. false --12-31 Q1 2023

0.001

5000000

0.001

100000000

29600323

28627827

59000

10-Q true 2023-03-31 false 001-37758 DE 47-4671997 5300 Memorial Drive, Suite 950 Houston TX 77007 713 300-5160 Yes Yes true Non-accelerated Filer false false Common Stock, par value $0.001 per share MBRX NASDAQ 29675510

37265000

43145000

2024000

2451000

39289000

45596000

244000

275000

11148000

381000

403000

51062000

57422000

1939000

2095000

3093000

2724000

5032000

4819000

308000

335000

38000

77000

5378000

5231000

30000

29000

155396000

153985000

8000

12000

-109750000

-101835000

45684000

52191000

51062000

57422000

5687000

4620000

2637000

2422000

30000

32000

8354000

7074000

-8354000

-7074000

-39000

-160000

8000

5000

392000

42000

-7915000

-6867000

-0.28

-0.24

28749974

28578338

-7915000

-6867000

-4000

12000

-7919000

-6855000

-7915000

-6867000

30000

32000

499000

527000

772000 0

-39000

-160000

110000 90000

-427000

-438000

-156000

860000

255000

275000

-6017000

-4805000

-0

6000

-6000

141000

-4000

12000

-5880000

-4799000

43145000

70903000

37265000

66104000

28627827

29000

153985000

-101835000

12000

52191000

150381

141000

822115 1000 771000 0 0 772000

499000

-7915000

-4000

29600323

30000

155396000

-109750000

8000

45684000

28578338

29000

151733000

-72810000

41000

78993000

527000

-6867000

12000

28578338

29000

152260000

-79677000

53000

72665000

1. Nature of Business The terms "MBI" or "the Company", "we", "our", and "us" are used herein to refer to Moleculin Biotech, Inc. MBI is a clinical-stage pharmaceutical company, organized as a Delaware corporation in July 2015, with clinical programs for hard-to-treat cancers and viruses. The Company has three core technologies, each of which have had one or more drugs successfully complete a Phase 1 clinical trial, based substantially on discoveries made at and licensed from The University of Texas System on behalf of the MD Anderson Cancer Center (MD Anderson) in Houston, Texas. The Company has two wholly owned subsidiaries, Moleculin Australia Pty. Ltd., which was set up to perform certain preclinical development and Moleculin Amsterdam B.V., which acts as its legal representative for clinical trials in Europe. The Company utilizes its own internal resources and funds to conduct some of these trials and also has trials being conducted via physician-sponsored trials. The physician-sponsored trials utilize primarily external funds, such as grant funds, which are not presented in these financial statements. The Company does not have manufacturing facilities and all manufacturing activities are contracted out to third parties. Additionally, the Company does not have a sales organization. The Company’s overall strategy is to seek potential out-licensing or outsourcing opportunities with development/commercialization strategic partners who are better suited for the marketing, sales and distribution of its drugs, if approved.

2. Basis of presentation, principles of consolidation, and significant accounting policies and liquidity Basis of Presentation – Condensed Consolidated Financial Information - The accompanying condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for financial information, and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements furnished reflect all normal adjustments, which are, in the opinion of management, necessary for a fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December 31, 2022 and for the year then ended, including the notes thereto contained in the Form 10-K filed with the SEC on March 22, 2023. Principles of Consolidation - The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All material long-lived assets of the Company reside in the U.S. Significant Accounting Policies - The Company's significant accounting policies are described in Note 2, Basis of Presentation, principles of consolidation and significant accounting policies, to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to the significant accounting policies during the three months ended March 31, 2023. Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes. Liquidity and Financial Condition - The Company is an early stage company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with early stage companies. Since inception, the Company has incurred losses and negative cash flows from operating activities. For the three months ended March 31, 2023 and 2022, the Company incurred net losses of $7.9 million and $6.9 million, respectively, and had net cash flows used in operating activities of $6.0 million and $4.8 million, respectively. At March 31, 2023, the Company had an accumulated deficit of $109.8 million and cash and cash equivalents of $37.3 million. The Company expects its cash on hand as of March 31, 2023 will be sufficient to fund the Company's operations beyond the near term. Such projections are subject to changes in the Company’s internally funded preclinical and clinical activities, including unplanned preclinical and clinical activity. The Company does not expect to experience positive cash flows from operating activities in the near future and anticipates incurring operating losses for the next few years as it supports the development of its core technologies to the point of generating revenue, most likely via out-licensing, and continues to invest in research and development for additional applications of the Company's core technologies and potentially increase its pipeline of drug candidates. If the Company needs to raise additional capital in order to continue to execute its business plan, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital could adversely impact the Company's ability to achieve its intended business objectives and meet its financial obligations as they become due and payable. In March 2022, the Company received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are the Company's officers or directors) and entities, and materials related to the development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. During the three months ended March 31, 2023 and 2022, the Company has expensed approximately $0.5 million and $0.1 million, respectively, in related general and administrative fees and expenses. Cash and Cash Equivalents - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation’s limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company’s management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held. Fair Value of Financial Instruments - The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such. The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 – Unadjusted quoted prices in active markets of identical assets or liabilities. Level 2 – Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 – Unobservable inputs for the asset or liability. The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 3. The following table provides the financial liabilities reported at fair value and measured on a recurring basis at March 31, 2023 and December 31, 2022 (table in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: thin solid rgb(0, 0, 0);"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Fair value of warrant liability as of March 31, 2023: </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">38</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">38</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Fair value of warrant liability as of December 31, 2022: </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of the first quarter and then is adjusted for changes in fair value that occurred during the first quarter. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant Liability Long-Term </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance, December 31, 2022 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Change in fair value - net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance, March 31, 2023 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> Loss Per Common Share - Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. For the three months ended March 31, 2023 and 2022, approximately 6.2 million and 4.8 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect. Subsequent Events - The Company’s management reviewed all material events through the date of these unaudited condensed consolidated financial statements. See Note 7 - Subsequent Events. Recent Accounting Pronouncements - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.

Basis of Presentation – Condensed Consolidated Financial Information - The accompanying condensed consolidated financial statements and related notes have been prepared in accordance with accounting principles generally accepted in the U.S. (U.S. GAAP) for financial information, and in accordance with the rules and regulations of the U.S. Securities and Exchange Commission (SEC) with respect to Form 10-Q and Article 8 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by U.S. GAAP for complete financial statements. The condensed consolidated financial statements furnished reflect all normal adjustments, which are, in the opinion of management, necessary for a fair statement of results for the interim periods presented. Interim results are not necessarily indicative of the results for the full year. These condensed consolidated financial statements should be read in conjunction with the audited financial statements of the Company as of December 31, 2022 and for the year then ended, including the notes thereto contained in the Form 10-K filed with the SEC on March 22, 2023.

Principles of Consolidation - The accompanying condensed consolidated financial statements include the accounts of the Company and its wholly owned subsidiaries. All intercompany balances and transactions have been eliminated in consolidation. Any reference in these notes to applicable guidance is meant to refer to U.S. GAAP. The Company views its operations and manages its business in one operating segment. All material long-lived assets of the Company reside in the U.S.

Significant Accounting Policies - The Company's significant accounting policies are described in Note 2, Basis of Presentation, principles of consolidation and significant accounting policies, to the consolidated financial statements included in the Company's Annual Report on Form 10-K for the year ended December 31, 2022. There have been no material changes to the significant accounting policies during the three months ended March 31, 2023.

Use of Estimates - The preparation of these condensed consolidated financial statements requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. Management considers many factors in selecting appropriate financial accounting policies and controls, and in developing the estimates and assumptions that are used in the preparation of these financial statements. Management must apply significant judgment in this process. In addition, other factors may affect estimates, including expected business and operational changes, sensitivity and volatility associated with the assumptions used in developing estimates, and whether historical trends are expected to be representative of future trends. The estimation process often may yield a range of potentially reasonable estimates of the ultimate future outcomes and management must select an amount that falls within that range of reasonable estimates. This process may result in actual results differing materially from those estimated amounts used in the preparation of financial statements. Estimates are used in the following areas, among others: fair value estimates on intangible assets, warrants, and stock-based compensation expense, as well as accrued expenses and taxes.

Liquidity and Financial Condition - The Company is an early stage company and has not generated any revenues to date. As such, the Company is subject to all of the risks associated with early stage companies. Since inception, the Company has incurred losses and negative cash flows from operating activities. For the three months ended March 31, 2023 and 2022, the Company incurred net losses of $7.9 million and $6.9 million, respectively, and had net cash flows used in operating activities of $6.0 million and $4.8 million, respectively. At March 31, 2023, the Company had an accumulated deficit of $109.8 million and cash and cash equivalents of $37.3 million. The Company expects its cash on hand as of March 31, 2023 will be sufficient to fund the Company's operations beyond the near term. Such projections are subject to changes in the Company’s internally funded preclinical and clinical activities, including unplanned preclinical and clinical activity. The Company does not expect to experience positive cash flows from operating activities in the near future and anticipates incurring operating losses for the next few years as it supports the development of its core technologies to the point of generating revenue, most likely via out-licensing, and continues to invest in research and development for additional applications of the Company's core technologies and potentially increase its pipeline of drug candidates. If the Company needs to raise additional capital in order to continue to execute its business plan, there is no assurance that additional financing will be available when needed or that management will be able to obtain financing on terms acceptable to the Company. A failure to raise sufficient capital could adversely impact the Company's ability to achieve its intended business objectives and meet its financial obligations as they become due and payable. In March 2022, the Company received a subpoena from the SEC requesting information and documents, including materials related to certain individuals (none of which are the Company's officers or directors) and entities, and materials related to the development of and statements regarding the Company's drug candidate for the treatment of COVID-19. The Company has received, and expects to continue to receive, periodic further requests from the SEC staff with respect to this matter. The Company is not aware of the specific nature of the underlying investigation by the SEC, and to the extent that this investigation relates to prior public disclosures that it has made, the Company believes in the accuracy and adequacy of such prior disclosures. The correspondence from the SEC transmitting the subpoena to the Company states that the SEC is trying to determine whether there have been any violations of federal securities laws, but that its investigation does not mean that the SEC has concluded that anyone has violated the law or that the SEC has a negative opinion of any person, entity, or security. The Company cannot predict when this matter will be resolved or what, if any, action the SEC may take following the conclusion of the investigation. During the three months ended March 31, 2023 and 2022, the Company has expensed approximately $0.5 million and $0.1 million, respectively, in related general and administrative fees and expenses.

-7900000

-6900000

-6000000.0

-4800000

-109800000

37300000

500000

100000

Cash and Cash Equivalents - Financial instruments that potentially subject the Company to a concentration of credit risk consist of cash and cash equivalents. The Company maintains cash accounts principally at one financial institution in the U.S., which at times, may exceed the Federal Deposit Insurance Corporation’s limit. The Company has not experienced any losses from cash balances in excess of the insurance limit. The Company’s management does not believe the Company is exposed to significant credit risk at this time due to the financial condition of the financial institution where its cash is held.

Fair Value of Financial Instruments - The Company's financial instruments consist primarily of non-trade receivables, accounts payable, accrued expenses and its warrant liability. The carrying amount of non-trade receivables, accounts payable, and accrued expenses approximates their fair value because of the short-term maturity of such. The Company has categorized its assets and liabilities that are valued at fair value on a recurring basis into a three-level fair value hierarchy in accordance with U.S. GAAP. Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or most advantageous market for the asset or liability in an orderly transaction between market participants on the measurement date. The fair value hierarchy gives the highest priority to quoted prices in active markets for identical assets and liabilities (Level 1) and lowest priority to unobservable inputs (Level 3). Assets and liabilities recorded in the balance sheets at fair value are categorized based on a hierarchy of inputs as follows: Level 1 – Unadjusted quoted prices in active markets of identical assets or liabilities. Level 2 – Quoted prices for similar assets or liabilities in active markets or inputs that are observable for the asset or liability, either directly or indirectly through market corroboration, for substantially the full term of the financial instrument. Level 3 – Unobservable inputs for the asset or liability. The Company’s financial assets and liabilities recorded at fair value on a recurring basis include the fair value of warrant liability discussed in Note 3. The following table provides the financial liabilities reported at fair value and measured on a recurring basis at March 31, 2023 and December 31, 2022 (table in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: thin solid rgb(0, 0, 0);"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Fair value of warrant liability as of March 31, 2023: </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">38</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">38</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Fair value of warrant liability as of December 31, 2022: </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> The table below of Level 3 liabilities (table in thousands) begins with the valuation as of the beginning of the first quarter and then is adjusted for changes in fair value that occurred during the first quarter. The ending balance of the Level 3 financial instrument presented above represents the Company's best estimates and may not be substantiated by comparison to independent markets and, in many cases, could not be realized in immediate settlement of the instruments. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant Liability Long-Term </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance, December 31, 2022 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Change in fair value - net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance, March 31, 2023 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 52%; border-bottom: thin solid rgb(0, 0, 0);"> Description </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Fair Value </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: thin solid rgb(0, 0, 0); width: 0%; padding: 0px;"> Level 1 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 2 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Level 3 </td><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> Fair value of warrant liability as of March 31, 2023: </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">38</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 3px double black;">38</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: "Times New Roman", Times, serif; font-size: 10pt;"> Fair value of warrant liability as of December 31, 2022: </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">—</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">77</td><td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 85%; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, 2023 </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Warrant Liability Long-Term </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance, December 31, 2022 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;">77</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Change in fair value - net </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid black;">(39</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">)</td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Balance, March 31, 2023 </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">38</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

38000

77000

-39000

38000

Loss Per Common Share - Basic net loss per common share is computed by dividing net loss available to common shareholders by the weighted-average number of common shares outstanding during the period. For purposes of this calculation, options to purchase common stock, restricted stock units subject to vesting and warrants to purchase common stock are considered to be common stock equivalents. Diluted net loss per common share is determined using the weighted-average number of common shares outstanding during the period, adjusted for the dilutive effect of common stock equivalents. In periods when losses are reported, the weighted-average number of common shares outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive. For the three months ended March 31, 2023 and 2022, approximately 6.2 million and 4.8 million, respectively, of potentially dilutive shares were excluded from the computation of diluted earnings per share due to their anti-dilutive effect.

6200000

4800000

Subsequent Events - The Company’s management reviewed all material events through the date of these unaudited condensed consolidated financial statements. See Note 7 - Subsequent Events.

Recent Accounting Pronouncements - There are no recently issued accounting standards updates that are currently expected to have a material impact on the Company.

3. Warrants Liability Classified Warrants The Company uses the Black-Scholes option pricing model (BSM) to determine the fair value of its warrants at the date of issue and outstanding at each reporting date. The risk-free interest rate assumption is based upon observed interest rates on zero coupon U.S. Treasury bonds linearly interpolated to obtain a maturity period commensurate with the term of the warrants. Estimated volatility is a measure of the amount by which the Company's stock price is expected to fluctuate each year during the expected life of the warrants. Only the volatility of the Company's own stock is used in the Black-Scholes option pricing model. The assumptions used in determining the fair value of the Company's outstanding liability classified warrants are as follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> March 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> December 31, 2022 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0"> Risk-free interest rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 4.0% to 4.9% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 4.2% to 4.8% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 58.4% to 67.6% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 63.1% to 76.3% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0"> Expected life (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 0.1 to 2.4 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 0.1 to 2.6 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> —% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> —% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> A summary of the Company's liability classified warrant activity during the three months ended March 31, 2023 and related information follows: <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Number of Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Range of Warrant Exercise </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Weighted Average </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Weighted Average Remaining Contractual </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Under Warrant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> Price per Share </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Life (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Balance at January 1, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,656,296</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.49</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Expired warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21,450</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Balance at March 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,634,846</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Exercisable at March 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,634,846</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table> For a summary of the changes in fair value associated with the Company's warrant liability for the three months ended March 31, 2023, see Note 2 - Basis of presentation, principles of consolidation and significant accounting policies - Fair Value of Financial Instruments. Equity Classified Warrants At March 31, 2023, the Company had 646,501 equity classified warrants outstanding and 404,434 warrants were exercisable. At December 31, 2022, the Company had 646,501 equity classified warrants outstanding and 400,859 warrants were exercisable. The Company recorded stock compensation expense for the non-employee consulting agreements of $46,000 and $83,000 for the three months ended March 31, 2023 and 2022, respectively. At March 31, 2023, there was $391,000 of unrecognized stock compensation expense related to the Company's equity classified warrants. <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> March 31, 2023 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="1" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 14%;"> December 31, 2022 </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0"> Risk-free interest rate </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 4.0% to 4.9% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 4.2% to 4.8% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0"> Volatility </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 58.4% to 67.6% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 63.1% to 76.3% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%; padding: 0; margin: 0"> Expected life (years) </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 0.1 to 2.4 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; text-align: center; padding: 0; margin: 0"> 0.1 to 2.6 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 68%;"> Dividend yield </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> —% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 14%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; text-align: center;"> —% </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table>

0.040

0.049

0.042

0.048

0.584

0.676

0.631

0.763

0.1

2.4

0.1

2.6

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: "Times New Roman", Times, serif; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Number of Shares </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 9%;"> Range of Warrant Exercise </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Weighted Average </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; width: 1%;"> Weighted Average Remaining Contractual </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Under Warrant </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="6" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 9%;"> Price per Share </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Exercise Price </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 1%;"> </td> <td colspan="2" style="text-align: center; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0); width: 1%;"> Life (Years) </td> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px; width: 1%;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Balance at January 1, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">2,656,296</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.49</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.7</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Expired warrants </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);">(21,450</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 1px;">)</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">—</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Balance at March 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,634,846</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: "Times New Roman", Times, serif; font-size: 10pt; width: 48%;"> Exercisable at March 31, 2023 </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; border-bottom: 3px double rgb(0, 0, 0);"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">2,634,846</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt; padding-bottom: 3px;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">6.30</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 5%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">16.80</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">$</td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">9.43</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt;"> </td> <td style="width: 9%; text-align: right; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;">1.4</td> <td style="width: 1%; font-family: "Times New Roman", Times, serif; font-size: 10pt; margin-left: 0pt;"> </td> </tr> </tbody> </table>

2656296

6.30

16.80

9.49

P1Y8M12D 21450 16.80 16.80 16.80

2634846

6.30

16.80

9.43

P1Y4M24D 2634846 6.30 16.80 9.43 P1Y4M24D

646501

404434

646501

400859

46000

83000

391000

4. Equity Lincoln Park Equity Line During the three months ended March 31, 2023, pursuant to the 2021 Lincoln Park purchase agreement, the Company issued to Lincoln Park 150,381 shares of common stock for gross proceeds of $0.1 million and in April 2023, the Company issued an additional 75,187 shares of common stock, resulting in gross proceeds of $0.1 million. The 2021 Lincoln Park Agreement, which has $19.8 million available, terminates in June 2024. Other Components of Equity In March 2023, the Company and WPD agreed to terminate the WPD Agreement. Pursuant to the termination, the Company agreed to pay WPD (or its designees) $700,000 in cash and shares of its common stock valued at $800,000. In March 2023, the Company issued 822,115 shares of common stock to WPD (or its designee) to satisfy this commitment. See Note 6 - Commitments and Contingencies. Stock-Based Compensation and Outstanding Awards The 2015 Stock Plan provides for the grant of stock options, stock awards, stock unit awards, and stock appreciation rights to employees, non-employee directors and consultants. As of March 31, 2023, there were 752,296 shares remaining to be issued under the 2015 Stock Plan. Stock-based compensation expense for the three months ended March 31, 2023 and 2022, respectively, is as follows (table in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> General and administrative </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">369</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">361</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Research and development </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">130</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">166</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Total stock-based compensation expense </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">499</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">527</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>

150381

100000

75187

100000

19800000 700000

800000

822115

752296

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"> <tbody> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> <td style="font-family: Times New Roman; font-size: 10pt;"> </td> <td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td> <td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> General and administrative </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">369</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">361</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Research and development </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">130</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> <td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td> <td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">166</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td> </tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"> <td style="font-family: Times New Roman; font-size: 10pt;"> Total stock-based compensation expense </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">499</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td> <td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">527</td> <td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td> </tr> </tbody> </table>

369000

361000

130000

166000

499000

527000

5. Income Taxes Deferred income tax assets and liabilities are determined based upon differences between the financial reporting and tax basis of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. The Company does not expect to pay any significant federal, state, or foreign income taxes in 2023 as a result of the losses recorded during the three months ended March 31, 2023 and the additional losses expected for the remainder of 2023 and cumulative net operating loss carryforwards. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is “more likely than not” that some component or all of the benefits of deferred tax assets will not be realized. As a result, as of March 31, 2023 and December 31, 2022 the Company maintained a full valuation allowance for all deferred tax assets. The Company recorded no income tax provision for the three months ended March 31, 2023 and 2022, respectively. The effective tax rate for the three months ended March 31, 2023 and 2022 is nil. The income tax rates vary from the federal and state statutory rates primarily due to the change in fair value of the stock warrants, Internal Revenue Code Section 162(m) limitations and ISO activity, as well as the valuation allowances on the Company’s deferred tax assets. The Company estimates its annual effective tax rate at the end of each quarterly period. Jurisdictions with a projected loss for the year where no tax benefit can be recognized due to the valuation allowance could result in a higher or lower effective tax rate during a particular quarter depending on the mix and timing of actual earnings versus annual projections.

6. Commitments and Contingencies In addition to the commitments and contingencies described elsewhere in these notes, see below for a discussion of the Company's commitments and contingencies as of March 31, 2023. Lease Obligations Payable The following summarizes quantitative information about the Company's operating leases for the three months ended March 31, 2023 and 2022, respectively (table in thousands): <table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Lease cost: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating lease cost </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Variable lease cost </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table> In June 2022, the Company extended the lab lease until September 30, 2027, with no further right or option to renew. The Company recorded approximately $12,000 and $10,000 in sublease income from a related party for the three months ended March 31, 2023 and 2022, respectively. Sublease income is recorded as other income, net on the Company's condensed consolidated statement of operations and comprehensive loss. Operating cash flows from operating leases was $38,000 and $35,000 for the three months ended March 31, 2023 and 2022, respectively. Licenses MD Anderson - Total expenses related to the Company's license agreements with MD Anderson were $64,000 and $76,000 for the three months ended March 31, 2023 and 2022, respectively. HPI - The Company has two agreements with a related party, Houston Pharmaceuticals, Inc. (HPI) with total expenses of $59,000 for each of the three months ended March 31, 2023 and 2022 Sponsored Research Agreements - The Company has a sponsored research agreement with MD Anderson expiring December 31, 2024. In April 2023, the Company entered into an amendment to the Sponsored Research Agreement with MD Anderson for total payment of $0.7 million to support the continuation of the project. In addition, the Company also has Sponsored Research Agreements with other universities, one in the US and one in Europe. The expenses recognized under the agreements were $155,000 and $187,000 for the three months ended March 31, 2023 and 2022, respectively. License Terminations Since February 2019, the Company was party to a sublicense agreement with WPD Pharmaceuticals (WPD), pursuant to which it sublicensed to WPD certain intellectual property rights, including rights to Annamycin, its WP1122 portfolio, and its WP1066 portfolio (as amended, the “WPD Agreement”). WPD is affiliated with Dr. Waldemar Priebe, the Company's founder. In March 2023, the Company and WPD agreed to terminate the WPD Agreement and agreed to pay WPD (or its designee) $700,000 in cash and shares of its common stock valued at $800,000. In March 2023, the Company issued 822,115 shares of common stock to WPD's designee to satisfy this commitment. With the termination of the WPD Agreement, the Company now has acquired the rights in certain territories previously sub-licensed to WPD to all of its licensed intellectual property, other than the rights related to non-human animals. Additionally, the Company acquired the in-process research and development that WPD has created during the term of the agreement. In February 2022, the Company and Exploration Invest Pte Ltd. (Exploration) entered into a license termination agreement pursuant to which the Company agreed to pay Exploration $400,000 to terminate certain License Agreements and extend confidentiality requirements until the 10-year anniversary of the license termination agreement. Total expenses, reflected in research and development expenses, related to the Company's license terminations were $1.5 million and $0.4 million for the three months ended March 31, 2023 and 2022, respectively.

<table border="0" cellpadding="0" cellspacing="0" class="finTable" style="width: 100%; font-size: 10pt; font-family: Times New Roman; text-indent: 0px;"><tbody><tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="6" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> Three Months Ended March 31, </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2023 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td colspan="2" style="text-align: center; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 1px solid rgb(0, 0, 0);"> 2022 </td><td style="font-family: Times New Roman; font-size: 10pt; padding-bottom: 1px;"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; width: 70%;"> Lease cost: </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td><td style="font-family: Times New Roman; font-size: 10pt;"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Operating lease cost </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">33</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0">29</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(204, 238, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> Variable lease cost </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td><td style="width: 1%; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);"> </td><td style="width: 12%; text-align: right; font-family: "Times New Roman"; font-size: 10pt; padding: 0px; margin: 0px; border-bottom: 1px solid rgb(0, 0, 0);">7</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding: 0; margin: 0"> </td></tr> <tr style="background-color: rgb(255, 255, 255); vertical-align: bottom"><td style="font-family: Times New Roman; font-size: 10pt;"> Total </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">40</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt;"> </td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">$</td><td style="width: 12%; text-align: right; font-family: Times New Roman; font-size: 10pt; margin-left: 0pt; border-bottom: 3px double rgb(0, 0, 0);">36</td><td style="width: 1%; font-family: Times New Roman; font-size: 10pt; padding-bottom: 3px; margin-left: 0pt;"> </td></tr> </tbody></table>

33000

29000

7000

40000

36000

12000

10000

38000

35000

64000 76000

59000

700000

155000

187000

700000

800000

822115

400000 1500000 400000

7. Subsequent Events In addition to the subsequent events discussed elsewhere in these notes, see below for a discussion of subsequent events occurring after March 31, 2023. On May 5, 2023, the Company received a letter from NASDAQ notifying the Company that for the last 30 consecutive business days the bid price for the Company's common stock had closed below the minimum $1.00 per share requirement for continued inclusion on the Nasdaq Capital Market pursuant to Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The deficiency letter does not result in the immediate delisting of the Company's common stock from the Nasdaq Capital Market. In accordance with Nasdaq Listing Rule 5810(c)(3)(A), the Company has been provided an initial period of 180 calendar days, or until November 1, 2023, to regain compliance with the Bid Price Rule. If, at any time before November 1, 2023, the bid price for the Company's common stock closes at $1.00 or more for a minimum of 10 consecutive business days, the Nasdaq Staff will provide written notification to the Company that it complies with the Bid Price Rule, unless the Staff exercises its discretion to extend this 10 day period pursuant to Nasdaq Listing Rule 5810(c)(3)(G). If the Company is not in compliance with the Bid Price Rule by November 1, 2023, the Company may be afforded a second 180 calendar day period to regain compliance. To qualify, the Company would be required to meet the continued listing requirement for market value of publicly held shares and all other initial listing standards for the Nasdaq Capital Market, except for the minimum bid price requirement. In addition, the Company would be required to notify Nasdaq of its intent to cure the minimum bid price deficiency, which may include, if necessary, implementing a reverse stock split. If the Company does not regain compliance with the Bid Price Rule by November 1, 2023, and is not eligible for an additional compliance period at that time, the Nasdaq Staff will provide written notification to the Company that its common stock may be delisted. The Company would then be entitled to appeal the Nasdaq Staff’s determination to a NASDAQ Listing Qualifications Panel and request a hearing. There can be no assurance that, if the Company does appeal a delisting determination by the Nasdaq Staff to the NASDAQ Listing Qualifications Panel, that such appeal would be successful. The Company intends to monitor the closing bid price of its common stock and may, if appropriate, consider available options to regain compliance with the Bid Price Rule, which could include effecting a reverse stock split. However, there can be no assurance that the Company will be able to regain compliance with the Bid Price Rule.

1.00 P180D 1.00

EXCEL 43 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 44 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 45 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 46 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 89 149 1 false 29 0 false 7 false false R1.htm 000 - Document - Document And Entity Information Sheet http://www.moleculin.com/20230331/role/statement-document-and-entity-information Document And Entity Information Cover 1 false false R2.htm 001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) Sheet http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited Condensed Consolidated Balance Sheets (Current Period Unaudited) Statements 2 false false R3.htm 002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Sheet http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals) Statements 3 false false R4.htm 003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited) Sheet http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited Condensed Consolidated Statements of Cash Flows (Unaudited) Statements 5 false false R6.htm 005 - Statement - Condensed Consolidated Statement of Stockholders Equity (Unaudited) Sheet http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited Condensed Consolidated Statement of Stockholders Equity (Unaudited) Statements 6 false false R7.htm 006 - Disclosure - Note 1 - Nature of Business Sheet http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business Note 1 - Nature of Business Notes 7 false false R8.htm 007 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity Sheet http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity Notes 8 false false R9.htm 008 - Disclosure - Note 3 - Warrants Sheet http://www.moleculin.com/20230331/role/statement-note-3-warrants Note 3 - Warrants Notes 9 false false R10.htm 009 - Disclosure - Note 4 - Equity Sheet http://www.moleculin.com/20230331/role/statement-note-4-equity Note 4 - Equity Notes 10 false false R11.htm 010 - Disclosure - Note 5 - Income Taxes Sheet http://www.moleculin.com/20230331/role/statement-note-5-income-taxes Note 5 - Income Taxes Notes 11 false false R12.htm 011 - Disclosure - Note 6 - Commitments and Contingencies Sheet http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies Note 6 - Commitments and Contingencies Notes 12 false false R13.htm 012 - Disclosure - Note 7 - Subsequent Events Sheet http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events Note 7 - Subsequent Events Notes 13 false false R14.htm 013 - Disclosure - Significant Accounting Policies (Policies) Sheet http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies Significant Accounting Policies (Policies) Policies http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity 14 false false R15.htm 014 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables) Sheet http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables) Tables http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity 15 false false R16.htm 015 - Disclosure - Note 3 - Warrants (Tables) Sheet http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables Note 3 - Warrants (Tables) Tables http://www.moleculin.com/20230331/role/statement-note-3-warrants 16 false false R17.htm 016 - Disclosure - Note 4 - Equity (Tables) Sheet http://www.moleculin.com/20230331/role/statement-note-4-equity-tables Note 4 - Equity (Tables) Tables http://www.moleculin.com/20230331/role/statement-note-4-equity 17 false false R18.htm 017 - Disclosure - Note 6 - Commitments and Contingencies (Tables) Sheet http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables Note 6 - Commitments and Contingencies (Tables) Tables http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies 18 false false R19.htm 018 - Disclosure - Note 1 - Nature of Business (Details Textual) Sheet http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business-details-textual Note 1 - Nature of Business (Details Textual) Details http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business 19 false false R20.htm 019 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual) Sheet http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual) Details http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables 20 false false R21.htm 020 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) Sheet http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details) Details 21 false false R22.htm 021 - Disclosure - Note 3 - Warrants (Details Textual) Sheet http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual Note 3 - Warrants (Details Textual) Details http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables 22 false false R23.htm 022 - Disclosure - Note 3 - Warrants - Assumptions Used (Details) Sheet http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details Note 3 - Warrants - Assumptions Used (Details) Details 23 false false R24.htm 023 - Disclosure - Note 3 - Warrants - Warrant Activity (Details) Sheet http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details Note 3 - Warrants - Warrant Activity (Details) Details 24 false false R25.htm 024 - Disclosure - Note 4 - Equity (Details Textual) Sheet http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual Note 4 - Equity (Details Textual) Details http://www.moleculin.com/20230331/role/statement-note-4-equity-tables 25 false false R26.htm 025 - Disclosure - Note 4 - Equity - Stock based Compensation (Details) Sheet http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details Note 4 - Equity - Stock based Compensation (Details) Details 26 false false R27.htm 026 - Disclosure - Note 5 - Income Taxes (Details Textual) Sheet http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual Note 5 - Income Taxes (Details Textual) Details http://www.moleculin.com/20230331/role/statement-note-5-income-taxes 27 false false R28.htm 027 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual) Sheet http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual Note 6 - Commitments and Contingencies (Details Textual) Details http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables 28 false false R29.htm 028 - Disclosure - Note 6 - Commitments and Contingencies - Lease Cost (Details) Sheet http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details Note 6 - Commitments and Contingencies - Lease Cost (Details) Details 29 false false R30.htm 029 - Disclosure - Note 7 - Subsequent Events (Details Textual) Sheet http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual Note 7 - Subsequent Events (Details Textual) Details http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events 30 false false All Reports Book All Reports [ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 23 fact(s) appearing in ix:hidden were eligible for transformation: dei:EntityRegistrantName, mbrx:NumberOfCoreDrugTechnologies, us-gaap:CommonStockParOrStatedValuePerShare, us-gaap:CommonStockSharesAuthorized, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EffectiveIncomeTaxRateContinuingOperations, us-gaap:IncomeTaxExpenseBenefit, us-gaap:NumberOfOperatingSegments, us-gaap:PreferredStockParOrStatedValuePerShare, us-gaap:PreferredStockSharesAuthorized, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:RelatedPartyTransactionAmountsOfTransaction - mbrx20230331_10q.htm 8, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36 mbrx20230331_10q.htm ex_468529.htm ex_468530.htm ex_468531.htm ex_468532.htm mbrx-20230331.xsd mbrx-20230331_cal.xml mbrx-20230331_def.xml mbrx-20230331_lab.xml mbrx-20230331_pre.xml moleculinnewlogoresized.jpg http://fasb.org/us-gaap/2023 http://xbrl.sec.gov/dei/2023 true true JSON 49 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "mbrx20230331_10q.htm": { "axisCustom": 0, "axisStandard": 15, "baseTaxonomies": { "http://fasb.org/us-gaap/2023": 275, "http://xbrl.sec.gov/dei/2023": 29 }, "contextCount": 89, "dts": { "calculationLink": { "local": [ "mbrx-20230331_cal.xml" ] }, "definitionLink": { "local": [ "mbrx-20230331_def.xml" ] }, "inline": { "local": [ "mbrx20230331_10q.htm" ] }, "labelLink": { "local": [ "mbrx-20230331_lab.xml" ] }, "presentationLink": { "local": [ "mbrx-20230331_pre.xml" ] }, "schema": { "local": [ "mbrx-20230331.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/currency/2023/currency-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd", "https://xbrl.sec.gov/exch/2023/exch-2023.xsd", "https://xbrl.sec.gov/naics/2023/naics-2023.xsd", "https://xbrl.sec.gov/sic/2023/sic-2023.xsd", "https://xbrl.sec.gov/stpr/2023/stpr-2023.xsd" ] } }, "elementCount": 245, "entityCount": 1, "hidden": { "http://fasb.org/us-gaap/2023": 23, "http://www.moleculin.com/20230331": 1, "http://xbrl.sec.gov/dei/2023": 6, "total": 30 }, "keyCustom": 26, "keyStandard": 123, "memberCustom": 12, "memberStandard": 17, "nsprefix": "mbrx", "nsuri": "http://www.moleculin.com/20230331", "report": { "R1": { "firstAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "000 - Document - Document And Entity Information", "menuCat": "Cover", "order": "1", "role": "http://www.moleculin.com/20230331/role/statement-document-and-entity-information", "shortName": "Document And Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "b", "p", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R10": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "009 - Disclosure - Note 4 - Equity", "menuCat": "Notes", "order": "10", "role": "http://www.moleculin.com/20230331/role/statement-note-4-equity", "shortName": "Note 4 - Equity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R11": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "010 - Disclosure - Note 5 - Income Taxes", "menuCat": "Notes", "order": "11", "role": "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes", "shortName": "Note 5 - Income Taxes", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:IncomeTaxDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R12": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "011 - Disclosure - Note 6 - Commitments and Contingencies", "menuCat": "Notes", "order": "12", "role": "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "shortName": "Note 6 - Commitments and Contingencies", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R13": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "012 - Disclosure - Note 7 - Subsequent Events", "menuCat": "Notes", "order": "13", "role": "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "shortName": "Note 7 - Subsequent Events", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SubsequentEventsTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R14": { "firstAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "013 - Disclosure - Significant Accounting Policies (Policies)", "menuCat": "Policies", "order": "14", "role": "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies", "shortName": "Significant Accounting Policies (Policies)", "subGroupType": "policies", "uniqueAnchor": { "ancestors": [ "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R15": { "firstAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "014 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables)", "menuCat": "Tables", "order": "15", "role": "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R16": { "firstAnchor": { "ancestors": [ "mbrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "015 - Disclosure - Note 3 - Warrants (Tables)", "menuCat": "Tables", "order": "16", "role": "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables", "shortName": "Note 3 - Warrants (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "mbrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R17": { "firstAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "016 - Disclosure - Note 4 - Equity (Tables)", "menuCat": "Tables", "order": "17", "role": "http://www.moleculin.com/20230331/role/statement-note-4-equity-tables", "shortName": "Note 4 - Equity (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R18": { "firstAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "017 - Disclosure - Note 6 - Commitments and Contingencies (Tables)", "menuCat": "Tables", "order": "18", "role": "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables", "shortName": "Note 6 - Commitments and Contingencies (Tables)", "subGroupType": "tables", "uniqueAnchor": { "ancestors": [ "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:LeaseCostTableTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R19": { "firstAnchor": null, "groupType": "disclosure", "isDefault": "false", "longName": "018 - Disclosure - Note 1 - Nature of Business (Details Textual)", "menuCat": "Details", "order": "19", "role": "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business-details-textual", "shortName": "Note 1 - Nature of Business (Details Textual)", "subGroupType": "details", "uniqueAnchor": null }, "R2": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "001 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited)", "menuCat": "Statements", "order": "2", "role": "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2023-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:PrepaidExpenseAndOtherAssetsCurrent", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R20": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "019 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual)", "menuCat": "Details", "order": "20", "role": "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:EarningsPerSharePolicyTextBlock", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-5", "lang": null, "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R21": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2022-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityLongTermMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "020 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)", "menuCat": "Details", "order": "21", "role": "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "ix:continuation", "us-gaap:FairValueOfFinancialInstrumentsPolicy", "us-gaap:SignificantAccountingPoliciesTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2022-12-31_FairValueByLiabilityClassAxis-WarrantLiabilityLongTermMember", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R22": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "021 - Disclosure - Note 3 - Warrants (Details Textual)", "menuCat": "Details", "order": "22", "role": "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "shortName": "Note 3 - Warrants (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "mbrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2023-03-31_ClassOfWarrantOrRightAxis-EquityClassifiedWarrantsMember", "decimals": "INF", "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R23": { "firstAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2023-03-31_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "022 - Disclosure - Note 3 - Warrants - Assumptions Used (Details)", "menuCat": "Details", "order": "23", "role": "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "shortName": "Note 3 - Warrants - Assumptions Used (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2023-03-31_MeasurementInputTypeAxis-MeasurementInputRiskFreeInterestRateMember_RangeAxis-MinimumMember", "decimals": "2", "first": true, "lang": null, "name": "us-gaap:WarrantsAndRightsOutstandingMeasurementInput", "reportCount": 1, "unique": true, "unitRef": "Pure", "xsiNil": "false" } }, "R24": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantActivityTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2022-12-31_ClassOfWarrantOrRightAxis-LiabilityClassifiedWarrantsMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:ClassOfWarrantOrRightOutstanding", "reportCount": 1, "unitRef": "Share", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "023 - Disclosure - Note 3 - Warrants - Warrant Activity (Details)", "menuCat": "Details", "order": "24", "role": "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details", "shortName": "Note 3 - Warrants - Warrant Activity (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mbrx:ScheduleOfWarrantActivityTableTextBlock", "mbrx:WarrantsDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_ClassOfWarrantOrRightAxis-LiabilityClassifiedWarrantsMember", "decimals": null, "lang": "en-US", "name": "mbrx:ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R25": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:ProceedsFromIssuanceOfCommonStock", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "024 - Disclosure - Note 4 - Equity (Details Textual)", "menuCat": "Details", "order": "25", "role": "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "shortName": "Note 4 - Equity (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_CounterpartyNameAxis-WPDPharmaceuticalsMember_TransactionTypeAxis-LicenseTerminationMember", "decimals": "INF", "lang": null, "name": "mbrx:PaymentRelatedToTerminationClause", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R26": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "025 - Disclosure - Note 4 - Equity - Stock based Compensation (Details)", "menuCat": "Details", "order": "26", "role": "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details", "shortName": "Note 4 - Equity - Stock based Compensation (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "mbrx:SharebasedPaymentArrangementExpensedAmountTableTextBlock", "us-gaap:StockholdersEquityNoteDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31_IncomeStatementLocationAxis-GeneralAndAdministrativeExpenseMember", "decimals": "-3", "lang": null, "name": "us-gaap:AllocatedShareBasedCompensationExpense", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R27": { "firstAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "026 - Disclosure - Note 5 - Income Taxes (Details Textual)", "menuCat": "Details", "order": "27", "role": "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual", "shortName": "Note 5 - Income Taxes (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "p", "us-gaap:IncomeTaxDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:IncomeTaxExpenseBenefit", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R28": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "027 - Disclosure - Note 6 - Commitments and Contingencies (Details Textual)", "menuCat": "Details", "order": "28", "role": "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "shortName": "Note 6 - Commitments and Contingencies (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SubleaseIncome", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R29": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "028 - Disclosure - Note 6 - Commitments and Contingencies - Lease Cost (Details)", "menuCat": "Details", "order": "29", "role": "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details", "shortName": "Note 6 - Commitments and Contingencies - Lease Cost (Details)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "us-gaap:LeaseCostTableTextBlock", "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:OperatingLeaseCost", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R3": { "firstAnchor": null, "groupType": "statement", "isDefault": "false", "longName": "002 - Statement - Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "menuCat": "Statements", "order": "3", "role": "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "shortName": "Condensed Consolidated Balance Sheets (Current Period Unaudited) (Parentheticals)", "subGroupType": "parenthetical", "uniqueAnchor": null }, "R30": { "firstAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2023-05-05_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "mbrx:NASDAQComplianceMinimumClosingBidPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "029 - Disclosure - Note 7 - Subsequent Events (Details Textual)", "menuCat": "Details", "order": "30", "role": "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual", "shortName": "Note 7 - Subsequent Events (Details Textual)", "subGroupType": "details", "uniqueAnchor": { "ancestors": [ "span", "p", "us-gaap:SubsequentEventsTextBlock", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2023-05-05_SubsequentEventTypeAxis-SubsequentEventMember", "decimals": "INF", "first": true, "lang": null, "name": "mbrx:NASDAQComplianceMinimumClosingBidPricePerShare", "reportCount": 1, "unique": true, "unitRef": "USDPerShare", "xsiNil": "false" } }, "R4": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "003 - Statement - Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "menuCat": "Statements", "order": "4", "role": "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "shortName": "Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:Revenues", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R5": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "first": true, "lang": null, "name": "us-gaap:NetIncomeLoss", "reportCount": 1, "unitRef": "USD", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "004 - Statement - Condensed Consolidated Statements of Cash Flows (Unaudited)", "menuCat": "Statements", "order": "5", "role": "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "shortName": "Condensed Consolidated Statements of Cash Flows (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": "-3", "lang": null, "name": "us-gaap:ShareBasedCompensation", "reportCount": 1, "unique": true, "unitRef": "USD", "xsiNil": "false" } }, "R6": { "firstAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" }, "groupType": "statement", "isDefault": "false", "longName": "005 - Statement - Condensed Consolidated Statement of Stockholders Equity (Unaudited)", "menuCat": "Statements", "order": "6", "role": "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "shortName": "Condensed Consolidated Statement of Stockholders Equity (Unaudited)", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "td", "tr", "tbody", "table", "div", "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "i_2021-12-31_StatementEquityComponentsAxis-CommonStockMember", "decimals": "INF", "first": true, "lang": null, "name": "us-gaap:SharesOutstanding", "reportCount": 1, "unique": true, "unitRef": "Share", "xsiNil": "false" } }, "R7": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "006 - Disclosure - Note 1 - Nature of Business", "menuCat": "Notes", "order": "7", "role": "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business", "shortName": "Note 1 - Nature of Business", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:NatureOfOperations", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R8": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "007 - Disclosure - Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity", "menuCat": "Notes", "order": "8", "role": "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "shortName": "Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "us-gaap:SignificantAccountingPoliciesTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } }, "R9": { "firstAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mbrx:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "disclosure", "isDefault": "false", "longName": "008 - Disclosure - Note 3 - Warrants", "menuCat": "Notes", "order": "9", "role": "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "shortName": "Note 3 - Warrants", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "body", "html" ], "baseRef": "mbrx20230331_10q.htm", "contextRef": "d_2023-01-01_2023-03-31", "decimals": null, "first": true, "lang": "en-US", "name": "mbrx:WarrantsDisclosureTextBlock", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 29, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentFiscalPeriodFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.", "label": "Document Fiscal Period Focus" } } }, "localname": "DocumentFiscalPeriodFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "fiscalPeriodItemType" }, "dei_DocumentFiscalYearFocus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.", "label": "Document Fiscal Year Focus" } } }, "localname": "DocumentFiscalYearFocus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "gYearItemType" }, "dei_DocumentInformationLineItems": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Document Information [Line Items]" } } }, "localname": "DocumentInformationLineItems", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "stringItemType" }, "dei_DocumentInformationTable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Container to support the formal attachment of each official or unofficial, public or private document as part of a submission package.", "label": "Document Information [Table]" } } }, "localname": "DocumentInformationTable", "nsuri": "http://xbrl.sec.gov/dei/2023", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "dateItemType" }, "dei_DocumentQuarterlyReport": { "auth_ref": [ "r421" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as an quarterly report.", "label": "Document Quarterly Report" } } }, "localname": "DocumentQuarterlyReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentTransitionReport": { "auth_ref": [ "r422" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true only for a form used as a transition report.", "label": "Document Transition Report" } } }, "localname": "DocumentTransitionReport", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityCommonStockSharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.", "label": "Entity Common Stock, Shares Outstanding" } } }, "localname": "EntityCommonStockSharesOutstanding", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "sharesItemType" }, "dei_EntityCurrentReportingStatus": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Current Reporting Status" } } }, "localname": "EntityCurrentReportingStatus", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "All the names of the entities being reported upon in a document. Any legal structure used to conduct activities or to hold assets. Some examples of such structures are corporations, partnerships, limited liability companies, grantor trusts, and other trusts. This item does not include business and geographical segments which are included in the geographical or business segments domains.", "label": "Entity [Domain]" } } }, "localname": "EntityDomain", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20230331/role/statement-document-and-entity-information", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity-tables", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual", "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "domainItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "fileNumberItemType" }, "dei_EntityFilerCategory": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.", "label": "Entity Filer Category" } } }, "localname": "EntityFilerCategory", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "filerCategoryItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInteractiveDataCurrent": { "auth_ref": [ "r423" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).", "label": "Entity Interactive Data Current" } } }, "localname": "EntityInteractiveDataCurrent", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "yesNoItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityShellCompany": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.", "label": "Entity Shell Company" } } }, "localname": "EntityShellCompany", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntitySmallBusiness": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).", "label": "Entity Small Business" } } }, "localname": "EntitySmallBusiness", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "booleanItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r419" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "employerIdItemType" }, "dei_LegalEntityAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The set of legal entities associated with a report.", "label": "Legal Entity [Axis]" } } }, "localname": "LegalEntityAxis", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20230331/role/statement-document-and-entity-information", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity-tables", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual", "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "normalizedStringItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r418" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r420" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-document-and-entity-information" ], "xbrltype": "tradingSymbolItemType" }, "mbrx_ClassOfWarrantOrRightCancelledDuringPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of warrants or rights cancelled during period.", "label": "mbrx_ClassOfWarrantOrRightCancelledDuringPeriod", "negatedLabel": "Expired warrants (in shares)" } } }, "localname": "ClassOfWarrantOrRightCancelledDuringPeriod", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "mbrx_ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share of warrants or rights cancelled during period.", "label": "Expired warrants (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightCancelledDuringPeriodExercisePrice", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "mbrx_ClassOfWarrantOrRightVestedAndExercisable": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights vested and exercisable.", "label": "Exercisable (in shares)", "terseLabel": "Class of Warrant or Right, Vested and Exercisable (in shares)" } } }, "localname": "ClassOfWarrantOrRightVestedAndExercisable", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "mbrx_ClassOfWarrantOrRightVestedAndExercisableExercisePrice": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights vested and exercisable.", "label": "Exercisable, warrant exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightVestedAndExercisableExercisePrice", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "mbrx_ClassOfWarrantOrRightVestedAndExercisableWeightedAverageRemainingContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of warrants or rights vested and exercisable.", "label": "Exercisable, weighted average remaining contractual life (Year)" } } }, "localname": "ClassOfWarrantOrRightVestedAndExercisableWeightedAverageRemainingContractualLife", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "durationItemType" }, "mbrx_ClassOfWarrantOrRightWeightedAverageRemainingContractualLife": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The weighted average remaining contractual life of warrants or rights outstanding.", "label": "Balance, weighted average remaining contractual life (Year)" } } }, "localname": "ClassOfWarrantOrRightWeightedAverageRemainingContractualLife", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "durationItemType" }, "mbrx_CommonStockIssuedForLicenceRightsUnderLicenseAgreement": { "auth_ref": [], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of common stock issued for license rights under license agreement.", "label": "License rights expense settled in stock" } } }, "localname": "CommonStockIssuedForLicenceRightsUnderLicenseAgreement", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "mbrx_EquityClassifiedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents equity classified warrants.", "label": "Equity Classified Warrants [Member]" } } }, "localname": "EquityClassifiedWarrantsMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_ExplorationInvestPteLtdExplorationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Exploration Invest Pte Ltd. (Exploration).", "label": "Exploration Invest Pte Ltd. (Exploration) [Member]" } } }, "localname": "ExplorationInvestPteLtdExplorationMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_HoustonPharmaceuticalsIncMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents Houston Pharmaceuticals, Inc.", "label": "Houston Pharmaceuticals, Inc [Member]" } } }, "localname": "HoustonPharmaceuticalsIncMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_LiabilityClassifiedWarrantsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents liability classified warrants.", "label": "Liability Classified Warrants [Member]" } } }, "localname": "LiabilityClassifiedWarrantsMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "domainItemType" }, "mbrx_LicenseAgreementsExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense for licensing agreements.", "label": "mbrx_LicenseAgreementsExpense", "terseLabel": "License Agreements Expense" } } }, "localname": "LicenseAgreementsExpense", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "mbrx_LicenseTerminationMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to a license termination agreement.", "label": "License Termination [Member]" } } }, "localname": "LicenseTerminationMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_LicenseTerminationsExpense": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of license terminations expense.", "label": "mbrx_LicenseTerminationsExpense", "terseLabel": "License Terminations Expense" } } }, "localname": "LicenseTerminationsExpense", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "mbrx_LincolnParkTransactionMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the Lincoln park transaction.", "label": "Lincoln Park Transaction [Member]" } } }, "localname": "LincolnParkTransactionMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_LiquidityAndFinancialConditionPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for liquidity and financial condition.", "label": "Liquidity and Financial Condition [Policy Text Block]" } } }, "localname": "LiquidityAndFinancialConditionPolicyTextBlock", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "mbrx_MDAndersonMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents MD Anderson.", "label": "MD Anderson [Member]" } } }, "localname": "MDAndersonMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_NASDAQComplianceExtensionPeriod": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to the extension period granted.", "label": "mbrx_NASDAQComplianceExtensionPeriod", "terseLabel": "NASDAQ Compliance, Extension Period (Day)" } } }, "localname": "NASDAQComplianceExtensionPeriod", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual" ], "xbrltype": "durationItemType" }, "mbrx_NASDAQComplianceMinimumClosingBidPricePerShare": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining to Nasdaq Global minimum bid price requirement.", "label": "mbrx_NASDAQComplianceMinimumClosingBidPricePerShare", "terseLabel": "NASDAQ Compliance, Minimum Closing Bid Price Per Share (in dollars per share)" } } }, "localname": "NASDAQComplianceMinimumClosingBidPricePerShare", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual" ], "xbrltype": "perShareItemType" }, "mbrx_NoteToFinancialStatementDetailsTextual": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note To Financial Statement Details Textual" } } }, "localname": "NoteToFinancialStatementDetailsTextual", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_NotesToFinancialStatementsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Notes To Financial Statements [Abstract]" } } }, "localname": "NotesToFinancialStatementsAbstract", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_NumberOfCoreDrugTechnologies": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of core drug technologies.", "label": "mbrx_NumberOfCoreDrugTechnologies", "terseLabel": "Number of Core Drug Technologies" } } }, "localname": "NumberOfCoreDrugTechnologies", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business-details-textual" ], "xbrltype": "integerItemType" }, "mbrx_OperatingLeaseNoncashExpenseNet": { "auth_ref": [], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 7.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of noncash expense for operating lease, net.", "label": "Operating lease, net" } } }, "localname": "OperatingLeaseNoncashExpenseNet", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "mbrx_PaymentRelatedToTerminationClause": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Information on payment made pursuant to the contract termination clause.", "label": "mbrx_PaymentRelatedToTerminationClause", "terseLabel": "Payment, Related to Termination Clause" } } }, "localname": "PaymentRelatedToTerminationClause", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "mbrx_PaymentsForResearchAndDevelopmentAgreement": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Represents payments for research and development agreement.", "label": "mbrx_PaymentsForResearchAndDevelopmentAgreement", "terseLabel": "Payments For Research And Development Agreement" } } }, "localname": "PaymentsForResearchAndDevelopmentAgreement", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "mbrx_PaymentsForTerminationOfCommitment": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of cash outflow for the termination of a commitment.", "label": "mbrx_PaymentsForTerminationOfCommitment", "terseLabel": "Payments for Termination of Commitment" } } }, "localname": "PaymentsForTerminationOfCommitment", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "mbrx_PurchaseAgreementCommonStockAvailableAmount": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The remaining amount of common stock that can be sold under the purchase agreement.", "label": "mbrx_PurchaseAgreementCommonStockAvailableAmount", "terseLabel": "Purchase Agreement, Common Stock, Available Amount" } } }, "localname": "PurchaseAgreementCommonStockAvailableAmount", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "mbrx_ScheduleOfWarrantActivityTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for warrant activity.", "label": "Schedule of Warrant Activity [Table Text Block]" } } }, "localname": "ScheduleOfWarrantActivityTableTextBlock", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables" ], "xbrltype": "textBlockItemType" }, "mbrx_ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The tabular disclosure for assumptions used for warrants or rights.", "label": "Schedule of Warrants or Rights, Assumptions Used [Table Text Block]" } } }, "localname": "ScheduleOfWarrantsOrRightsAssumptionsUsedTableTextBlock", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables" ], "xbrltype": "textBlockItemType" }, "mbrx_SharebasedPaymentArrangementExpensedAmountTableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of allocation of amount expensed for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.", "label": "Share-based Payment Arrangement, Expensed, Amount [Table Text Block]" } } }, "localname": "SharebasedPaymentArrangementExpensedAmountTableTextBlock", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity-tables" ], "xbrltype": "textBlockItemType" }, "mbrx_SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount": { "auth_ref": [], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.", "label": "mbrx_SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount", "terseLabel": "Share-based Payment Arrangement, Nonvested Award, Cost Not yet Recognized, Amount" } } }, "localname": "SharebasedPaymentArrangementNonvestedAwardCostNotYetRecognizedAmount", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual" ], "xbrltype": "monetaryItemType" }, "mbrx_SignificantAccountingPoliciesPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Policy Text Block]" } } }, "localname": "SignificantAccountingPoliciesPolicyTextBlock", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "mbrx_SponsoredResearchMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Related to sponsored research.", "label": "Sponsored Research [Member]" } } }, "localname": "SponsoredResearchMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_StockIssuedDuringPeriodSharesLicenseRights": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The number of shares of stock issued during the period for license rights.", "label": "Common stock issued for license rights (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesLicenseRights", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "mbrx_StockIssuedDuringPeriodValueLicenseRights": { "auth_ref": [], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The amount of stock issued during the period for license rights.", "label": "Common stock issued for license rights" } } }, "localname": "StockIssuedDuringPeriodValueLicenseRights", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "mbrx_The2015StockPlanMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents the 2015 stock plan.", "label": "The 2015 Stock Plan [Member]" } } }, "localname": "The2015StockPlanMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_WPDPharmaceuticalsMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents information related to WPD Pharmaceuticals.", "label": "WPD Pharmaceuticals [Member]" } } }, "localname": "WPDPharmaceuticalsMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "mbrx_WarrantLiabilityLongTermMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information pertaining the long term warrant liability.", "label": "Warrant Liability Long Term [Member]" } } }, "localname": "WarrantLiabilityLongTermMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "mbrx_WarrantLiabilityMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Represents warrant liability.", "label": "Warrant Liability [Member]" } } }, "localname": "WarrantLiabilityMember", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "mbrx_WarrantsDisclosureTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for warrants.", "label": "Warrants Disclosure [Text Block]" } } }, "localname": "WarrantsDisclosureTextBlock", "nsuri": "http://www.moleculin.com/20230331", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants" ], "xbrltype": "textBlockItemType" }, "mbrx_statement-statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity - Schedule of Fair Value Measurements, Recurring and Nonrecurring (Details)" } } }, "localname": "statement-statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 2 - Basis of Presentation, Principles of Consolidation, Significant Accounting Policies and Liquidity" } } }, "localname": "statement-statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-3-warrants-assumptions-used-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Warrants - Assumptions Used (Details)" } } }, "localname": "statement-statement-note-3-warrants-assumptions-used-details", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-3-warrants-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Warrants" } } }, "localname": "statement-statement-note-3-warrants-tables", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-3-warrants-warrant-activity-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 3 - Warrants - Warrant Activity (Details)" } } }, "localname": "statement-statement-note-3-warrants-warrant-activity-details", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-4-equity-stock-based-compensation-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Equity - Stock based Compensation (Details)" } } }, "localname": "statement-statement-note-4-equity-stock-based-compensation-details", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-4-equity-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 4 - Equity" } } }, "localname": "statement-statement-note-4-equity-tables", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-6-commitments-and-contingencies-lease-cost-details": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Commitments and Contingencies - Lease Cost (Details)" } } }, "localname": "statement-statement-note-6-commitments-and-contingencies-lease-cost-details", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-note-6-commitments-and-contingencies-tables": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Note 6 - Commitments and Contingencies" } } }, "localname": "statement-statement-note-6-commitments-and-contingencies-tables", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "mbrx_statement-statement-significant-accounting-policies-policies": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Significant Accounting Policies" } } }, "localname": "statement-statement-significant-accounting-policies-policies", "nsuri": "http://www.moleculin.com/20230331", "xbrltype": "stringItemType" }, "srt_CounterpartyNameAxis": { "auth_ref": [ "r100", "r101", "r160", "r165", "r275", "r389", "r391" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Axis]" } } }, "localname": "CounterpartyNameAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "srt_MaximumMember": { "auth_ref": [ "r147", "r148", "r149", "r150", "r186", "r283", "r312", "r324", "r325", "r378", "r379", "r380", "r381", "r382", "r386", "r387", "r396", "r399", "r403", "r406", "r438", "r446", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Maximum [Member]" } } }, "localname": "MaximumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "domainItemType" }, "srt_MinimumMember": { "auth_ref": [ "r147", "r148", "r149", "r150", "r186", "r283", "r312", "r324", "r325", "r378", "r379", "r380", "r381", "r382", "r386", "r387", "r396", "r399", "r403", "r406", "r438", "r446", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Minimum [Member]" } } }, "localname": "MinimumMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "domainItemType" }, "srt_RangeAxis": { "auth_ref": [ "r147", "r148", "r149", "r150", "r178", "r186", "r210", "r211", "r212", "r282", "r283", "r312", "r324", "r325", "r378", "r379", "r380", "r381", "r382", "r386", "r387", "r396", "r399", "r403", "r406", "r409", "r434", "r438", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Axis]" } } }, "localname": "RangeAxis", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "stringItemType" }, "srt_RangeMember": { "auth_ref": [ "r147", "r148", "r149", "r150", "r178", "r186", "r210", "r211", "r212", "r282", "r283", "r312", "r324", "r325", "r378", "r379", "r380", "r381", "r382", "r386", "r387", "r396", "r399", "r403", "r406", "r409", "r434", "r438", "r447", "r448", "r449", "r450", "r451" ], "lang": { "en-us": { "role": { "label": "Statistical Measurement [Domain]" } } }, "localname": "RangeMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "domainItemType" }, "srt_RepurchaseAgreementCounterpartyNameDomain": { "auth_ref": [ "r100", "r101", "r160", "r165", "r275", "r390", "r391" ], "lang": { "en-us": { "role": { "label": "Counterparty Name [Domain]" } } }, "localname": "RepurchaseAgreementCounterpartyNameDomain", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "srt_WeightedAverageMember": { "auth_ref": [ "r386", "r387", "r446", "r448", "r451" ], "lang": { "en-us": { "role": { "label": "Weighted Average [Member]" } } }, "localname": "WeightedAverageMember", "nsuri": "http://fasb.org/srt/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_AccountingPoliciesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Accounting Policies [Abstract]" } } }, "localname": "AccountingPoliciesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_AccountsPayableCurrent": { "auth_ref": [ "r15", "r405" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "Accounts payable" } } }, "localname": "AccountsPayableCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccruedLiabilitiesCurrent": { "auth_ref": [ "r17" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesCurrent", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).", "label": "us-gaap_AccruedLiabilitiesCurrent", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "AccruedLiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AccumulatedOtherComprehensiveIncomeMember": { "auth_ref": [ "r2", "r10", "r21", "r238", "r241", "r272", "r313", "r314", "r425", "r426", "r427", "r429", "r430", "r431" ], "lang": { "en-us": { "role": { "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.", "label": "AOCI Attributable to Parent [Member]" } } }, "localname": "AccumulatedOtherComprehensiveIncomeMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdditionalPaidInCapitalCommonStock": { "auth_ref": [ "r43" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Value received from shareholders in common stock-related transactions that are in excess of par value or stated value and amounts received from other stock-related transactions. Includes only common stock transactions (excludes preferred stock transactions). May be called contributed capital, capital in excess of par, capital surplus, or paid-in capital.", "label": "Additional paid-in capital" } } }, "localname": "AdditionalPaidInCapitalCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdditionalPaidInCapitalMember": { "auth_ref": [ "r215", "r216", "r217", "r322", "r429", "r430", "r431", "r439", "r454" ], "lang": { "en-us": { "role": { "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.", "label": "Additional Paid-in Capital [Member]" } } }, "localname": "AdditionalPaidInCapitalMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": { "auth_ref": [ "r33", "r34", "r187" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.", "label": "Stock-based compensation" } } }, "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Adjustments to reconcile net loss to net cash used in operating activities:" } } }, "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AllocatedShareBasedCompensationExpense": { "auth_ref": [ "r214", "r218" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.", "label": "Share-Based Payment Arrangement, Expense", "terseLabel": "Share-Based Payment Arrangement, Expense" } } }, "localname": "AllocatedShareBasedCompensationExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": { "auth_ref": [ "r121" ], "lang": { "en-us": { "role": { "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.", "label": "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "terseLabel": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount (in shares)" } } }, "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_AociBeforeTaxAttributableToParent": { "auth_ref": [], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount before tax of increase (decrease) in accumulated equity from transactions and other events and circumstances from non-owner sources, attributable to parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners (distributions to owners).", "label": "Accumulated other comprehensive income" } } }, "localname": "AociBeforeTaxAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_Assets": { "auth_ref": [ "r65", "r81", "r98", "r124", "r131", "r135", "r140", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r233", "r235", "r255", "r301", "r346", "r405", "r417", "r436", "r437", "r444" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_Assets", "totalLabel": "Total assets" } } }, "localname": "Assets", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrent": { "auth_ref": [ "r78", "r82", "r98", "r140", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r233", "r235", "r255", "r405", "r436", "r437", "r444" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.", "label": "us-gaap_AssetsCurrent", "totalLabel": "Total current assets" } } }, "localname": "AssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_AssetsCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current assets:" } } }, "localname": "AssetsCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_AwardTypeAxis": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Information by type of award under share-based payment arrangement.", "label": "Award Type [Axis]" } } }, "localname": "AwardTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).", "label": "Basis of Accounting, Policy [Policy Text Block]" } } }, "localname": "BasisOfAccountingPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashAndCashEquivalentsAtCarryingValue": { "auth_ref": [ "r23", "r80", "r388" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.", "label": "Cash and cash equivalents", "terseLabel": "Cash and Cash Equivalents, at Carrying Value" } } }, "localname": "CashAndCashEquivalentsAtCarryingValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashAndCashEquivalentsPolicyTextBlock": { "auth_ref": [ "r24" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.", "label": "Cash and Cash Equivalents, Policy [Policy Text Block]" } } }, "localname": "CashAndCashEquivalentsPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r23", "r54", "r95" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "periodEndLabel": "Cash and cash equivalents, - end of period", "periodStartLabel": "Cash and cash equivalents, - beginning of period" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": { "auth_ref": [ "r1", "r54" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "totalLabel": "Net decrease in cash and cash equivalents" } } }, "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ClassOfWarrantOrRightAxis": { "auth_ref": [ "r31" ], "lang": { "en-us": { "role": { "documentation": "Information by type of warrant or right issued.", "label": "Class of Warrant or Right [Axis]" } } }, "localname": "ClassOfWarrantOrRightAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "stringItemType" }, "us-gaap_ClassOfWarrantOrRightDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the class or type of warrant or right outstanding. Warrants and rights represent derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months.", "label": "Class of Warrant or Right [Domain]" } } }, "localname": "ClassOfWarrantOrRightDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "domainItemType" }, "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1": { "auth_ref": [ "r176" ], "lang": { "en-us": { "role": { "documentation": "Exercise price per share or per unit of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "periodEndLabel": "Balance, warrant exercise price (in dollars per share)", "periodStartLabel": "Balance, warrant exercise price (in dollars per share)" } } }, "localname": "ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "perShareItemType" }, "us-gaap_ClassOfWarrantOrRightOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of warrants or rights outstanding.", "label": "us-gaap_ClassOfWarrantOrRightOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)", "terseLabel": "Class of Warrant or Right, Outstanding (in shares)" } } }, "localname": "ClassOfWarrantOrRightOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details" ], "xbrltype": "sharesItemType" }, "us-gaap_CommitmentsAndContingencies": { "auth_ref": [ "r19", "r39", "r302", "r333" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Represents the caption on the face of the balance sheet to indicate that the entity has entered into (1) purchase or supply arrangements that will require expending a portion of its resources to meet the terms thereof, and (2) is exposed to potential losses or, less frequently, gains, arising from (a) possible claims against a company's resources due to future performance under contract terms, and (b) possible losses or likely gains from uncertainties that will ultimately be resolved when one or more future events that are deemed likely to occur do occur or fail to occur.", "label": "Commitments and contingencies (Note 6)" } } }, "localname": "CommitmentsAndContingencies", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": { "auth_ref": [ "r59", "r145", "r146", "r385", "r435" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for commitments and contingencies.", "label": "Commitments and Contingencies Disclosure [Text Block]" } } }, "localname": "CommitmentsAndContingenciesDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies" ], "xbrltype": "textBlockItemType" }, "us-gaap_CommonStockMember": { "auth_ref": [ "r407", "r408", "r409", "r411", "r412", "r413", "r414", "r429", "r430", "r439", "r453", "r454" ], "lang": { "en-us": { "role": { "documentation": "Stock that is subordinate to all other stock of the issuer.", "label": "Common Stock [Member]" } } }, "localname": "CommonStockMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_CommonStockParOrStatedValuePerShare": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of common stock.", "label": "Common stock, par or stated value per share ( (in dollars per share)" } } }, "localname": "CommonStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_CommonStockSharesAuthorized": { "auth_ref": [ "r42", "r334" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.", "label": "Common stock, shares authorized (in shares)" } } }, "localname": "CommonStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesIssued": { "auth_ref": [ "r42" ], "lang": { "en-us": { "role": { "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.", "label": "Common stock, shares issued (in shares)" } } }, "localname": "CommonStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockSharesOutstanding": { "auth_ref": [ "r11", "r42", "r334", "r352", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.", "label": "Common stock, shares outstanding (in shares)" } } }, "localname": "CommonStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_CommonStockValue": { "auth_ref": [ "r42", "r304", "r405" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Common stock, $0.001 par value; 100,000,000 shares authorized; 29,600,323 and 28,627,827 shares issued and outstanding at March 31, 2023 and December 31, 2022, respectively" } } }, "localname": "CommonStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ComprehensiveIncomeNetOfTax": { "auth_ref": [ "r22", "r85", "r87", "r92", "r297", "r309" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.", "label": "us-gaap_ComprehensiveIncomeNetOfTax", "totalLabel": "Comprehensive loss" } } }, "localname": "ComprehensiveIncomeNetOfTax", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ConsolidationPolicyTextBlock": { "auth_ref": [ "r35", "r392" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy regarding (1) the principles it follows in consolidating or combining the separate financial statements, including the principles followed in determining the inclusion or exclusion of subsidiaries or other entities in the consolidated or combined financial statements and (2) its treatment of interests (for example, common stock, a partnership interest or other means of exerting influence) in other entities, for example consolidation or use of the equity or cost methods of accounting. The accounting policy may also address the accounting treatment for intercompany accounts and transactions, noncontrolling interest, and the income statement treatment in consolidation for issuances of stock by a subsidiary.", "label": "Consolidation, Policy [Policy Text Block]" } } }, "localname": "ConsolidationPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_DepreciationDepletionAndAmortization": { "auth_ref": [ "r6", "r127" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.", "label": "Depreciation and amortization" } } }, "localname": "DepreciationDepletionAndAmortization", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DerivativeLiabilitiesNoncurrent": { "auth_ref": [ "r83" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value, after the effects of master netting arrangements, of a financial liability or contract with one or more underlyings, notional amount or payment provision or both, and the contract can be net settled by means outside the contract or delivery of an asset, expected to be settled after one year or the normal operating cycle, if longer. Includes assets not subject to a master netting arrangement and not elected to be offset.", "label": "Warrant liability - long-term" } } }, "localname": "DerivativeLiabilitiesNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_DisclosureTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_DisclosureTextBlockAbstract", "terseLabel": "Notes to Financial Statements" } } }, "localname": "DisclosureTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events" ], "xbrltype": "stringItemType" }, "us-gaap_EarningsPerShareBasic": { "auth_ref": [ "r93", "r107", "r108", "r109", "r110", "r111", "r115", "r116", "r118", "r119", "r120", "r122", "r245", "r246", "r298", "r310", "r393" ], "lang": { "en-us": { "role": { "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.", "label": "Net loss per common share - basic and diluted (in dollars per share)" } } }, "localname": "EarningsPerShareBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "perShareItemType" }, "us-gaap_EarningsPerSharePolicyTextBlock": { "auth_ref": [ "r25", "r26" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.", "label": "Earnings Per Share, Policy [Policy Text Block]" } } }, "localname": "EarningsPerSharePolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": { "auth_ref": [ "r256" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of increase (decrease) from effect of exchange rate changes on cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; held in foreign currencies. Excludes amounts for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.", "label": "Effect of exchange rate changes on cash and cash equivalents" } } }, "localname": "EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_EffectiveIncomeTaxRateContinuingOperations": { "auth_ref": [ "r222" ], "lang": { "en-us": { "role": { "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_EffectiveIncomeTaxRateContinuingOperations", "terseLabel": "Effective Income Tax Rate Reconciliation, Percent" } } }, "localname": "EffectiveIncomeTaxRateContinuingOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "percentItemType" }, "us-gaap_EquityComponentDomain": { "auth_ref": [ "r11", "r76", "r88", "r89", "r90", "r102", "r103", "r104", "r106", "r112", "r114", "r123", "r141", "r142", "r177", "r215", "r216", "r217", "r226", "r227", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r257", "r258", "r259", "r260", "r261", "r262", "r272", "r313", "r314", "r315", "r322", "r372" ], "lang": { "en-us": { "role": { "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.", "label": "Equity Component [Domain]" } } }, "localname": "EquityComponentDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueAdjustmentOfWarrants": { "auth_ref": [ "r0", "r6" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 8.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of expense (income) related to adjustment to fair value of warrant liability.", "label": "Change in fair value of warrant liability", "negatedLabel": "Gain from change in fair value of warrant liability" } } }, "localname": "FairValueAdjustmentOfWarrants", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock": { "auth_ref": [ "r13", "r36", "r37", "r64" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of financial instruments measured at fair value, including those classified in shareholders' equity measured on a recurring or nonrecurring basis. Disclosures include, but are not limited to, fair value measurements recorded and the reasons for the measurements, level within the fair value hierarchy in which the fair value measurements are categorized and transfers between levels 1 and 2. Nonrecurring fair value measurements are those that are required or permitted in the statement of financial position in particular circumstances.", "label": "Fair Value Measurements, Recurring and Nonrecurring [Table Text Block]" } } }, "localname": "FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_FairValueByFairValueHierarchyLevelAxis": { "auth_ref": [ "r161", "r179", "r180", "r181", "r182", "r183", "r184", "r249", "r279", "r280", "r281", "r397", "r398", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.", "label": "Fair Value Hierarchy and NAV [Axis]" } } }, "localname": "FairValueByFairValueHierarchyLevelAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByLiabilityClassAxis": { "auth_ref": [ "r37", "r63" ], "lang": { "en-us": { "role": { "documentation": "Information by class of liability.", "label": "Liability Class [Axis]" } } }, "localname": "FairValueByLiabilityClassAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueByMeasurementFrequencyAxis": { "auth_ref": [ "r248", "r249", "r251", "r252", "r254" ], "lang": { "en-us": { "role": { "documentation": "Information by measurement frequency.", "label": "Measurement Frequency [Axis]" } } }, "localname": "FairValueByMeasurementFrequencyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "stringItemType" }, "us-gaap_FairValueInputsLevel1Member": { "auth_ref": [ "r161", "r179", "r184", "r249", "r279", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.", "label": "Fair Value, Inputs, Level 1 [Member]" } } }, "localname": "FairValueInputsLevel1Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel2Member": { "auth_ref": [ "r161", "r179", "r184", "r249", "r280", "r397", "r398", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.", "label": "Fair Value, Inputs, Level 2 [Member]" } } }, "localname": "FairValueInputsLevel2Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueInputsLevel3Member": { "auth_ref": [ "r161", "r179", "r180", "r181", "r182", "r183", "r184", "r249", "r281", "r397", "r398", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "Fair Value, Inputs, Level 3 [Member]" } } }, "localname": "FairValueInputsLevel3Member", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain": { "auth_ref": [ "r12" ], "lang": { "en-us": { "role": { "documentation": "Represents classes of liabilities measured and disclosed at fair value.", "label": "Fair Value by Liability Class [Domain]" } } }, "localname": "FairValueLiabilitiesMeasuredOnRecurringBasisUnobservableInputReconciliationByLiabilityClassDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementFrequencyDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement frequency.", "label": "Measurement Frequency [Domain]" } } }, "localname": "FairValueMeasurementFrequencyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings": { "auth_ref": [ "r253" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of gain (loss) recognized in income from liability measured at fair value on recurring basis using unobservable input (level 3).", "label": "Change in fair value - net" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityGainLossIncludedInEarnings", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue": { "auth_ref": [ "r12" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial instrument classified as a liability measured using unobservable inputs that reflect the entity's own assumption about the assumptions market participants would use in pricing.", "label": "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "periodEndLabel": "Balance", "periodStartLabel": "Balance" } } }, "localname": "FairValueMeasurementWithUnobservableInputsReconciliationsRecurringBasisLiabilityValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": { "auth_ref": [ "r161", "r179", "r180", "r181", "r182", "r183", "r184", "r279", "r280", "r281", "r397", "r398", "r400", "r401", "r402" ], "lang": { "en-us": { "role": { "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.", "label": "Fair Value Hierarchy and NAV [Domain]" } } }, "localname": "FairValueMeasurementsFairValueHierarchyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueMeasurementsRecurringMember": { "auth_ref": [ "r247", "r254" ], "lang": { "en-us": { "role": { "documentation": "Frequent fair value measurement. Includes, but is not limited to, fair value adjustment for impairment of asset, liability or equity, frequently measured at fair value.", "label": "Fair Value, Recurring [Member]" } } }, "localname": "FairValueMeasurementsRecurringMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "domainItemType" }, "us-gaap_FairValueOfFinancialInstrumentsPolicy": { "auth_ref": [ "r8", "r14" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.", "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]" } } }, "localname": "FairValueOfFinancialInstrumentsPolicy", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_GeneralAndAdministrativeExpense": { "auth_ref": [ "r51", "r356" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.", "label": "General and administrative" } } }, "localname": "GeneralAndAdministrativeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_GeneralAndAdministrativeExpenseMember": { "auth_ref": [ "r49" ], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption encompassing general and administrative expense.", "label": "General and Administrative Expense [Member]" } } }, "localname": "GeneralAndAdministrativeExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeStatementAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Income Statement [Abstract]" } } }, "localname": "IncomeStatementAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationAxis": { "auth_ref": [ "r143", "r144", "r357" ], "lang": { "en-us": { "role": { "documentation": "Information by location in the income statement.", "label": "Income Statement Location [Axis]" } } }, "localname": "IncomeStatementLocationAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details" ], "xbrltype": "stringItemType" }, "us-gaap_IncomeStatementLocationDomain": { "auth_ref": [ "r144", "r357" ], "lang": { "en-us": { "role": { "documentation": "Location in the income statement.", "label": "Income Statement Location [Domain]" } } }, "localname": "IncomeStatementLocationDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details" ], "xbrltype": "domainItemType" }, "us-gaap_IncomeTaxDisclosureTextBlock": { "auth_ref": [ "r99", "r220", "r223", "r224", "r225", "r228", "r230", "r231", "r232", "r321" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.", "label": "Income Tax Disclosure [Text Block]" } } }, "localname": "IncomeTaxDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes" ], "xbrltype": "textBlockItemType" }, "us-gaap_IncomeTaxExpenseBenefit": { "auth_ref": [ "r68", "r74", "r113", "r114", "r128", "r221", "r229", "r311" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.", "label": "us-gaap_IncomeTaxExpenseBenefit", "terseLabel": "Income Tax Expense (Benefit)" } } }, "localname": "IncomeTaxExpenseBenefit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccountsPayable": { "auth_ref": [ "r5" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 5.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.", "label": "us-gaap_IncreaseDecreaseInAccountsPayable", "terseLabel": "Accounts payable" } } }, "localname": "IncreaseDecreaseInAccountsPayable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInAccruedLiabilities": { "auth_ref": [ "r5" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid.", "label": "us-gaap_IncreaseDecreaseInAccruedLiabilities", "terseLabel": "Accrued expenses and other current liabilities" } } }, "localname": "IncreaseDecreaseInAccruedLiabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Changes in operating assets and liabilities:" } } }, "localname": "IncreaseDecreaseInOperatingCapitalAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_IncreaseDecreaseInPrepaidExpense": { "auth_ref": [ "r5" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 6.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The increase (decrease) during the reporting period in the amount of outstanding money paid in advance for goods or services that bring economic benefits for future periods.", "label": "us-gaap_IncreaseDecreaseInPrepaidExpense", "negatedTerseLabel": "Prepaid expenses and other current assets" } } }, "localname": "IncreaseDecreaseInPrepaidExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_IntangibleAssetsNetIncludingGoodwill": { "auth_ref": [], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Carrying amount of finite-lived intangible assets, indefinite-lived intangible assets and goodwill. Goodwill is an asset representing the future economic benefits arising from other assets acquired in a business combination that are not individually identified and separately recognized. Intangible assets are assets, not including financial assets, lacking physical substance.", "label": "Intangible assets" } } }, "localname": "IntangibleAssetsNetIncludingGoodwill", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterestIncomeExpenseNonoperatingNet": { "auth_ref": [], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 2.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net amount of nonoperating interest income (expense).", "label": "Interest income, net" } } }, "localname": "InterestIncomeExpenseNonoperatingNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_InterimPeriodCostsNotAllocableDomain": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "This element represents the type of costs and expenses incurred during an interim period that cannot be readily identified with the activities or benefits of other interim periods and are charged to the interim period in which incurred.", "label": "Interim Period, Costs Not Allocable [Domain]" } } }, "localname": "InterimPeriodCostsNotAllocableDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_LeaseCost": { "auth_ref": [ "r267", "r404" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lease cost recognized by lessee for lease contract.", "label": "us-gaap_LeaseCost", "totalLabel": "Total" } } }, "localname": "LeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_LeaseCostTableTextBlock": { "auth_ref": [ "r442" ], "lang": { "en-us": { "role": { "documentation": "Tabular disclosure of lessee's lease cost. Includes, but is not limited to, interest expense for finance lease, amortization of right-of-use asset for finance lease, operating lease cost, short-term lease cost, variable lease cost and sublease income.", "label": "Lease, Cost [Table Text Block]" } } }, "localname": "LeaseCostTableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables" ], "xbrltype": "textBlockItemType" }, "us-gaap_LegalFees": { "auth_ref": [ "r50" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The amount of expense provided in the period for legal costs incurred on or before the balance sheet date pertaining to resolved, pending or threatened litigation, including arbitration and mediation proceedings.", "label": "us-gaap_LegalFees", "terseLabel": "Legal Fees" } } }, "localname": "LegalFees", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_Liabilities": { "auth_ref": [ "r16", "r98", "r140", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r234", "r235", "r236", "r255", "r332", "r394", "r417", "r436", "r444", "r445" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.", "label": "us-gaap_Liabilities", "totalLabel": "Total liabilities" } } }, "localname": "Liabilities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesAndStockholdersEquity": { "auth_ref": [ "r47", "r66", "r306", "r405", "r428", "r433", "r441" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": null, "parentTag": null, "root": true, "weight": null } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.", "label": "us-gaap_LiabilitiesAndStockholdersEquity", "totalLabel": "Total liabilities and stockholders\u2019 equity" } } }, "localname": "LiabilitiesAndStockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrent": { "auth_ref": [ "r18", "r79", "r98", "r140", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r234", "r235", "r236", "r255", "r405", "r436", "r444", "r445" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 2.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.", "label": "us-gaap_LiabilitiesCurrent", "totalLabel": "Total current liabilities" } } }, "localname": "LiabilitiesCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_LiabilitiesCurrentAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Current liabilities:" } } }, "localname": "LiabilitiesCurrentAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_LiabilitiesFairValueDisclosure": { "auth_ref": [ "r36" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Fair value of financial and nonfinancial obligations.", "label": "Fair value of warrant liability" } } }, "localname": "LiabilitiesFairValueDisclosure", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_MeasurementInputExpectedTermMember": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using period financial instrument is expected to be outstanding. Excludes maturity date.", "label": "Measurement Input, Expected Term [Member]" } } }, "localname": "MeasurementInputExpectedTermMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputPriceVolatilityMember": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using rate at which price of security will increase (decrease) for given set of returns.", "label": "Measurement Input, Price Volatility [Member]" } } }, "localname": "MeasurementInputPriceVolatilityMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputRiskFreeInterestRateMember": { "auth_ref": [ "r440" ], "lang": { "en-us": { "role": { "documentation": "Measurement input using interest rate on instrument with zero risk of financial loss.", "label": "Measurement Input, Risk Free Interest Rate [Member]" } } }, "localname": "MeasurementInputRiskFreeInterestRateMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details" ], "xbrltype": "domainItemType" }, "us-gaap_MeasurementInputTypeAxis": { "auth_ref": [ "r250" ], "lang": { "en-us": { "role": { "documentation": "Information by type of measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Axis]" } } }, "localname": "MeasurementInputTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details" ], "xbrltype": "stringItemType" }, "us-gaap_MeasurementInputTypeDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Measurement input used to determine value of asset and liability.", "label": "Measurement Input Type [Domain]" } } }, "localname": "MeasurementInputTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details" ], "xbrltype": "domainItemType" }, "us-gaap_NatureOfExpenseAxis": { "auth_ref": [ "r27" ], "lang": { "en-us": { "role": { "documentation": "Information by type of cost or expense.", "label": "Nature of Expense [Axis]" } } }, "localname": "NatureOfExpenseAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_NatureOfOperations": { "auth_ref": [ "r69", "r75" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for the nature of an entity's business, major products or services, principal markets including location, and the relative importance of its operations in each business and the basis for the determination, including but not limited to, assets, revenues, or earnings. For an entity that has not commenced principal operations, disclosures about the risks and uncertainties related to the activities in which the entity is currently engaged and an understanding of what those activities are being directed toward.", "label": "Nature of Operations [Text Block]" } } }, "localname": "NatureOfOperations", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business" ], "xbrltype": "textBlockItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 2.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.", "label": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "totalLabel": "Net cash provided by financing activities" } } }, "localname": "NetCashProvidedByUsedInFinancingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from financing activities:" } } }, "localname": "NetCashProvidedByUsedInFinancingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivities": { "auth_ref": [ "r94" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 3.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.", "label": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "totalLabel": "Net cash used in investing activities" } } }, "localname": "NetCashProvidedByUsedInInvestingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from investing activities:" } } }, "localname": "NetCashProvidedByUsedInInvestingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivities": { "auth_ref": [ "r54", "r55", "r56" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect", "weight": 1.0 } }, "lang": { "en-us": { "role": { "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.", "label": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "terseLabel": "Net Cash Provided by (Used in) Operating Activities", "totalLabel": "Net cash used in operating activities" } } }, "localname": "NetCashProvidedByUsedInOperatingActivities", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Cash flows from operating activities:" } } }, "localname": "NetCashProvidedByUsedInOperatingActivitiesContinuingOperationsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NetIncomeLoss": { "auth_ref": [ "r48", "r56", "r67", "r77", "r84", "r86", "r90", "r98", "r105", "r107", "r108", "r109", "r110", "r113", "r114", "r117", "r124", "r130", "r134", "r136", "r140", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r246", "r255", "r308", "r354", "r370", "r371", "r395", "r415", "r436" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 }, "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.", "label": "Net loss", "terseLabel": "Net Income (Loss) Attributable to Parent", "totalLabel": "Net loss" } } }, "localname": "NetIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.", "label": "New Accounting Pronouncements, Policy [Policy Text Block]" } } }, "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_NonoperatingIncomeExpenseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other income:" } } }, "localname": "NonoperatingIncomeExpenseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_NumberOfOperatingSegments": { "auth_ref": [ "r432" ], "lang": { "en-us": { "role": { "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.", "label": "us-gaap_NumberOfOperatingSegments", "terseLabel": "Number of Operating Segments" } } }, "localname": "NumberOfOperatingSegments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual" ], "xbrltype": "integerItemType" }, "us-gaap_OperatingExpenses": { "auth_ref": [], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_OperatingIncomeLoss", "weight": -1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.", "label": "us-gaap_OperatingExpenses", "totalLabel": "Total operating expenses" } } }, "localname": "OperatingExpenses", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingExpensesAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Operating expenses:" } } }, "localname": "OperatingExpensesAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OperatingIncomeLoss": { "auth_ref": [ "r124", "r130", "r134", "r136", "r395" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The net result for the period of deducting operating expenses from operating revenues.", "label": "us-gaap_OperatingIncomeLoss", "totalLabel": "Loss from operations" } } }, "localname": "OperatingIncomeLoss", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseCost": { "auth_ref": [ "r268", "r404" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details": { "order": 1.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.", "label": "Operating lease cost" } } }, "localname": "OperatingLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseLiabilityNoncurrent": { "auth_ref": [ "r265" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Liabilities", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.", "label": "Operating lease liability - long-term, net of current portion" } } }, "localname": "OperatingLeaseLiabilityNoncurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeasePayments": { "auth_ref": [ "r266", "r271" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.", "label": "us-gaap_OperatingLeasePayments", "terseLabel": "Operating Lease, Payments" } } }, "localname": "OperatingLeasePayments", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_OperatingLeaseRightOfUseAsset": { "auth_ref": [ "r264" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of lessee's right to use underlying asset under operating lease.", "label": "Operating lease right-of-use asset" } } }, "localname": "OperatingLeaseRightOfUseAsset", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent": { "auth_ref": [ "r4", "r9", "r62" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 0.0, "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount after tax and reclassification adjustments of gain (loss) on foreign currency translation adjustments, foreign currency transactions designated and effective as economic hedges of a net investment in a foreign entity and intra-entity foreign currency transactions that are of a long-term-investment nature, attributable to parent entity.", "label": "Foreign currency translation" } } }, "localname": "OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Other comprehensive loss:" } } }, "localname": "OtherComprehensiveIncomeLossNetOfTaxPeriodIncreaseDecreaseAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_OtherNonoperatingIncomeExpense": { "auth_ref": [ "r52" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 4.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.", "label": "Other income, net" } } }, "localname": "OtherNonoperatingIncomeExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": { "auth_ref": [ "r53" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities", "weight": -1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.", "label": "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment", "negatedLabel": "Purchase of fixed assets" } } }, "localname": "PaymentsToAcquirePropertyPlantAndEquipment", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PolicyTextBlockAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_PolicyTextBlockAbstract", "terseLabel": "Accounting Policies" } } }, "localname": "PolicyTextBlockAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_PreferredStockParOrStatedValuePerShare": { "auth_ref": [ "r41", "r163" ], "lang": { "en-us": { "role": { "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.", "label": "Preferred stock, par value (in dollars per share)" } } }, "localname": "PreferredStockParOrStatedValuePerShare", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "perShareItemType" }, "us-gaap_PreferredStockSharesAuthorized": { "auth_ref": [ "r41", "r334" ], "lang": { "en-us": { "role": { "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.", "label": "Preferred stock, shares authorized (in shares)" } } }, "localname": "PreferredStockSharesAuthorized", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesIssued": { "auth_ref": [ "r41", "r163" ], "lang": { "en-us": { "role": { "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.", "label": "Preferred stock, shares issued (in shares)" } } }, "localname": "PreferredStockSharesIssued", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockSharesOutstanding": { "auth_ref": [ "r41", "r334", "r352", "r454", "r455" ], "lang": { "en-us": { "role": { "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.", "label": "Preferred stock, shares outstanding (in shares)" } } }, "localname": "PreferredStockSharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals" ], "xbrltype": "sharesItemType" }, "us-gaap_PreferredStockValue": { "auth_ref": [ "r41", "r303", "r405" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 4.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.", "label": "Preferred stock, $0.001 par value; 5,000,000 shares authorized, no shares issued or outstanding" } } }, "localname": "PreferredStockValue", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": { "auth_ref": [ "r424" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 0.0, "parentTag": "us-gaap_AssetsCurrent", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.", "label": "Prepaid expenses and other current assets" } } }, "localname": "PrepaidExpenseAndOtherAssetsCurrent", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ProceedsFromIssuanceOfCommonStock": { "auth_ref": [ "r3" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 0.0, "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The cash inflow from the additional capital contribution to the entity.", "label": "Proceeds from sale of common stock, net of issuance costs", "terseLabel": "Proceeds from Issuance of Common Stock" } } }, "localname": "ProceedsFromIssuanceOfCommonStock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_PropertyPlantAndEquipmentNet": { "auth_ref": [ "r7", "r300", "r307", "r405" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 3.0, "parentTag": "us-gaap_Assets", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.", "label": "Furniture and equipment, net" } } }, "localname": "PropertyPlantAndEquipmentNet", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyDomain": { "auth_ref": [ "r185", "r273", "r274", "r327", "r328", "r329", "r330", "r331", "r351", "r353", "r377" ], "lang": { "en-us": { "role": { "documentation": "Related parties include affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Domain]" } } }, "localname": "RelatedPartyDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_RelatedPartyTransactionAmountsOfTransaction": { "auth_ref": [ "r38", "r273" ], "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of transactions with related party during the financial reporting period.", "label": "us-gaap_RelatedPartyTransactionAmountsOfTransaction", "terseLabel": "Related Party Transaction, Amounts of Transaction" } } }, "localname": "RelatedPartyTransactionAmountsOfTransaction", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RelatedPartyTransactionsByRelatedPartyAxis": { "auth_ref": [ "r185", "r273", "r274", "r285", "r286", "r287", "r288", "r289", "r290", "r291", "r292", "r293", "r294", "r295", "r296", "r327", "r328", "r329", "r330", "r331", "r351", "r353", "r377", "r443" ], "lang": { "en-us": { "role": { "documentation": "Information by type of related party. Related parties include, but not limited to, affiliates; other entities for which investments are accounted for by the equity method by the entity; trusts for benefit of employees; and principal owners, management, and members of immediate families. It also may include other parties with which the entity may control or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.", "label": "Related Party, Type [Axis]" } } }, "localname": "RelatedPartyTransactionsByRelatedPartyAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_ResearchAndDevelopmentExpense": { "auth_ref": [ "r40", "r219", "r452" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 2.0, "parentTag": "us-gaap_OperatingExpenses", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.", "label": "Research and development", "terseLabel": "Research and Development Expense" } } }, "localname": "ResearchAndDevelopmentExpense", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_ResearchAndDevelopmentExpenseMember": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.", "label": "Research and Development Expense [Member]" } } }, "localname": "ResearchAndDevelopmentExpenseMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details" ], "xbrltype": "domainItemType" }, "us-gaap_RetainedEarningsAccumulatedDeficit": { "auth_ref": [ "r44", "r61", "r305", "r316", "r317", "r320", "r335", "r405" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_StockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of accumulated undistributed earnings (deficit).", "label": "Accumulated deficit", "terseLabel": "Retained Earnings (Accumulated Deficit)" } } }, "localname": "RetainedEarningsAccumulatedDeficit", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_RetainedEarningsMember": { "auth_ref": [ "r76", "r102", "r103", "r104", "r106", "r112", "r114", "r141", "r142", "r215", "r216", "r217", "r226", "r227", "r237", "r239", "r240", "r242", "r244", "r313", "r315", "r322", "r454" ], "lang": { "en-us": { "role": { "documentation": "Accumulated undistributed earnings (deficit).", "label": "Retained Earnings [Member]" } } }, "localname": "RetainedEarningsMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "domainItemType" }, "us-gaap_Revenues": { "auth_ref": [ "r91", "r98", "r125", "r126", "r129", "r132", "r133", "r137", "r138", "r139", "r140", "r151", "r152", "r153", "r154", "r155", "r156", "r157", "r158", "r159", "r255", "r299", "r436" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited": { "order": 3.0, "parentTag": "us-gaap_NetIncomeLoss", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss).", "label": "Revenues" } } }, "localname": "Revenues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_SaleOfStockNameOfTransactionDomain": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.", "label": "Sale of Stock [Domain]" } } }, "localname": "SaleOfStockNameOfTransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_ShareBasedCompensation": { "auth_ref": [ "r5" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited": { "order": 1.0, "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of noncash expense for share-based payment arrangement.", "label": "us-gaap_ShareBasedCompensation", "terseLabel": "Stock-based compensation" } } }, "localname": "ShareBasedCompensation", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant": { "auth_ref": [ "r32" ], "lang": { "en-us": { "role": { "documentation": "The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.", "label": "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "terseLabel": "Share-Based Compensation Arrangement by Share-Based Payment Award, Number of Shares Available for Grant (in shares)" } } }, "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain": { "auth_ref": [ "r188", "r189", "r190", "r191", "r192", "r193", "r194", "r195", "r196", "r197", "r198", "r199", "r200", "r201", "r202", "r203", "r204", "r205", "r206", "r207", "r208", "r209", "r210", "r211", "r212", "r213" ], "lang": { "en-us": { "role": { "documentation": "Award under share-based payment arrangement.", "label": "Award Type [Domain]" } } }, "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SharesOutstanding": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Number of shares issued which are neither cancelled nor held in the treasury.", "label": "us-gaap_SharesOutstanding", "periodEndLabel": "Balance (in shares)", "periodStartLabel": "Balance (in shares)" } } }, "localname": "SharesOutstanding", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "sharesItemType" }, "us-gaap_SignificantAccountingPoliciesTextBlock": { "auth_ref": [ "r57", "r96" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.", "label": "Significant Accounting Policies [Text Block]" } } }, "localname": "SignificantAccountingPoliciesTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity" ], "xbrltype": "textBlockItemType" }, "us-gaap_StatementEquityComponentsAxis": { "auth_ref": [ "r11", "r20", "r76", "r88", "r89", "r90", "r102", "r103", "r104", "r106", "r112", "r114", "r123", "r141", "r142", "r177", "r215", "r216", "r217", "r226", "r227", "r237", "r238", "r239", "r240", "r241", "r242", "r244", "r257", "r258", "r259", "r260", "r261", "r262", "r272", "r313", "r314", "r315", "r322", "r372" ], "lang": { "en-us": { "role": { "documentation": "Information by component of equity.", "label": "Equity Components [Axis]" } } }, "localname": "StatementEquityComponentsAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StatementLineItems": { "auth_ref": [ "r102", "r103", "r104", "r123", "r284", "r318", "r323", "r326", "r327", "r328", "r329", "r330", "r331", "r334", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r353", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r372", "r410" ], "lang": { "en-us": { "role": { "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.", "label": "Statement [Line Items]" } } }, "localname": "StatementLineItems", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity-tables", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual", "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StatementOfCashFlowsAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Cash Flows [Abstract]" } } }, "localname": "StatementOfCashFlowsAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfFinancialPositionAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Financial Position [Abstract]" } } }, "localname": "StatementOfFinancialPositionAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementOfStockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Statement of Stockholders' Equity [Abstract]" } } }, "localname": "StatementOfStockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "xbrltype": "stringItemType" }, "us-gaap_StatementTable": { "auth_ref": [ "r102", "r103", "r104", "r123", "r284", "r318", "r323", "r326", "r327", "r328", "r329", "r330", "r331", "r334", "r337", "r338", "r339", "r340", "r341", "r342", "r343", "r344", "r345", "r347", "r348", "r349", "r350", "r351", "r353", "r355", "r356", "r358", "r359", "r360", "r361", "r362", "r363", "r364", "r365", "r366", "r367", "r368", "r369", "r372", "r410" ], "lang": { "en-us": { "role": { "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.", "label": "Statement [Table]" } } }, "localname": "StatementTable", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited-parentheticals", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-cash-flows-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business", "http://www.moleculin.com/20230331/role/statement-note-1-nature-of-business-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-schedule-of-fair-value-measurements-recurring-and-nonrecurring-details", "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-details-textual", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-warrant-activity-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-4-equity-stock-based-compensation-details", "http://www.moleculin.com/20230331/role/statement-note-4-equity-tables", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes", "http://www.moleculin.com/20230331/role/statement-note-5-income-taxes-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual", "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "stringItemType" }, "us-gaap_StockIssuedDuringPeriodSharesNewIssues": { "auth_ref": [ "r11", "r41", "r42", "r61", "r319", "r372", "r383" ], "lang": { "en-us": { "role": { "documentation": "Number of new stock issued during the period.", "label": "Issuance of common stock with equity purchase agreement (in shares)", "terseLabel": "Stock Issued During Period, Shares, New Issues (in shares)" } } }, "localname": "StockIssuedDuringPeriodSharesNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "sharesItemType" }, "us-gaap_StockIssuedDuringPeriodValueNewIssues": { "auth_ref": [ "r11", "r41", "r42", "r61", "r322", "r372", "r383", "r416" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.", "label": "Issuance of common stock with equity purchase agreement", "terseLabel": "Stock Issued During Period, Value, New Issues" } } }, "localname": "StockIssuedDuringPeriodValueNewIssues", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquity": { "auth_ref": [ "r42", "r45", "r46", "r58", "r336", "r352", "r373", "r374", "r405", "r417", "r428", "r433", "r441", "r454" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited": { "order": 1.0, "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity", "weight": 1.0 } }, "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of equity (deficit) attributable to parent. Excludes temporary equity and equity attributable to noncontrolling interest.", "label": "us-gaap_StockholdersEquity", "periodEndLabel": "Balance", "periodStartLabel": "Balance", "totalLabel": "Total stockholders\u2019 equity" } } }, "localname": "StockholdersEquity", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited", "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statement-of-stockholders-equity-unaudited" ], "xbrltype": "monetaryItemType" }, "us-gaap_StockholdersEquityAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "Stockholders' equity" } } }, "localname": "StockholdersEquityAbstract", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-balance-sheets-current-period-unaudited" ], "xbrltype": "stringItemType" }, "us-gaap_StockholdersEquityNoteDisclosureTextBlock": { "auth_ref": [ "r60", "r97", "r162", "r164", "r166", "r167", "r168", "r169", "r170", "r171", "r172", "r173", "r174", "r175", "r177", "r243", "r375", "r376", "r384" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for equity.", "label": "Equity [Text Block]" } } }, "localname": "StockholdersEquityNoteDisclosureTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubleaseIncome": { "auth_ref": [ "r270", "r404" ], "crdr": "credit", "lang": { "en-us": { "role": { "documentation": "Amount of sublease income excluding finance and operating lease expense.", "label": "us-gaap_SubleaseIncome", "terseLabel": "Sublease Income" } } }, "localname": "SubleaseIncome", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "monetaryItemType" }, "us-gaap_SubsequentEventMember": { "auth_ref": [ "r263", "r277" ], "lang": { "en-us": { "role": { "documentation": "Identifies event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event [Member]" } } }, "localname": "SubsequentEventMember", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventTypeAxis": { "auth_ref": [ "r263", "r277" ], "lang": { "en-us": { "role": { "documentation": "Information by event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Axis]" } } }, "localname": "SubsequentEventTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_SubsequentEventTypeDomain": { "auth_ref": [ "r263", "r277" ], "lang": { "en-us": { "role": { "documentation": "Event that occurred after the balance sheet date but before financial statements are issued or available to be issued.", "label": "Subsequent Event Type [Domain]" } } }, "localname": "SubsequentEventTypeDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events", "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_SubsequentEventsPolicyPolicyTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for reporting subsequent events.", "label": "Subsequent Events, Policy [Policy Text Block]" } } }, "localname": "SubsequentEventsPolicyPolicyTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsequentEventsTextBlock": { "auth_ref": [ "r276", "r278" ], "lang": { "en-us": { "role": { "documentation": "The entire disclosure for significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued. Examples include: the sale of a capital stock issue, purchase of a business, settlement of litigation, catastrophic loss, significant foreign exchange rate changes, loans to insiders or affiliates, and transactions not in the ordinary course of business.", "label": "Subsequent Events [Text Block]" } } }, "localname": "SubsequentEventsTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-7-subsequent-events" ], "xbrltype": "textBlockItemType" }, "us-gaap_SubsidiarySaleOfStockAxis": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Information by type of sale of the entity's stock.", "label": "Sale of Stock [Axis]" } } }, "localname": "SubsidiarySaleOfStockAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_TableTextBlock": { "auth_ref": [], "lang": { "en-us": { "role": { "label": "us-gaap_TableTextBlock", "terseLabel": "Notes Tables" } } }, "localname": "TableTextBlock", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-2-basis-of-presentation-principles-of-consolidation-significant-accounting-policies-and-liquidity-tables", "http://www.moleculin.com/20230331/role/statement-note-3-warrants-tables", "http://www.moleculin.com/20230331/role/statement-note-4-equity-tables", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-tables" ], "xbrltype": "stringItemType" }, "us-gaap_TransactionDomain": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction [Domain]" } } }, "localname": "TransactionDomain", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "domainItemType" }, "us-gaap_TransactionTypeAxis": { "auth_ref": [ "r391" ], "lang": { "en-us": { "role": { "documentation": "Information by type of agreement between buyer and seller for the exchange of financial instruments.", "label": "Transaction Type [Axis]" } } }, "localname": "TransactionTypeAxis", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-4-equity", "http://www.moleculin.com/20230331/role/statement-note-4-equity-details-textual", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies", "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-details-textual" ], "xbrltype": "stringItemType" }, "us-gaap_UseOfEstimates": { "auth_ref": [ "r28", "r29", "r30", "r70", "r71", "r72", "r73" ], "lang": { "en-us": { "role": { "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.", "label": "Use of Estimates, Policy [Policy Text Block]" } } }, "localname": "UseOfEstimates", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-significant-accounting-policies-policies" ], "xbrltype": "textBlockItemType" }, "us-gaap_VariableLeaseCost": { "auth_ref": [ "r269", "r404" ], "calculation": { "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details": { "order": 0.0, "parentTag": "us-gaap_LeaseCost", "weight": 1.0 } }, "crdr": "debit", "lang": { "en-us": { "role": { "documentation": "Amount of variable lease cost, excluded from lease liability, recognized when obligation for payment is incurred for finance and operating leases.", "label": "Variable lease cost" } } }, "localname": "VariableLeaseCost", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-6-commitments-and-contingencies-lease-cost-details" ], "xbrltype": "monetaryItemType" }, "us-gaap_WarrantsAndRightsOutstandingMeasurementInput": { "auth_ref": [ "r252" ], "lang": { "en-us": { "role": { "documentation": "Value of input used to measure outstanding warrant and right embodying unconditional obligation requiring redemption by transferring asset at specified or determinable date or upon event certain to occur.", "label": "Warrants, assumptions" } } }, "localname": "WarrantsAndRightsOutstandingMeasurementInput", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-note-3-warrants-assumptions-used-details" ], "xbrltype": "decimalItemType" }, "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": { "auth_ref": [ "r115", "r120" ], "lang": { "en-us": { "role": { "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.", "label": "Weighted average common shares outstanding, basic and diluted (in shares)" } } }, "localname": "WeightedAverageNumberOfSharesOutstandingBasic", "nsuri": "http://fasb.org/us-gaap/2023", "presentation": [ "http://www.moleculin.com/20230331/role/statement-condensed-consolidated-statements-of-operations-and-comprehensive-loss-unaudited" ], "xbrltype": "sharesItemType" } }, "unitCount": 7 } }, "std_ref": { "r0": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "25", "SubTopic": "10", "Topic": "480", "URI": "https://asc.fasb.org//1943274/2147481766/480-10-25-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r1": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r10": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c),(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r100": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(1)(iii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r101": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(m)(2)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r102": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r103": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r104": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r105": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(2)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r106": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)(3)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r107": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r108": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r109": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r11": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r110": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r111": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r112": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r113": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r114": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483443/250-10-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r115": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r116": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r117": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r118": { "Name": "Accounting Standards Codification", "Paragraph": "60B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-60B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r119": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482689/260-10-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r12": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r120": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r121": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r122": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r123": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "272", "URI": "https://asc.fasb.org//1943274/2147483014/272-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r124": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r125": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r126": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r127": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r128": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-22", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r129": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r13": { "Name": "Accounting Standards Codification", "Paragraph": "2C", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2C", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r130": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r131": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r132": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r133": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r134": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r135": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r136": { "Name": "Accounting Standards Codification", "Paragraph": "32", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-32", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r137": { "Name": "Accounting Standards Codification", "Paragraph": "40", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-40", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r138": { "Name": "Accounting Standards Codification", "Paragraph": "41", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-41", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r139": { "Name": "Accounting Standards Codification", "Paragraph": "42", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-42", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r14": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "60", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482053/820-10-60-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r140": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r141": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r142": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)(2)", "Topic": "326", "URI": "https://asc.fasb.org//1943274/2147479654/326-10-65-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r143": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r144": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "420", "URI": "https://asc.fasb.org//1943274/2147482017/420-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r145": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r146": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "440", "URI": "https://asc.fasb.org//1943274/2147482648/440-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r147": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r148": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147483076/450-20-50-9", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r149": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q2)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r15": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19(a))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r150": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "20", "Subparagraph": "(SAB Topic 5.Y.Q4)", "Topic": "450", "URI": "https://asc.fasb.org//1943274/2147480102/450-20-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r151": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r152": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r153": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r154": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r155": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(i))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r156": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r157": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r158": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(4)(iv))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r159": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-02(a)(5))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r16": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.19-26)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r160": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r161": { "Name": "Accounting Standards Codification", "Paragraph": "1D", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1D", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r162": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r163": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r164": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r165": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r166": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(g)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r167": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r168": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(i)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r169": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r17": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.20)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r170": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r171": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r172": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-16", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r173": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r174": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r175": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-18", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r176": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r177": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r178": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(i)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r179": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r18": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.21)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r180": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r181": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(A)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r182": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(B)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r183": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(02)(C)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r184": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(03)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r185": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(n)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r186": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "80", "Subparagraph": "(d)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480576/715-80-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r187": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "35", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480483/718-10-35-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r188": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r189": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r19": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.25)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r190": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)(3)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r191": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r192": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r193": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r194": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r195": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r196": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r197": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r198": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)(iv)(04)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r199": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r2": { "Name": "Accounting Standards Codification", "Paragraph": "10A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-10A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r20": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02.29-31)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r200": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r201": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r202": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(01)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r203": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(02)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r204": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(2)(iii)(03)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r205": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r206": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r207": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r208": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(e)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r209": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r21": { "Name": "Accounting Standards Codification", "Paragraph": "14A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-14A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r210": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(ii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r211": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iii)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r212": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(iv)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r213": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)(2)(v)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r214": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(h)(1)(i)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r215": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(e)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r216": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(1)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r217": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(f)(2)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480336/718-10-65-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r218": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 14.F)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147479830/718-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r219": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "730", "URI": "https://asc.fasb.org//1943274/2147482916/730-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r22": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-5", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r220": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "740", "URI": "https://asc.fasb.org//740/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r221": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-10", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r222": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r223": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-14", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r224": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r225": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482685/740-10-50-21", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r226": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(2)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r227": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(d)(3)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482615/740-10-65-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r228": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.5.Q1)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r229": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB TOPIC 6.I.7)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r23": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r230": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.C)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147479360/740-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r231": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "270", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482526/740-270-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r232": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482603/740-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r233": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r234": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-25", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r235": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bb)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r236": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r237": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r238": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r239": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(i)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r24": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r240": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iii)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r241": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(h)(1)(iv)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r242": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "20", "Subparagraph": "(i)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480528/815-20-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r243": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(a)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480237/815-40-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r244": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r245": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(4)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r246": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r247": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r248": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r249": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r25": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r250": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r251": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r252": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)(2)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r253": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(1)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r254": { "Name": "Accounting Standards Codification", "Paragraph": "6A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-6A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r255": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r256": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "230", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481877/830-230-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r257": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-17", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r258": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(a)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r259": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(b)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r26": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482662/260-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r260": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r261": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "30", "Subparagraph": "(d)", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481694/830-30-45-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r262": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r263": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Topic": "830", "URI": "https://asc.fasb.org//1943274/2147481674/830-30-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r264": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r265": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r266": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479041/842-20-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r267": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r268": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r269": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r27": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "270", "URI": "https://asc.fasb.org//1943274/2147482989/270-10-45-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r270": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(e)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r271": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(g)(1)", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r272": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(a)(3)(iii)(03)", "Topic": "848", "URI": "https://asc.fasb.org//1943274/2147483550/848-10-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r273": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r274": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r275": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r276": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "855", "URI": "https://asc.fasb.org//855/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r277": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r278": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "855", "URI": "https://asc.fasb.org//1943274/2147483399/855-10-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r279": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r28": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-4", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r280": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r281": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(bb)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r282": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r283": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "910", "URI": "https://asc.fasb.org//1943274/2147482546/910-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r284": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 11.L)", "Topic": "924", "URI": "https://asc.fasb.org//1943274/2147479941/924-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r285": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r286": { "Name": "Accounting Standards Codification", "Paragraph": "15", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-15", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r287": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r288": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-20", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r289": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r29": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-8", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r290": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-28", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r291": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r292": { "Name": "Accounting Standards Codification", "Paragraph": "33", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-33", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r293": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r294": { "Name": "Accounting Standards Codification", "Paragraph": "35A", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(b)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-35A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r295": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(1)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r296": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(c)(2)", "Topic": "932", "URI": "https://asc.fasb.org//1943274/2147482274/932-235-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r297": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(26))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r298": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(27))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r299": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "235", "Subparagraph": "(SX 210.9-05(b)(2))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479557/942-235-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r3": { "Name": "Accounting Standards Codification", "Paragraph": "14", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-14", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r30": { "Name": "Accounting Standards Codification", "Paragraph": "9", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-9", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r300": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "360", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147480842/942-360-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r301": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(12))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r302": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(19))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r303": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(21))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r304": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r305": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r306": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(25))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r307": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.7-03(a)(8))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147479440/944-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r308": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(18))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r309": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(22))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r31": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r310": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(23))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r311": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.7-04(9))", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147483586/944-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r312": { "Name": "Accounting Standards Codification", "Paragraph": "7A", "Publisher": "FASB", "Section": "50", "SubTopic": "40", "Subparagraph": "(d)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480081/944-40-50-7A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r313": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r314": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(1)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r315": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(f)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r316": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(g)(2)(i)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r317": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(h)(2)", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480016/944-40-65-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r318": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r319": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.6-03(i)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479886/946-10-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r32": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147480429/718-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r320": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r321": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480990/946-20-50-13", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r322": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r323": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480555/946-210-45-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r324": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(e)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r325": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(f)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r326": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r327": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r328": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r329": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(12)(b)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r33": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-12", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r330": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r331": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(13)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r332": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(14))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r333": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(15))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r334": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(16)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r335": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(17))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r336": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(19))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r337": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r338": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(2)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r339": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r34": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "718", "URI": "https://asc.fasb.org//1943274/2147481089/718-20-55-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r340": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r341": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(3)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r342": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r343": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r344": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r345": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(6)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r346": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(8))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r347": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r348": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(c))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r349": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r35": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r350": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-04(9)(e))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r351": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r352": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.6-05(4))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147479617/946-210-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r353": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Subparagraph": "(b)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r354": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "45", "SubTopic": "220", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483581/946-220-45-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r355": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r356": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r357": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(2)(g)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r358": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r359": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r36": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r360": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r361": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r362": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r363": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(a)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r364": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(1))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r365": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r366": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(3))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r367": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(5))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r368": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r369": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(7)(c)(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r37": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r370": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-07(9))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r371": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(1)(d))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r372": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r373": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(6))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r374": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r375": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r376": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "235", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481062/946-235-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r377": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r378": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r379": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r38": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r380": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r381": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r382": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r383": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r384": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "505", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147481004/946-505-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r385": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "440", "Subparagraph": "(a)", "Topic": "954", "URI": "https://asc.fasb.org//1943274/2147480327/954-440-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r386": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(c)", "Topic": "976", "URI": "https://asc.fasb.org//1943274/2147482856/976-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r387": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "310", "Subparagraph": "(b)", "Topic": "978", "URI": "https://asc.fasb.org//1943274/2147482707/978-310-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r388": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r389": { "Name": "Accounting Standards Codification", "Paragraph": "16", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-16", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r39": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03.17)", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r390": { "Name": "Accounting Standards Codification", "Paragraph": "21", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-21", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r391": { "Name": "Accounting Standards Codification", "Paragraph": "22", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483444/210-20-55-22", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r392": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-4", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r393": { "Name": "Accounting Standards Codification", "Paragraph": "52", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "260", "URI": "https://asc.fasb.org//1943274/2147482635/260-10-55-52", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r394": { "Name": "Accounting Standards Codification", "Paragraph": "30", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-30", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r395": { "Name": "Accounting Standards Codification", "Paragraph": "31", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-31", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r396": { "Name": "Accounting Standards Codification", "Paragraph": "12A", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147481933/310-10-55-12A", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r397": { "Name": "Accounting Standards Codification", "Paragraph": "69B", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69B", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r398": { "Name": "Accounting Standards Codification", "Paragraph": "69C", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481568/470-20-55-69C", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r399": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(d)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147481112/505-10-50-13", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r4": { "Name": "Accounting Standards Codification", "Paragraph": "20", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-20", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r40": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "985", "URI": "https://asc.fasb.org//1943274/2147481283/985-20-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r400": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(ii)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r401": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)(iv)(01)", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480506/715-20-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r402": { "Name": "Accounting Standards Codification", "Paragraph": "17", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480482/715-20-55-17", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r403": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "55", "SubTopic": "80", "Topic": "715", "URI": "https://asc.fasb.org//1943274/2147480547/715-80-55-8", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r404": { "Name": "Accounting Standards Codification", "Paragraph": "53", "Publisher": "FASB", "Section": "55", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147479589/842-20-55-53", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r405": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "10", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481372/852-10-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r406": { "Name": "Accounting Standards Codification", "Paragraph": "29F", "Publisher": "FASB", "Section": "55", "SubTopic": "40", "Topic": "944", "URI": "https://asc.fasb.org//1943274/2147480046/944-40-55-29F", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r407": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(b)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r408": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "210", "Subparagraph": "(a)(1)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480524/946-210-50-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r409": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "55", "SubTopic": "210", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480493/946-210-55-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r41": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(28))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r410": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "310", "Subparagraph": "(d)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480833/946-310-45-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r411": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12(Column A)(Footnote 2)(i))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-1", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r412": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12A(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-2", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r413": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-12B(Column A)(Footnote 1)(a))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-3", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r414": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "S99", "SubTopic": "320", "Subparagraph": "(SX 210.12-14(Column A)(Footnote 2))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480032/946-320-S99-6", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r415": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-10", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r416": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-11", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r417": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "55", "SubTopic": "830", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480167/946-830-55-12", "role": "http://www.xbrl.org/2003/role/exampleRef" }, "r418": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r419": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r42": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(29))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r420": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r421": { "Name": "Form 10-Q", "Number": "240", "Publisher": "SEC", "Section": "308", "Subsection": "a", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r422": { "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Publisher": "SEC", "Section": "13", "Subsection": "a-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r423": { "Name": "Regulation S-T", "Number": "232", "Publisher": "SEC", "Section": "405", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r424": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r425": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r426": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r427": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r428": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r429": { "Name": "Accounting Standards Codification", "Paragraph": "23", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-23", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r43": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r430": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-24", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r431": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "250", "URI": "https://asc.fasb.org//1943274/2147483421/250-10-45-5", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r432": { "Name": "Accounting Standards Codification", "Paragraph": "18", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "280", "URI": "https://asc.fasb.org//1943274/2147482810/280-10-50-18", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r433": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "323", "URI": "https://asc.fasb.org//1943274/2147481687/323-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r434": { "Name": "Accounting Standards Codification", "Paragraph": "10", "Publisher": "FASB", "Section": "50", "SubTopic": "30", "Subparagraph": "(c)", "Topic": "410", "URI": "https://asc.fasb.org//1943274/2147481931/410-30-50-10", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r435": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "450", "URI": "https://asc.fasb.org//450/tableOfContent", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r436": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(ii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r437": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.13-01(a)(4)(iii))", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147480097/470-10-S99-1A", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r438": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(d)", "Topic": "470", "URI": "https://asc.fasb.org//1943274/2147481139/470-20-50-1B", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r439": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "65", "SubTopic": "40", "Subparagraph": "(e)(3)", "Topic": "815", "URI": "https://asc.fasb.org//1943274/2147480175/815-40-65-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r44": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30)(a)(3))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r440": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(bbb)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r441": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(f)", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-28", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r442": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "842", "URI": "https://asc.fasb.org//1943274/2147478964/842-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r443": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "850", "URI": "https://asc.fasb.org//1943274/2147483326/850-10-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r444": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r445": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "852", "URI": "https://asc.fasb.org//1943274/2147481404/852-10-50-7", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r446": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r447": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r448": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r449": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(1)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r45": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(30))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r450": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(2)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r451": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(b)(3)", "Topic": "860", "URI": "https://asc.fasb.org//1943274/2147481326/860-20-50-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r452": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "25", "SubTopic": "730", "Topic": "912", "URI": "https://asc.fasb.org//1943274/2147482517/912-730-25-1", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r453": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "45", "SubTopic": "205", "Subparagraph": "(a)", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147480767/946-205-45-4", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r454": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(4)(b))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r455": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.6-09(7))", "Topic": "946", "URI": "https://asc.fasb.org//1943274/2147483575/946-220-S99-3", "role": "http://www.xbrl.org/2009/role/commonPracticeRef" }, "r46": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(31))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r47": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(32))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r48": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(20))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r49": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(4))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r5": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r50": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.3)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r51": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.4)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r52": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03.9)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r53": { "Name": "Accounting Standards Codification", "Paragraph": "13", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-13", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r54": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r55": { "Name": "Accounting Standards Codification", "Paragraph": "25", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-25", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r56": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r57": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "235", "URI": "https://asc.fasb.org//235/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r58": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SAB Topic 4.E)", "Topic": "310", "URI": "https://asc.fasb.org//1943274/2147480418/310-10-S99-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r59": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "440", "URI": "https://asc.fasb.org//440/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r6": { "Name": "Accounting Standards Codification", "Paragraph": "28", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-28", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r60": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "505", "URI": "https://asc.fasb.org//505/tableOfContent", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r61": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.3-04)", "Topic": "505", "URI": "https://asc.fasb.org//1943274/2147480008/505-10-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r62": { "Name": "Accounting Standards Codification", "Paragraph": "19", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481231/810-10-45-19", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r63": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r64": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "820", "URI": "https://asc.fasb.org//1943274/2147482106/820-10-50-2", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r65": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(11))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r66": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "210", "Subparagraph": "(SX 210.9-03(23))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147479853/942-210-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r67": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "220", "Subparagraph": "(SX 210.9-04(22))", "Topic": "942", "URI": "https://asc.fasb.org//1943274/2147483589/942-220-S99-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r68": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "45", "SubTopic": "20", "Subparagraph": "(a)", "Topic": "740", "URI": "https://asc.fasb.org//1943274/2147482659/740-20-45-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r69": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r7": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "360", "URI": "https://asc.fasb.org//1943274/2147482099/360-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r70": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r71": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r72": { "Name": "Accounting Standards Codification", "Paragraph": "11", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-11", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r73": { "Name": "Accounting Standards Codification", "Paragraph": "12", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "275", "URI": "https://asc.fasb.org//1943274/2147482861/275-10-50-12", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r74": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r75": { "Name": "Accounting Standards Codification", "Publisher": "FASB", "Topic": "275", "URI": "https://asc.fasb.org//275/tableOfContent", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r76": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "65", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "105", "URI": "https://asc.fasb.org//1943274/2147479343/105-10-65-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r77": { "Name": "Accounting Standards Codification", "Paragraph": "7", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Topic": "205", "URI": "https://asc.fasb.org//1943274/2147483499/205-20-50-7", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r78": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r79": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483467/210-10-45-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r8": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "825", "URI": "https://asc.fasb.org//1943274/2147482907/825-10-50-1", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r80": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(1))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r81": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(18))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r82": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-02(9))", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147480566/210-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r83": { "Name": "Accounting Standards Codification", "Paragraph": "3", "Publisher": "FASB", "Section": "50", "SubTopic": "20", "Subparagraph": "(c)", "Topic": "210", "URI": "https://asc.fasb.org//1943274/2147483466/210-20-50-3", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r84": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r85": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(c)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1A", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r86": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(a)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r87": { "Name": "Accounting Standards Codification", "Paragraph": "1B", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Subparagraph": "(b)", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482790/220-10-45-1B", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r88": { "Name": "Accounting Standards Codification", "Paragraph": "4", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-4", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r89": { "Name": "Accounting Standards Codification", "Paragraph": "5", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-5", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r9": { "Name": "Accounting Standards Codification", "Paragraph": "1A", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Subparagraph": "(c)(3)", "Topic": "810", "URI": "https://asc.fasb.org//1943274/2147481203/810-10-50-1A", "role": "http://fasb.org/us-gaap/role/ref/legacyRef" }, "r90": { "Name": "Accounting Standards Codification", "Paragraph": "6", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147482765/220-10-50-6", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r91": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(1))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r92": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(24))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r93": { "Name": "Accounting Standards Codification", "Paragraph": "2", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.5-03(25))", "Topic": "220", "URI": "https://asc.fasb.org//1943274/2147483621/220-10-S99-2", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r94": { "Name": "Accounting Standards Codification", "Paragraph": "24", "Publisher": "FASB", "Section": "45", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482740/230-10-45-24", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r95": { "Name": "Accounting Standards Codification", "Paragraph": "8", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "230", "URI": "https://asc.fasb.org//1943274/2147482913/230-10-50-8", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r96": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "50", "SubTopic": "10", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147483426/235-10-50-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r97": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(e)(1))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r98": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(g)(1)(ii))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" }, "r99": { "Name": "Accounting Standards Codification", "Paragraph": "1", "Publisher": "FASB", "Section": "S99", "SubTopic": "10", "Subparagraph": "(SX 210.4-08(h)(2))", "Topic": "235", "URI": "https://asc.fasb.org//1943274/2147480678/235-10-S99-1", "role": "http://www.xbrl.org/2003/role/disclosureRef" } }, "version": "2.2" } ZIP 50 0001437749-23-013582-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001437749-23-013582-xbrl.zip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